

MICHAEL JOSEPH WELCH, MD, FAAAAI, FAAP, CPI

Co-Director, Allergy & Asthma Medical Group and Research Center, A P.C.
1982-present

5776 Ruffin Rd
San Diego, California 92123
(858) 292-1144 ph
(858) 268-5145 fx

625 W. Citracado Parkway, Ste 206
Escondido, California 92025
(760) 755-7650 ph
(760) 755-7699 fx

Clinical Professor, Department of Pediatrics, Division of Allergy and Immunology
University of California, San Diego School of Medicine

Certified Physician Investigator,
Academy of Pharmaceutical Physicians and Investigators

E-mail: mwelch@allergyandasthma.com

California Medical License Number: G34844

PERSONAL DATA:

Born: April 20, 1951 (Minneapolis, Minnesota)
Status: Married

EDUCATION:

University: University of California at San Diego, BA in Biology, 1968-1972.

Medical School: University of California at Los Angeles, 1972-1976.

Internship: University of California at Los Angeles, Pediatrics, 1976-1977.

Residency: University of California at Los Angeles, Pediatrics, 1977-1979.

Fellowships: University of California at Los Angeles
Pediatric Immunology/Allergy/Rheumatology, 1979-1981.
(E. Richard Stiehm, MD, Program Director)

Scripps Clinic and Research Foundation, La Jolla, California
Clinical Immunology Research, 1981-1982.
(John Vaughan, MD and Dennis Carson, MD, Research Directors)

BOARD CERTIFICATIONS:

Diplomate, American Board of Pediatrics, December, 1980

Diplomate, American Board of Allergy and Immunology, October, 1983

SOCIETY MEMBERSHIPS:

American Academy of Pediatrics, Fellow, 1980 to present

Member, Section on Allergy and Immunology, 1981 to present

Chair, Executive Committee, Section on Allergy and Immunology, 2001 to 2004

Member, Executive Committee, Section on Allergy and Immunology, 1994 to 2006

Section liaison to Consortium of Children's Asthma Camps, 1992-present

Fellow-in-Training Travel Grant Selection Committee, 1997 to present

American Academy of Allergy, Asthma and Immunology; Fellow, 1982 to present

Committee on Drugs, 1985 to present

Chairman, 1995-1997

Chair, Asthma Camp Committee, 2002-2003

Steering Committee, Educational Research Trust, 1997 to 2000

Undergraduate Education Committee, 1997 to 2000

Joint Committee on Primary Care Rotations in Allergy, 1996 to 2002

Abstract review committee, ARRD Interest Section, 1996 to 1999; 2001

Co-chair, Allied Health Section, 1998 to 2001

ARRD Interest Section, Member. 1996 – 2007

Asthma Diagnosis and Treatment Interest Section, Member, 2007- present

California Medical Association, Member 1982 - present

California Society of Allergy, Asthma and Clinical Immunology. Member, 1985 to present

Socioeconomic Committee, 1987 to 1995

Regional and Local Allergy Societies Committee, Chairman, 1988-1991

Executive Council, 1988 to 1994

Secretary-Treasurer, 1990-1991

President Elect, 1991-1992

President, 1992-1993

Past-President, 1993-1994

San Diego Allergy Society, Member, 1983 - present

Vice-president, 1987-1988

President, 1988-1989

VOLUNTEER ORGANIZATIONS/POSITIONS:

American Lung Association, San Diego and Imperial Counties Chapter

SCAMP Camp Medical Committee, 1983 to present

Medical Director, SCAMP Camp, 1987 to present

Board Member, 1999 to 2006

Executive Committee of Board, 2000 to 2006

Chairman, Board of Directors, San Diego and Imperial Chapter 2003-2004

Arthritis Foundation, San Diego Chapter

Medical Advisor, Parents of Children with Arthritis, 1982 to 1994

Patient Services Committee, 1988 to 1990

Medical Director, San Diego Camp Stepping Stone (Arthritis Camp)

Program, 1991 to 1994

Juvenile Arthritis Committee, 1990 to 1995

Asthma and Allergy Foundation of America, San Diego Chapter
Medical Advisory Committee
President, 1983-1984
Parents of Children with Asthma Support Group, Medical Advisor, 1988-1993
Painted Turtle Medical Specialty Camp
Volunteer Medical Director, October 6-8, 2006
Volunteer Medical Director, November 30-December 2, 2007
Volunteer Medical Director, November 28 –30, 2008
San Diego Food Allergy Support Group
Medical Advisor, 2008-present

PROFESSIONAL POSITIONS/APPOINTMENTS:

Arthritis Clinic, Children's Hospital and Health Center, San Diego.
Co-Director, 1983-1994
Asthma and Allergy Clinic, Children's Hospital and Health Center, San Diego. Co-Director,
1993-1994
University of California, San Diego, School of Medicine
Assistant Clinical Professor, Department of Pediatrics, Division of Allergy and
Immunology, 1982-1989
Associate Clinical Professor, Department of Pediatrics, Division of Allergy and
Immunology, 1989 to 1998
Clinical Professor, Department of Pediatrics, Division of Allergy and
Immunology, 1998 to present
Teacher, AIR (Allergy-Immunology-Rheumatology) elective program for UCSD pediatric
residents, 1993 to present
Children's Hospital and Health Center, San Diego
Senior Staff Member, 1986 - present
Pharmacy and Therapeutics Committee, member, 1984 to 2002
Chairman, 1996 to 2001
Advisory Committee for Asthma Disease Management, 1997 to 1998
Rehabilitation Committee, 1985-1993
Member, Division of Allergy/Immunology/Rheumatology, 1987 to present
Vice-Chair, Division of Allergy/Immunology/Rheumatology, 2005-present
Chair, Division of Allergy and Immunology, 1996 - 1999
Adverse Drug Reaction Committee, 1988 to 1996
By-laws Committee, 1989-1991
Pediatric Specialty Medical Group, Board of Directors, 1990-1996
Ad Hoc Committee for delayed skin testing, 1991
Ad Hoc Committee for Clinical Pathway for Asthma, 1993-1995
Scripps Clinic Research Foundation, San Diego, California
Clinical Instructor, Allergy and Immunology Fellowship Training Program, 1987 to present
Sharp Community Medical Group, San Diego, California
Pharmacy and Therapeutics Committee, 2008-2009
Consortium of Children's Asthma Camps, AAP representative, 1992-present
Vice-President, 2000-2001
President, 2001-present
1/2002 IAQ: Asthma and Allergens
Environmental Protection Agency

The Problem Based Learning Institute, LLC, Diplomat, 2008

AWARDS:

Annual Leadership Award - American Lung Association of San Diego and Imperial Counties, 1995
Children's Hospital San Diego CME Physician Recognition Award for outstanding contributions to CME, 1997
1998 Health Hero of San Diego – Combined Health Agencies, San Diego, 1998
Volunteer Excellence Award Nominee – American Lung Association of San Diego and Imperial Counties, 1999
Physician Citizen of the Year, San Diego Medical Society, 1999
Special Recognition Award, AAAAI Annual Meeting, 2001
Honorary Life Member Award, American Lung Association of San Diego County, 2001
San Diego Top Doctors, Allergy & Immunology, San Diego Magazine, 2002, 2003, 2004, 2005, 2007, 2008, 2009, 2010, 2011, 2012, 2013
2004 Volunteer Excellence Award – American Lung Association
Blue Cross Community Service Award, San Diego, 2006
Certificate of Appreciation – Pediatric Nurse Practitioner Program, Arizona State University College of Nursing & Healthcare Innovation, 2008
Mariel C. Furlong Award for Making a Difference - Food Allergy & Anaphylaxis Network (FAAN), 2011
Clean Air Circle Honoree – American Lung Association, 2011

EDITORIAL BOARDS:

Editorial Board, Journal of Allergy and Clinical Immunology, 1999 to present
Editorial Advisory Board, AAP News, American Academy of Pediatrics, 1999 to 2002
Editorial Board, Pediatric Allergy, Asthma and Immunology, 1999 to present

MEDICAL STAFF:

Rady Children's Hospital and Health Center, San Diego, California (Senior Staff)
Sharp Memorial Hospital, San Diego, California
Scripps Mercy Hospital, San Diego, California

EXPERT DESIGNATION IN MEDICAL LEGAL MATTERS:

Has performed expert medical evaluation work for over 100 cases from 1989-present
Full list available upon request

PUBLICATIONS: MICHAEL J. WELCH, MD

1. Welch MJ, Markham CH, Jenden DJ: Acetylcholine and choline in cerebrospinal fluid of patients with Parkinson's disease and Huntington's chorea. *J Neurol Neurosurg Psychiatry* 1976;39:367.
2. Billet E, Welch MJ: Usefulness of laboratory values in evaluating acutely ill children. *Critical Care Quarterly* 1979;2:19.
3. Welch MJ, Correa GA: PCP intoxication in young children. *Clin Pediatr* 19:510, 1980.
4. Welch MJ, Phelps D, Osher AB: Breast feeding by a mother with cystic fibrosis. *Pediatrics* 1981;67:662.
5. Welch MJ, Sparkes R: Klinefelter syndrome and chronic pulmonary disease. *Clin Genet* 1981;19:181.
6. Lippe BM, Hensen L, Mendoza G, Finerman MA, Welch MJ: Chronic vitamin A intoxication: A multisystem disease which could reach epidemic proportions. *Am J Dis Child* 1981;135:634.
7. Welch MJ, Ank MB, Stiehm ER: Autostimulatory activity of mitogen and antigen-activated human mononuclear cells. (abstr) *Clin Res* 1981;29:31.
8. Dudley JP, Welch MJ, Stiehm ER, Carney JM: Scanning and transmission electron microscopic aspects of the nasal acilia syndrome. *Laryngoscope* 1982;92:297.
9. DiSessa TG, Klitzner T, Hirashi S, Welch MJ, Kangaroo H: The cardiovascular effects of Kawasaki's disease. *J Cardiovasc Med* 1981;6:1159.
10. Hamosh M, Bitman J, Wood DL, Mehta NR, Welch MJ, Osher AB, Jones JB, Hamosh P: Human milk in cystic fibrosis: composition and enzyme content. *Pediatr Res* 1982;16:164A.
11. Moon HW, Schwartz A, Welch MJ, McCann PP, Runnels PL: Experimental fecal transmission of human cryptosporidia to pigs, and attempted treatment with an ornithine decarboxylase inhibitor. *Vet Pathol* 1982;19:700.
12. Welch MJ, Fong S, Vaughan J, Carson DA: Increased frequency of rheumatoid factor precursor B lymphocytes after immunization of normal adults with tetanus toxoid. *Clin Exp Immunol* 1983;51:299.
13. Welch MJ, Stiehm ER: Successful use of slow subcutaneous immunoglobulin replacement therapy in a patient with severe reactions to conventional therapy. *J Allergy Clin Immunol* 1983;3:285.
14. Welch MJ, Stiehm ER, Dudley JP: Isolated absence of nasal cilia: A case report. *Ann Allergy* 1984;52:32.
15. Sly RM, Anderson JA, Bierman CW, Chervinsky P, Cogen FC, Easton JG, Glazer I, Kemp JP, Knight A, Krumholz RA, Nicklas RA, Rudolph BM, Schuller DE, Segal AT, Szeffler SJ, Welch MJ, Whitcomb, NJ, Yamate M: Adverse effects and complications of treatment with beta-adrenergic agonist drugs. (Committee Position Statement) *J Allergy Clin Immunol* 1985;75:443.
16. Orgel HA, Meltzer EO, Welch MJ, Kemp JP: Inhaled albuterol powder for the treatment of asthma - A dose-response study. *J Allergy Clin Immunol* 1985;75:468-71.
17. Meltzer EO, Kemp JP, Welch MJ, Orgel HA: Effect of dosing schedule on efficacy of beclomethasone dipropionate aerosol in chronic asthma. *Am Rev Respir Dis* 1985;131:732-6.
18. Welch MJ, Meltzer EO, Orgel HA, Kemp JP: Assessment of the correlation of rhinometry with the symptoms and signs of allergic rhinitis in children. *Ann Allergy* 1985;55:577-9.

PUBLICATIONS: MICHAEL J. WELCH, MD

19. Kemp JP, Welch MJ, Meltzer EO, Orgel HA: Therapeutic efficacy and equivalence of tablet and syrup formulations of procaterol hydrochloride in childhood asthma. *Ann Allergy* 1985;55:588-92.
20. Welch MJ, Kemp JP, Orgel HA, Meltzer EO: Steady-state evaluation of twice-a-day dosing of a new sustained-release theophylline preparation for young children. *J Asthma* 1985;22:249-52.
21. Meltzer EO, Busse WW, Bush RK, Kemp JP, Orgel HA, Welch MJ: Beclomethasone dipropionate nasal aerosol spray in allergic rhinitis: a comparison of three delivery systems. *Ann Allergy* 1985;55:802-4.
22. Rosen JP, Chervinsky P, Renard RL, Kemp JP, Mendelson LM, Selcow JE, Noyes JH, Meltzer EO, Welch MJ, Orgel HA, Trochelmann L, Wessell M: Duration of action of oral albuterol in an asthmatic population. *Ann Allergy* 1986;56:28-33.
23. Kemp JP, Pinnas JL, Tinkelman DG, Meltzer EO, Campbell SC, Orgel HA, Welch MJ, Mingo TS: Comparison of bronchodilator responses with bitolterol mesylate solution with the use of two different nebulizer systems in asthma. *J Allergy Clin Immunol* 1986;77:509-15.
24. Orgel HA, Meltzer EO, Kemp JP, Welch MJ: Clinical, rhinomanometric, and cytologic evaluation of seasonal allergic rhinitis treated with beclomethasone dipropionate as aqueous nasal spray or pressurized aerosol. *J Allergy Clin Immunol* 1986;77:858-64.
25. van As A, Chick TW, Bodman SF, Storms WW, Nathan RA, Selner JC, Koepke JW, Townley RG, Bewtra AK, Nair N, Kemp JP, Meltzer EO, Welch MJ, Prenner BM: A group comparative study of the safety and efficacy of nedocromil sodium (Tilade^R) in reversible airways disease: a preliminary report. *Eur J Respir Dis* 1986;69 (Suppl 147):143-8.
26. Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Bucholtz GA, Middleton E, Spector SL, Newton JJ, Perhach JL: A dose-response study of the bronchodilator action of azelastine in asthma. *J Allergy Clin Immunol* 1987;79:893-99.
27. Welch MJ, Orgel HA, Meltzer EO, Kemp JP, Gawchik S, Rooklin AR, Tinkelman DG: Comparison of a new sustained-release theophylline preparation, Theobeads with Theo-Dur tablets in children with asthma. *J of Asthma* 1988;25:269-274.
28. American Academy of Allergy and Immunology, Committee on Drugs: The use of inhaled medications in school by students with asthma. (Position Statement) *J Allergy Clin Immunol* 1989;84:400.
29. Welch MJ, Kemp JP, Bierman CW, Bronsky EA, Buckley RH, Bush RK, Dockhorn RJ, Falliers CJ, Mendelson L, Mingo TS, Nathan RA, Tinkelman DG: Comparison of bitolterol mesylate and isoproterenol by metered-dose inhaler for regular, long-term treatment in asthmatic children. *Pediatric Asthma Allergy and Immunol* 1989;3:27-36.
30. Kemp JP, Meltzer EO, Orgel HA, Welch MJ: Effects of albuterol and procaterol on exercise-induced asthma. *Ann Allergy* 1990;65:273-76.
31. Altman L, Findlay S, Lopez M, Lukacsko P, Morris R, Pinnas J, Ratner P, Szeffler S, Welch M: Adrenal function in adult asthmatics during long-term daily treatment with 800, 1,200, and 1,600 ug triamcinolone acetonide. *Chest* 1992;101:1250-56.
32. Welch MJ, Kemp JP, Ostrom NK, Orgel HA, Meltzer EO, Romero LT, Klinger N, McCarville S, Harrison LI: A comparative study of a new once-a-day theophylline preparation with Theo-Dur given twice daily. *J of Asthma* 1993;30(3):211-18.

PUBLICATIONS: MICHAEL J. WELCH, MD

33. Winder J, Bell T, Brodsky L, English G, LaForce C, Lopez M, Welch M, Feiss G, Tobey R, Smith J: A comparative study of intranasal triamcinolone acetonide aerosol and intranasal beclomethasone dipropionate aqueous spray in perennial allergic rhinitis. *Immunol Allergy Prac* 1993;15(7):203-9.
34. Welch MJ, Bronsky E, Findlay S, Pearlman DS, Southern DL, Storms WW, Weakley S. Long term safety of triamcinolone acetonide nasal aerosol for the treatment of perennial allergic rhinitis. *Clin Therapeutics* 1994;16(2):253-62.
35. Welch MJ, Nelson HS, Paull BR, Smith JA, Feiss G, Tobey RE: The effect of RG 12525, a new leukotriene antagonist, on pulmonary function of asthmatic adults. *Ann Allergy* 1994;72(4):348-52.
36. Konig P, Eigen H, Ellis M, Ellis E, Blake K, Geller D, Shapiro G, Welch M, Scott C. The effect of nedocromil sodium on childhood asthma during the viral season. *Amer J Resp Crit Care Med* 1995;152:1879-86.
37. Welch MJ, Levy S, Smith JA, Feiss G, Farrar JR. Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma. *Chest* 1997;112:597-606.
38. Allergy Skin Test Project Team (California State Society of Allergy Asthma and Immunology). Prevalence of sensitization to aeroallergens in California patients with respiratory allergy. *Ann Allergy Asthma Immunol* 1998;81:203-210.
39. Welch MJ. Asthma needlessly takes another life. *San Diego Union Tribune*, July 15, 1998.
40. Welch M, Bernstein D, Gross G, Kane RE, Banerji D, the Azmacort HFA Study Group. A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. *Chest* 1999;116:1304-12.
41. Nayak A, Lanier R, Weinstein S, Stampone P, Welch MJ. Efficacy and safety of beclomethasone dipropionate extrafine aerosol in childhood asthma: a 12-week, randomized, double-blind, placebo-controlled study. *Chest* 2002; 122: 1956-65.
42. Welch MJ, Nelson HS, Shapiro G, Bensch GW, Sokol WN, Smith JA, Parasuraman BM. Comparison of patient preference and ease of teaching inhaler technique for Pulmicort Turbuhaler® versus pressurized metered-dose inhalers. *Am J Managed Care*. (accepted for publication).
43. Clinical profile of children attending asthma camps. *Journal of Allergy and Clinical Immunology*. February 2004, Supplement, Volume 113, Number 2, pS275.
44. Welch MJ, Nelson HS, Shapiro G, Bensch GW, Sokol WN, Smith JA, Parasuraman BM. Comparison of patient preference and ease of teaching inhaler technique for Pulmicort Turbuhaler® versus pressurized metered-dose inhalers. *Journal of Aerosol Medicine*. 2004; 17 : 129-139.
45. Welch MJ. Treatment of Pediatric Asthma: Latest Strategies. *Understanding of the Allergic Inflammatory Continuum: From the Nose to the Lung*. Mailed CME publication, December 2005: 23-28.
48. Welch MJ. Petition Drive for Tobacco Tax: Doctors can help place initiative on November 2006 California ballot. *San Diego Physician Magazine*, April 2006, p. 33.
49. Meltzer EO, Welch MJ, Ostrom NK. Pill Swallowing Ability and training in Children 6 to 11 Years of Age. *Clinical Pediatrics* 2006;45:725-733.

ABSTRACTS: MICHAEL J. WELCH, MD

1. Kemp JP, Orgel HA, Meltzer EO, Welch MJ: Terbutaline sulfate and isoproterenol sulfate (metered-dose aerosols) in the treatment of asthma. (abstr) *Ann Allergy* 1983;51:436.
2. Asser S, Welch MJ, Hamburger RN: Correlation of a MAST profile with RAST. (abstr) *Ann Allergy* 1984;52:244.
3. Orgel HA, Kemp JP, Welch MJ, Meltzer EO: Rotahaler^R - a new mode of delivery of albuterol powder for inhalation treatment of asthma. (abstr) *J Allergy Clin Immunol* 1984;73:110.
4. Kemp JP, Pinnas JL, Tinkelman DG, Meltzer EO, Campbell SC, Orgel HA, Welch MJ, Mingo TS: Comparison of the cardiopulmonary responses of bitolterol mesylate solution (BMS) in 2 different nebulizer system. (abstr) *J Allergy Clin Immunol* 1984;73:110.
5. Romero LT, Kemp JP, Orgel HA, Meltzer EO, Welch MJ: Evaluation of procaterol liquid and tablets in the treatment of asthma in children. (abstr) *J Allergy Clin Immunol* 1984;73:132.
6. Welch MJ, Meltzer EO, Orgel HA, Kemp JP: Assessment of the correlation of rhinometry with the symptoms and signs of allergic rhinitis in children. (abstr) *J Allergy Clin Immunol* 1984;73:143.
7. Meltzer EO, Orgel HA, Kemp JP, Welch MJ: Rhinometric, clinical and cytologic evaluation of allergic rhinitis treated with beclomethasone dipropionate (BDP) as pressurized aerosol or aqueous nasal spray. (abstr) *J Allergy Clin Immunol* 1984;73:145.
8. Renard RL, Kemp JP, Meltzer EO, Welch MJ, Wessel M, Orgel HA: Duration of action of albuterol tablets in bronchial asthma - a ten hour study. (abstr) *Ann Allergy* 1984;52:228.
9. Orgel HA, Kemp JP, Welch MJ, Meltzer EO: Single-dose comparison of subcutaneous (SC), intramuscular (IM) and intravenous (IV) injectable albuterol in acute asthma. (abstr) *J Allergy Clin Immunol* 1985;75:162.
10. Welch MJ, Kemp JP, Meltzer EO, Orgel HA: Comparison of terbutaline (T) and isoetharine (I) when delivered by a closed intermittent flow nebulizer system. (abstr) *J Allergy Clin Immunol* 1985;75:162.
11. Kemp JP, Orgel HA, Meltzer EO, Welch MJ: Comparison of subcutaneous albuterol (Alb), terbutaline (Ter) and epinephrine (Epi) in acute asthma. (abstr) *J Allergy Clin Immunol* 1985;75:162.
12. Mingo T, Kemp JP, Meltzer EO, Welch MJ, Orgel HA: Bitolterol mesylate (BMS) and isoproterenol (ISO) solutions by open, continuous flow nebulization in asthma. (abstr) *J Allergy Clin Immunol* 1985;75:163.
13. Hoernke JA, Kemp JP, Meltzer EO, Welch MJ, Orgel HA: Subcutaneous albuterol (ALB) and terbutaline (TER): A single-dose, crossover comparison in acute asthma. (abstr) *J Allergy Clin Immunol* 1985;75:179.
14. Meltzer EO, Kemp JP, Welch MJ, Orgel HA: An improved delivery system for nasal beclomethasone dipropionate (BDP). (abstr) *Ann Allergy* 1985;54:354.
15. Meltzer EO, Orgel HA, Welch MJ, Kemp JP: Rhinomanometric and clinical comparison of intranasal fluocortin butyl powder (FCB) and beclomethasone dipropionate aerosol (BDP) for the treatment of perennial rhinitis. (abstr) *J Allergy Clin Immunol* 1986;77:140.

ABSTRACTS: MICHAEL J. WELCH, MD

16. Furukawa CT, Kemp JP, Shapiro GG, Meltzer EO, Pierson WE, Welch MJ, Walker SB, Orgel HA, Bierman CW: Cardiopulmonary effects of albuterol aerosol versus albuterol rotacaps versus placebo in asthmatic children. (abstr) *J Allergy Clin Immunol* 1986;77:144.
17. Welch MJ, Orgel HA, Meltzer EO, Kemp JP, Tinkelman DG: Comparison of a new sustained-release theophylline preparation, Theobeads, with Theo-Dur tablets in children with asthma. (abstr) *J Allergy Clin Immunol* 1986;77:147.
18. Orgel HA, Bronsky EA, Meltzer EO, Kemp JP, Welch MJ: Evaluation of ketotifen in children with chronic extrinsic asthma. (abstr) *J Allergy Clin Immunol* 77:148, 1986.
19. Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Lockey RF, Middleton E, Spector SL, Perhach JL, Newton JJ: A dose-response study of the bronchodilator action of azelastine (Azela) in asthma. (abstr) *J Allergy Clin Immunol* 1986;77:249.
20. Shapiro G, Furukawa C, Pierson W, Kemp J, Meltzer E, Orgel A, Welch M: Two-center, double-blind, crossover trial of procaterol (P), albuterol (A) and placebo (P1) in the prevention of exercise-induced asthma. (abstr) *Scientific Sessions of the Section on Allergy and Immunology of the American Academy of Pediatrics*, p. 21, November, 1986.
21. Jalowayski AA, Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Ostrom NK: Flow-volume curves in young children aided by a hugger pressurized system (HPS). (abstr) *J Allergy Clin Immunol* 1987;79:147.
22. Shapiro G, Furukawa C, Pierson W, Bierman W, Kemp J, Meltzer E, Orgel A, Welch M: Two-center, double-blind, crossover trial of procaterol (P), albuterol (A) and placebo (P1) in the prevention of exercise-induced asthma (EIA). (abstr) *J Allergy Clin Immunol* 1987;79:148.
23. Welch MJ, Kemp JP, Bierman CW, Bronsky E, Buckley R, Bush RK, Dockhorn R, Falliers CJ, Mendelson L, Nathan R, Tinkelman DG: Comparison of bitolterol mesylate and isoproterenol by metered-dose inhaler for regular, long-term treatment in asthmatic children. (abstr) *J Allergy Clin Immunol* 1987;79:150.
24. Orgel HA, Kemp JP, Meltzer EO, Welch MJ, Bernstein IL, Podleski WK, Prenner BM, Schoenwetter WF, Stroh JE: A tolerance study of terfenadine-pseudoephedrine combination (TERF-PE) in comparison to pseudoephedrine (PE) in patients with allergic rhinitis (AR). (abstr) *J Allergy Clin Immunol* 1987;79:189.
25. Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Bahna SL, Chervinsky P, Rachelefsky GS, Seltzer JM, Vande Stouwe RA, Valero RN: A comparison of loratadine, clemastine and placebo in patients with seasonal rhinitis. (abstr) *J Allergy Clin Immunol* 1987;79:190.
26. Novey HS, Imam AA, Orgel HA, Meltzer EO, Kemp JP, Welch MJ, Klein GL, Ziering RW, Miller, MF: Multi-allergen dipstick screening test for specific serum IgE (sIgE). (abstr) *J Allergy Clin Immunol* 1987;79:243.
27. Meltzer EO, Orgel HA, Kemp JP, Welch MJ, Perhach JL, Hemsworth GR: Azelastine for perennial allergic rhinitis (PAR): Clinical and rhinomanometric evaluation. (abstr) *Ann Allergy* 1987;58:281.
28. Tinkelman D, Falliers C, Gross G, Segal A, Southern L, Welch M, Yeates H, Gorder J, Garcia J: Triamcinolone acetonide (TA) nasal aerosol in the treatment of seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1988;81:256.

ABSTRACTS: MICHAEL J. WELCH, MD

29. Shapiro GG, Furukawa CT, Bierman CW, Pierson WE, Altman LC, Kemp JP, Meltzer EO, Orgel HA, Welch MJ: Assessment of efficacy and duration-of-action of procaterol (P), albuterol (A) and placebo (P1) for prevention of EIA using repeated treadmill exercise. (abstr) *J Allergy Clin Immunol* 1988;81:278.
30. Welch MJ, Kemp JP, Rooklin A, Gawchik SM, Meltzer EO, Orgel HA, Tinkelman DG: Diurnal variation of serum theophylline levels in children on BID Theo-Dur. (abstr) *J Allergy Clin Immunol* 1988;81:279.
31. Welch MJ, Meltzer EO, Orgel HA, Kemp JP: Treatment of seasonal allergic rhinitis (SAR) with triamcinolone acetonide (TA) nasal aerosol. (abstr) *Ann Allergy* 1988;60:166.
32. Meltzer EO, Kemp JP, Orgel HA, Ostrom NK, Welch MJ: Intranasal fluticasone propionate for treatment of seasonal allergic rhinitis. (abstr) *N Engl Reg Allergy Proc* 1988;9:387.
33. Grossman J, Bronsky E, Findlay S, Pinnas J, Rosenberg S, Rosenthal R, Tinkelman D, Weakley S, Welch M, Garcia J: WHR-5029 (triamcinolone acetonide nasal aerosol) in the treatment of perennial nonallergic rhinitis. (abstr) *N Engl Reg Allergy Proc* 1988;9:387.
34. Orgel HA, Kemp JP, Meltzer EO, Ostrom NK, Welch MJ: Severe vocal cord dysfunction in a child with asthma. (abstr) *J Allergy Clin Immunol* 1989;83:176.
35. Welch MJ, Meltzer EO, Orgel HA, Ostrom NK, Kemp JP: Evaluation of self-administered blood theophylline testing in patients on regular theophylline therapy. (abstr) *J Allergy Clin Immunol* 1989;83:180.
36. Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Ostrom NK, Gowarty HA, Cocchetto DM: A comparative study of salmeterol, albuterol and placebo via MDI in asthmatic adults. (abstr) *J Allergy Clin Immunol* 1989;83:186.
37. Ostrom NK, Kemp JP, Meltzer EO, Orgel HA, Welch MJ: Use of anterior rhinometry (AR) in assessing clinical response to a new inhaled nasal steroid in children. (abstr) *J Allergy and Clin Immunol* 1989;83:278.
38. Storms, W, Bronsky E, Findlay S, Pearlman D, Rosenberg S, Shapiro G, Southern L, Tinkelman D, Weakley S, Welch M, Zeitz H, Garcia J, Wilkinson D: Once-a-day triamcinolone acetonide (TA) nasal aerosol is effective for perennial allergic rhinitis (PAR). (abstr) *Ann Allergy* 1989;62:239.
39. Meltzer EO, Kemp JP, Orgel HA, Ostrom NK, Welch MJ: Evaluation of two formulations of flunisolide nasal spray in patients with perennial allergic rhinitis. (abstr) *Ann Allergy* 1989;62:239.
40. Welch MJ, Meltzer EO, Ostrom NK, Kemp JP, Orgel HA, Betlach CJ: Pharmacokinetic evaluation of Theo-Dur 450 mg (Theo 450) tablets given BID vs. Theo-Dur 300 mg (Theo 300) TID. (abstr) *Ann Allergy* 1989;62:267.
41. Welch MJ, Orgel HA, Meltzer EO, Bierman CW, Bronsky E, Connell JT, Lieberman PL, Nathan R, Pearlman DS, Pence HL, Slavin RG, Naadimuthu A: Intranasal fluocortin butyl in patients with perennial rhinitis: A 12-month study including nasal biopsy. (abstr) *J Allergy and Clin Immunol* 1990;85:163.
42. Ostrom NK, Welch MJ, Bronsky EA, Grossman J, Shapiro GG, Tinkelman DG, Garcia JD, Gillen MS: Clinical and rhinomanometric evaluation of triamcinolone acetonide nasal aerosol (TANA) in children with perennial allergic rhinitis. (abstr) *J Allergy and Clin Immunol* 1990;85:237.
43. Kemp JP, Meltzer EO, Orgel HA, Ostrom NK, Welch MJ: Evaluation of tolerance during 8 weeks of astemizole or terfenadine therapy in patients with perennial allergic rhinitis. (abstr) *J Allergy and Clin Immunol* 1990;85:243.

ABSTRACTS: MICHAEL J. WELCH, MD

44. Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Ostrom NK: A comparison of the bronchodilator and adverse effects of a liposome-encapsulated metaproterenol (LMS) and metaproterenol sulfate (MS) nebulizer solutions in patients with asthma. (abstr) *Ann Allergy* 1990;64:78.
45. Welch MJ, Bronsky EA, Grossman J, Shapiro GG, Tinkelman DG, Garcia JD, Gillen MS: Clinical evaluation of triamcinolone acetonide nasal aerosol in children with perennial allergic rhinitis. (abstr) *Ann Allergy* 1991;67:493.
46. Welch MJ, Meltzer EO, Kemp JP, Orgel HA, Ostrom NK, Jalowayski AA: Comparison of two different techniques for obtaining specimens for nasal cytology: Nose-blowing vs. nasal mucosa scraping. (abstr) *J Allergy Clin Immunol* 1991;87:144.
47. Jalowayski AA, Meltzer EO, Orgel HA, Welch MJ, Ostrom NK, Kemp JP: Nasal histamine levels in young children with allergic and non-allergic rhinitis and chronic otitis. (abstr) *J Allergy Clin Immunol* 1991;87:146.
48. Konig P, Eigen H, Ellis M, Ellis E, Geller D, Shapiro G, Welch M: Effect of nedocromil sodium on symptomatic respiratory infection (SRI)-induced asthma exacerbations. (abstr) *Amer Rev Resp Dis* 1992;145:A421.
49. Ostrom NK, Welch MJ, Klinger N, Romero L, McCarville S, and Harrison L: Comparison of a new once-daily theophylline preparation with Theo-dur (T) given BID. (abstr) *J Allergy Clin Immunol* 1992;89:191.
50. Feiss G, Welch M, Meltzer E, Alderfer V, Smith J, Tobey R: The predictive value of nasal eosinophilia for therapeutic response to intranasal corticosteroid treatment in perennial allergic rhinitis (PAR). (abstr) *J Allergy Clin Immunol* 1992;89:209.
51. Konig P, Eigen H, Ellis M, Ellis E, Geller D, Scott C, Shapiro G, Welch M: Nedocromil sodium prevents increased asthma symptoms in children whose asthma is exacerbated during the viral season. (abstr) *J Allergy Clin Immunol* 1992;89:235.
52. Welch M, Feiss G, Nelson H, Paull B, Smith J, Tobey R: The effect of RG 12525, a novel leukotriene antagonist, on the pulmonary function of asthmatics. (abstr) *J Allergy Clin Immunol* 1992;89:236.
53. Orgel HA, Meltzer EO, Welch MJ, Banov C, Georgitis J, Morris R, Pedinoff A, Storms, W: Comparison of intranasal therapy with beclomethasone dipropionate (BDP) vs. cromolyn sodium (CS) vs. placebo (P) in children with seasonal allergic rhinitis. (abstr) *J Allergy Clin Immunol* 1992;89:303.
54. Kemp JP, Meltzer EO, Welch MJ, Ostrom NK, Orgel HA, Robinson RE: Effectiveness of MDL 26,024GO in suppressing skin reactivity to antigen challenge. (abstr) *J Allergy Clin Immunol* 1993;91:379.
55. Jalowayski AA, Meltzer EO, Orgel HA, Kemp JP, Ostrom NK, Welch MJ, Basch C, Bynum L, Munchi A. Anterior rhinomanometry in allergic rhinitis patients treated with flunisolide, beclomethasone dipropionate or placebo nasal spray. (abstr) *J Allergy Clin Immunol* 1994;93:164.
56. Ostrom N, Welch M, Morris R, Rosen J, Wanderer A, Dockhorn R, Tinkelman D, Vandewalker M, Ziering W: Evaluation of ebastine (Eba), a new non-sedating antihistamine, in children with seasonal allergic rhinitis (SAR). (abstr) *J Allergy Clin Immunol* 1994;93:163.

ABSTRACTS: MICHAEL J. WELCH, MD

57. Wood R, Adinoff A, Bell T, Bronsky E, Bukstein D, Geller D, Klimas J, Kraemer M, Lemen R, Mellon M, Pearlman D, Smith T, Szeffler S, Thomas M, Welch M: 0.5% Nebulized nedocromil sodium reduces asthma symptoms in children 2-4 years of age. (abstr) *J Allergy Clin Immunol* 1994;93:260.
58. Welch MJ, Segal A, Tobey R, Szeffler S, Simons FE (a subcommittee of the AAAI Committee on Drugs): Inhaled corticosteroids (ICS) and viral infections. (abstr) *J Allergy Clin Immunol* 1994;93(1):198.
59. The impact of budesonide inhalation suspension on symptom-free days and use of asthma-related services in infants and young children. (abstr) *J Allergy Clin Immunol*;1999.
60. Inhaled corticosteroid-induced growth retardation in asthmatic children in a “real world setting. (abstr) *J Allergy Clin Immunol* 1999;103:1.
61. Welch MJ, Kane RE, Fite T, Banerji D. Azmacort HFA (triamcinolone acetonide) inhalation aerosol administered once daily is effective in the treatment of mild and moderate persistent asthma. (abstr) *J Allergy Clin Immunol* 2000;105;S11.
62. Welch M, Kalberg C, Edwards L, Johnson M, Rickard K. Low-dose inhaled fluticasone propionate provides greater asthma symptom control as compared with oral zafirlukast in patients with persistent asthma. (abstr) *J Allergy Clin Immunol* 2000;105;S14.
63. Welch MJ, Gallet C, Ostrom NK, Meltzer EO. Evaluation of efficacy and patient preference of albuterol delivered via the PocketChamber (PC) versus the AeroChamber (AC Plus) in patients with asthma. (abstr) *J Allergy Clin Immunol* 2003;111;S145.
64. Ostrom NK, Meltzer EO, Welch MJ. At what age can a child swallow a pill? (abstr) *J Allergy Clin Immunol* 2005; 115: S42.

PUBLICATIONS, GENERAL REVIEWS: MICHAEL J. WELCH, MD

1. Welch MJ: Diseases of cilia. *West J Med* 1984;141:509.
2. Welch MJ, Kemp JP: Allergy in children. *Primary Care* 1987;14(3):575.
3. Maternal and Child Health Nursing, Section on Juvenile Rheumatoid Arthritis and Rheumatic Fever. Editorial assistance with 7th Edition. School of Nursing, College of Health and Human Services, San Diego State University, San Diego, California, 1990.
4. Welch MJ, Heiner D, editors: Epitomes in allergy and immunology. *West J Med* 1991;154:455-61.
5. Welch MJ: New generation antihistamines. *West J Med* 1991;154:455.
6. Kemp JP, Welch MJ: Metered dose inhalers: a valuable tool for asthma self-management. *Sharp HEALTH Newsletter*, 1993.
7. Welch MJ: Topical nasal steroids for allergic rhinitis. *West J Med* 1993;158:616.
8. Welch MJ, Meltzer EO: Allergic rhinitis: a disease for all seasons. *J Am Acad Phys Assist* 1993;6:553-60.
9. Welch MJ. Inhaled steroids and severe viral infections. *J Asthma* 1994;31(1):43-50.
10. Welch MJ. Latex allergy: Children's Hospital, San Diego - 12/17/93. *Ped Asthma, Allergy Immunol* 1994;8(4):245-7.
11. Welch MJ. Caution with inhaled corticosteroids in childhood asthma. *West J Med* 1995;163:371-2.
12. MDI technique can make the difference in asthma. *Ped News* 1998;10:50-53.
13. Welch MJ. Inhaled corticosteroids and growth in children. *Ped Annals* 1998;27(11):752-58.
14. Welch MJ. New medications offer options. *New York Times Magazine (Suppl) From Cause to Cure*, March 28, 1999.
15. Welch MJ. Breathing easy. *Parenting* 1999;141-148.
16. Welch, MJ. Allergy attack. *Good Housekeeping* 1999;78-81.
17. Welch MJ. Challenges in evaluating controller asthma therapy in children. *J Allergy Clin Immunol* 2000;106:S165-70.
18. Reagan E. Review of *Guide to Your Child's Allergies and Asthma: Breathing Easy and Bringing Up Healthy, Active Children* edited by M.J. Welch, MD. *Becoming Family: Helping to Build Stronger Families* 2000;1:73-4.
19. Welch MJ. Inhaled corticosteroids and growth in children. *California Pediatrician* 2000;Fall:39-40.
20. Welch MJ. Challenges in evaluating controller asthma therapy in children. *J Allergy Clin Immunol* 2000;106:S165-70.
21. Welch MJ. Patient and caregiver perspectives on the pharmacologic treatment of asthma and its impact on asthma management. *Living With Asthma: Current Perspectives in the Management of Pediatric Asthma*. Monograph based on a symposium held in San Francisco, California, October 21, 2001.
22. Welch MJ, Smaldone GC. Effective use of nebulizer systems in pediatric asthma therapy. *ADVANCE for Physician Assistants*, 2002;10:52-61.
23. Stoloff S, Blessing-Moore J, Chipps B, Hitchcock B, Jones C, Ostrom NK, Welch MJ. Optimizing Care of Children with Persistent Asthma: Assessing Severity and Monitoring Control. *Dialogues in Clinical Practice*, an ongoing CME series 2006; Vol 1:1-6.
24. Welch MJ, Carlson AM, Larson D, Fena P. Clinical profile, health-related quality of life, and asthma control in children attending US asthma camps. *Ann Allergy Asthma Immunol*. 2007;99:496-501.

PUBLICATIONS, GENERAL REVIEWS: MICHAEL J. WELCH, MD

25. Welch MJ. Nebulization Therapy for Asthma: A Practical Guide for the Busy Pediatrician. *Clinical Pediatrics* 2008; 47: 744-56.
26. Welch MJ (guest editor), Bernstein DI, Stoloff SW, Chipps BE, Gelfand EW. The current and future state of asthma treatment. *Clinical Cornerstone* 2008; 8 (no 4): 8.
27. Welch MJ. New NHLBI Guidelines for Asthma – Is Anything Really New? *Audio-Digest Pediatrics* 2010; Vol. 56: Issue 1.
28. Welch MJ, Williams P, Farber HJ, Jones CA. Hot Topics: Asthma Gadgets 2010 [online course]. *PediaLink. American Academy of Pediatrics*. May 11, 2010-2013. www.pedialink.org/cme/asthmagadgets. Accessed June 10, 2010.
29. Welch MJ, Martin ML, Williams PV, Gallet CL, Miller MC, Bennett AV, May RW, Lampl KL, Ramachandran S. Evaluation of Inhaler Device Technique in Caregivers of Young Children with Asthma. *Pediatric Allergy Immunology and Pulmonology*; 2010: 23;113-120.
30. Welch MJ. Clean air and AB 32 help to keep us healthy. *San Diego Union Tribune*. Published August 29, 2012.

CHAPTERS IN BOOKS: MICHAEL J. WELCH, MD

1. Stiehm ER, Welch MJ, Rosenblatt HR, Peerless AP: Pediatric rheumatology, in T. Spiegel, editor: Practical Rheumatology. New York, 1983, John Wiley and Son, pp. 295-335.
2. Welch MJ, Carson DA: Inborn errors of metabolism, in M.E. Gershwin and D.L. Robbins, editors: Musculoskeletal Diseases of Children: A Textbook of Pediatric Rheumatology. New York, 1983, Grune and Stratton, Inc., pp. 369-79.
3. Meltzer EO, Orgel HA, Welch MJ, Kemp JP: Nonpharmacologic approaches to the management of asthma, in Tinkelman DG, Falliers CJ, Naspitz CK (editors): Childhood asthma: pathophysiology and treatment. New York, 1987, Marcel Dekker, Inc., pp. 281-326.
4. Welch MJ, Ostrom NK, Meltzer EO, Orgel HA. Nonpharmacologic approaches to the management of asthma. In: Tinkelman DG, Falliers CJ, Naspitz CK (eds): Childhood asthma: pathophysiology and treatment. New York, 1993, Marcel Dekker, Inc., pp. 457-95.
5. Meltzer EO, Welch MJ. Adverse effects of H₁-receptor antagonists in the central nervous system. In: Histamine and H₁-Receptor Antagonists in Allergic Disease, Simons FER (ed), New York, Marcel Dekker, 1996;pp. 357-81.
6. Welch MJ, Meltzer EO, Simons FER. Antihistamines: Potential Adverse Effects. Central Nervous System. In: Histamine and H₁-Antihistamines in Allergic Diseases, Simons FER (ed), New York, Marcel Dekker, 2002; pp.337-388

BOOKS: MICHAEL J. WELCH, MD

1. Welch M. Guide to Your Child's Allergies and Asthma. New York: Villard; 2000. 191pages. (This book received the 2001 National Health Information Awards- Silver Award for Patient Education.)
2. Welch M. Allergies and Asthma: What Every Parent Needs to Know, 2nd Edition. American Academy of Pediatrics; 2011. 174 pages.

MEDIA: MICHAEL J. WELCH, MD

1. "Allergy & Asthma." For a Healthier You, KSDO/AM Talk Show. San Diego, California, April 2, 1994.
2. "Health Issues in the School: Asthma." Panel Coordinator, KPBS Television, 8-9am, March 30, 1996.
3. "The Scope and Impact of Asthma in Children of San Diego." Community Health Education, The Gerry Graf Show, Instructional Television Program, KPBS Television, San Diego, California, 8-10am, July 27, 1996.
4. "Allergies." Community Health Education, The Gerry Graf Show, ITV Program, KPBS Television, San Diego, California, March 29, 1997.
5. "Allergies and Asthma." Community Health Education, The Gerry Graf Show, ITV Program, KPBS Television, San Diego, California, April 25, 1998.
6. "Asthma." Community Health Education, The Gerry Graf Show, ITV Program, KPBS Television, San Diego, California, April 17, 1999.
7. "Environmental Allergies and Asthma." 'These Days' Program, KPBS, San Diego, California, September 22, 1999.
8. "New Therapies in Allergic Disease." Community Health Education, The Gerry Graf Show, ITV Program, April 8, 2000, Carlsbad, California.
9. "How the Living Environment Affects an Allergy Sufferer." WebMD iXL-Live™ internet chat program, Friday, June 9, 2000.
10. "School Health USA: Asthma and Allergies." UCSD-TV: MDTV internet and cable program, April 18, 2002.
11. "School Health USA: Asthma and Allergies." UCSD-TV: MDTV internet and cable program, April 19, 2002.
12. "The KFMB Health Hour." 760 KFMB radio station, San Diego, California, June 28, 2003.
13. "Using Asthma Medications Correctly." (Video demonstration of how to use inhaled asthma medications correctly). California Asthma Public Health Initiative (CAPI) online CME course, www.betterasthmacare.org.
14. "Pediatric Asthma", KUSI television station, San Diego, California, September 21, 2006.
15. American Lung Association – 2007 Asthma Walk Promotion. KUSI Television, San Diego, California, August 23, 2007.
16. "UCSD Health Matters-Asthma." UCSD Educational TV, San Diego, California, June 20, 2008.
17. Welch M. Does a Diagnosis Mean Fido and Fluffy have to go? Retrieved March 22, 2011, from <http://3boysandadog.com/2011/03/children-allergies-and-family-pets/>
18. Welch M. Children and Food Allergies. Retrieved May 6, 2011, from <http://dadofdivas.com/guest-post-2/children-and-food-allergies>
19. Welch M. Children & Food Allergies: How You can Help Manage Your Child's Allergies. Genesee Valley Parent Magazine April 2011. Retrieved September 2011, from <http://gvparent.com/articles/k/11-04-allergies.html>.
20. Laser Treatments to Cure Food Allergy Lack Scientific Evidence. The Food Allergy & Anaphylaxis Network Newsletter August – September – October 2012. www.foodallergy.org.

RESEARCH: MICHAEL J. WELCH, MD

1. A comparative efficacy and safety study of procaterol HCl and metaproterenol So₄ tablets in pediatric patients with reversible bronchial airway obstruction.
2. A 10-hour duration-of-action study of albuterol tablets in bronchial asthma.
3. A double-blind, crossover study of the therapeutic equivalence of liquid and tablet formulations of procaterol HCl in pediatric patients with reversible bronchial airway obstruction.
4. A dose-ranging study of bitolterol mesylate solution in a closed system nebulizer with an actuator valve.
5. A dose-ranging study of the cardiopulmonary effects of an inhaled powder formulation albuterol (Rotacap with Rotahaler) in patients with reversible obstructive airway disease.
6. A clinical, pulmonary and pharmacokinetic evaluation of Theo-Dur sprinkle in asthmatic children.
7. A double-blind, placebo-controlled long term (6 month) study of terfenadine tablets in the treatment of allergic rhinitis/conjunctivitis.
8. Comparative study of tixocortol pivalate and a placebo inhaler in the treatment of patients with asthma.
9. Dose-ranging study of bitolterol mesylate solution in an open continuous flow nebulizer system.
10. Comparative study of tixocortol pivalate nasal inhaler, beclomethasone nasal inhaler and a placebo nasal inhaler in the treatment of patients with allergic rhinitis.
11. A comparative efficacy and safety study of procaterol HCl and metaproterenol SO₄ syrup in pediatric patients with reversible bronchial airway obstruction.
12. Dose-ranging study of bitolterol mesylate metered-dose inhaler in pediatric asthmatic patients.
13. Comparative study of the efficacy of beclomethasone dipropionate as an aqueous nasal spray and a pressurized aerosol nasal spray in the treatment of seasonal rhinitis.
14. A single dose, double-blind, placebo-controlled, cross-over study of the cardiopulmonary effects of parenteral preparations of albuterol in patients with chronic reversible obstructive airway disease.
15. A study of the safety and efficacy of terfenadine suspension in children in the treatment of acute pollenosis.
16. A double-blind, placebo-controlled evaluation of acrivastine in the treatment of seasonal allergic rhinitis.
17. Comparative trial of azelastine, albuterol sulfate and placebo in bronchial asthma.
18. A one year open study of the safety, tolerance and efficacy of fluocortin butyl in patients with perennial rhinitis.
19. The comparison of ketotifen syrup and placebo in the prophylaxis of bronchial asthma in children.
20. A long-term study of terfenadine tablets in the treatment of nasal allergy.
21. An open study of long-term acrivastine safety and efficacy in patients with allergic rhinitis or allergic dermatosis.
22. A one month comparison of bitolterol mesylate and isoproterenol solution administered from a continuous flow nebulizer to asthmatic patients.
23. Comparison of the cardiopulmonary effects of single doses of injectable albuterol and terbutaline in the treatment of acute asthma.

RESEARCH: MICHAEL J. WELCH, MD

24. Double-blind group trial comparing nedocromil sodium and placebo in the management of bronchial asthma.
25. Bitolterol mesylate metered-dose aerosol three month study in pediatric patients with asthma.
26. A placebo-controlled, multicenter study of the efficacy and safety of procaterol metered-dose aerosol in out-patients with reversible airway obstruction.
27. An open dose-response study of the cardiopulmonary effects of subcutaneous albuterol, epinephrine and terbutaline in the treatment of acute asthma.
28. A comparative patient preference study of three nasal adapters for beclomethasone aerosol nasal spray.
29. A six week comparative evaluation of subcutaneous human IgE pentapeptide and placebo in the treatment of allergic rhinitis.
30. The efficacy and safety of tiprinast when administered as a nasal spray to subjects experiencing allergic rhinitis.
31. A double-blind, placebo-controlled study of the efficacy of beclomethasone dipropionate aqueous nasal spray.
32. A comparison of mequitazine with brompheniramine in the treatment of seasonal allergic rhinitis.
33. A one week dose ranging trial of SKF 93944 in seasonal allergic rhinitis patients.
34. A long term evaluation of ketotifen in asthmatic children.
35. A six month study of the cardiopulmonary responses to procaterol delivered by a metered-dose inhaler in adult asthma.
36. An open label evaluation of the continued clinical response to terfenadine 60 mg tablets in the treatment of seasonal allergic rhinitis.
37. A double-blind, parallel study of the efficacy of powdered albuterol delivered by rotacap vs. aerosolized albuterol delivered by metered-dose inhaler in children with chronic reversible obstructive airway disease.
38. An eight week evaluation of acrivastine plus pseudoephedrine in patients with allergic rhinitis.
39. A placebo-controlled evaluation of the safety and bronchodilating activity of single doses of 2, 4, 8, 12 or 16 mg of azelastine in patients with bronchial asthma.
40. A comparative safety and efficacy study of bitolterol mesylate and isoproterenol sulfate delivered by a metered-dose aerosol in pediatric patients with bronchial asthma.
41. A comparative efficacy, safety and theophylline pharmacokinetic study of Theo-Dur and TheoBeads in pediatric asthma patients.
42. A double-blind, placebo-controlled, crossover evaluation of the safety and efficacy of azelastine in the treatment of perennial rhinitis.
43. Comparison of the relative effectiveness of aerosol procaterol, albuterol and placebo in the prevention of exercise-induced asthma.
44. A double-blind, placebo-controlled study of the effects of a new formulation of tiprinast meglumine nasal spray in patients with seasonal allergic rhinitis.
45. A double-blind, comparative study of the efficacy and safety of nedocromil sodium in the management of asthma.
46. Evaluation of the safety and efficacy of acute and chronic administration of azelastine in asthmatic patients subjected to an exercise challenge.
47. Evaluation of AccuLevel theophylline spiked sample test precision.

RESEARCH: MICHAEL J. WELCH, MD

48. A one-year, open study of the safety, tolerance and efficacy of azelastine in the treatment of perennial rhinitis.
49. Acrivastine plus pseudoephedrine HCl, acrivastine, pseudoephedrine HCl and placebo in six to twelve year old patients with allergic rhinitis.
50. A dose ranging study of bitolterol mesylate solution in pediatric asthma patients using a continuous flow, open nebulizer system.
51. A double-blind, placebo- and clemastine-controlled evaluation of loratadine in patients with seasonal allergic rhinitis.
52. A comparative efficacy study of two formulations of flunisolide nasal spray in patients with perennial allergic rhinitis.
53. A three-month, double-blind, placebo-controlled study of the safety and efficacy of 2, 4, 6 or 8 mg of azelastine in patients with asthma.
54. A twelve-week, double-blind, parallel group, multicenter phase III study to compare the efficacy and safety of flurbiprofen with that of aspirin in the treatment of patients with active juvenile rheumatoid arthritis, followed by a thirty-six week open label treatment period to evaluate long-term safety and tolerance of flurbiprofen.
55. A double-blind study of triamcinolone acetonide nasal aerosol and placebo in patients with seasonal allergic rhinitis.
56. LY171883 vs. placebo in asthmatics using beta-agonist therapy.
57. Three month study of the comparative efficacy and safety of procaterol and isoproterenol aerosol inhalation in pediatric outpatients with reversible bronchial airway obstruction.
58. The effect of one week of oral AHR-11325 (10, 25 and 50 mg), brompheniramine (4 mg) or placebo in allergic rhinitis patients.
59. A comparison of bitolterol and metaproterenol administered to bronchial asthmatic patients from a metered-dose inhaler.
60. A study of the efficacy and safety of loratadine in patients 6-12 years of age with seasonal allergic rhinitis.
61. A parallel group study comparing the efficacy and safety of albuterol Rotacaps^R (200 mcg) vs. albuterol aerosol (180 mcg) administered to children ages 4-11 years with chronic reversible obstructive airway disease (asthma).
62. A comparative study of triamcinolone acetonide and flunisolide nasal solution sprays in subjects with seasonal allergic rhinitis.
63. A one-month study of the safety and efficacy of procaterol syrup in 2-6 year old children with reversible bronchial airway obstruction.
64. A tolerance study of terfenadine-pseudoephedrine combination tablets in comparison to pseudoephedrine tablets in patients with seasonal or perennial allergic rhinitis.
65. A placebo-controlled comparison of azelastine, controlled release theophylline and combined azelastine-theophylline therapy in the management of patients with nonsteroid dependent bronchial asthma.
66. An open, long-term study of the safety and efficacy of cetirizine in chronic allergic diseases.
67. A crossover comparison of the duration of effectiveness of aerosol procaterol and albuterol in the prevention of exercise-induced asthma.
68. The role of ketotifen as an additive therapy in the prophylactic treatment of moderate asthma.

RESEARCH: MICHAEL J. WELCH, MD

69. A controlled study of triamcinolone acetonide nasal aerosol and placebo in patients with perennial rhinitis.
70. The effects of rocastine, chlorpheniramine (4 mg) or placebo in adults with symptomatic seasonal allergic rhinitis.
71. A comparison of the therapies for children with chronic asthma of inhaled albuterol plus BID oral theophylline to inhaled albuterol plus QID inhaled beclomethasone to inhaled albuterol plus BID oral theophylline and QID inhaled beclomethasone.
72. A parallel study of the effectiveness and safety of azelastine, clemastine and placebo for the management of perennial allergic rhinitis.
73. A comparison of terfenadine 60 mg BID, chlorpheniramine 4 mg TID and placebo in patients with perennial allergic rhinitis.
74. An open-label, long-term study of triamcinolone acetonide nasal aerosol in patients with perennial rhinitis.
75. LY171883 vs. placebo in theophylline-controlled asthmatics.
76. A comparison of the safety and efficacy of cromolyn sodium 4% nasal solution and terfenadine tablets in the treatment of allergic rhinitis.
77. A safety evaluation of metaproterenol sulfate liposome inhalant concentrate.
78. A 12-week, placebo-controlled trial of oxitropium bromide for asthma.
79. A double-blind study of triamcinolone acetonide nasal aerosol and placebo in patients with perennial rhinitis.
80. An open-label, one month study of procaterol syrup in young children with reversible bronchial airway obstruction.
81. Comparison of efficacy and side effects of enprofylline, theophylline and placebo in patients with mild to moderate asthma.
82. The clinical evaluation of the safety and efficacy of astemizole as compared to terfenadine in the treatment of perennial allergic rhinitis.
83. Comparison of cetirizine with chlorpheniramine in the treatment of seasonal allergic rhinitis in children, 6-11 years of age.
84. A long-term, safety study of triamcinolone acetonide nasal aerosol in patients with perennial rhinitis.
85. Dose-ranging study of the comparative efficacy and safety of tazifylline and placebo in patients with allergic seasonal rhinitis.
86. A pharmacokinetic and pharmacodynamic study of metaproterenol in asthmatic children.
87. A study evaluating the efficacy and safety of daily administration of 100, 400 and 1600 mcg aqueous fluticasone propionate vs. placebo in patients with allergic seasonal rhinitis.
88. A placebo-controlled comparison of the effectiveness and safety of azelastine and oral albuterol sulfate in the management of symptomatic bronchial asthma.
89. A parallel study of intranasal ipratropium bromide nasal spray versus placebo in nonallergic perennial rhinitis.
90. Placebo-controlled evaluation of the protective activity of azelastine in methacholine-induced bronchoprovocation.
91. An evaluation of two formulations of flunisolide nasal spray in patients with perennial allergic rhinitis.
92. A three-month study of the efficacy and safety of procaterol and metaproterenol in pediatric patients with asthma.

RESEARCH: MICHAEL J. WELCH, MD

93. Multiple dose pharmacokinetic evaluation of Theo-Dur 450 mg tablets in adult asthmatic patients.
94. A study of triamcinolone acetonide nasal aerosol and placebo in pediatric patients with perennial allergic rhinitis.
95. A safety and efficacy evaluation of several single doses of salmeterol hydroxynaphthoate in asthmatic patients.
96. A comparison of terfenadine 60 mg BID and 120 mg BID in the treatment of patients with seasonal allergic rhinitis who are less than optimal responders to terfenadine 60 mg BID.
97. A study comparing two single doses of BMY 26517-31 to placebo in patients with exercise-induced bronchospasms.
98. A dose-ranging study of twice-daily intranasal administration of aqueous fluticasone propionate in adult patients with seasonal allergic rhinitis.
99. A single dose, duration-of-action comparative study of pirbuterol, albuterol and placebo aerosols.
100. A comparison of azelastine and clemastine fumarate to placebo in the management of perennial allergic rhinitis.
101. An albuterol-controlled, 12-week study of procaterol TID in outpatients with reversible bronchial airway obstruction.
102. A controlled study of HEPP (IgE pentapeptide) nasal solution as treatment of seasonal allergic rhinitis.
103. A comparison of the efficacy and duration-of-action of two different albuterol delivery systems: the DiskhalerTM vs. the Rotahaler^R.
104. A placebo-controlled park study of Rynatan tablets in subjects with allergic rhinitis.
105. A placebo-controlled park study of Rynatan suspension in subjects with allergic rhinitis.
106. A parallel comparison of intranasal atrovent nasal spray versus placebo in nonallergic perennial rhinitis.
107. Placebo-controlled comparison of azelastine and oral albuterol sulfate in the management of symptomatic bronchial asthma.
108. A placebo-controlled study of once- versus twice-daily intranasal fluticasone propionate for patients with seasonal allergic rhinitis.
109. A tablet comparison study of Theo-Dur 300 mg TID and 450 mg BID.
110. Study of adrenal function in adult asthmatics during chronic treatment with 800, 1200 and 1600 mcg aerosolized triamcinolone acetonide.
111. A clinical trial of four dosage regimens of salmeterol hydroxynaphthoate versus placebo in patients with chronic reversible obstructive airways disease.
112. Intranasal ipratropium bromide nasal spray versus placebo in allergic perennial rhinitis.
113. An open-label clinical evaluation of Uni-Dur^R, a twenty-four hour theophylline sustained release tablet.
114. BMY-26517/placebo group study of patients with chronic, asthma requiring bronchodilator therapy.
115. Pentigetide for injection an open label safety study.
116. A comparison of oral theophylline and aerosol beclomethasone dipropionate therapy of asthma.
117. A placebo-controlled assessment of flunisolide nasal spray as an adjunct in the treatment of sinusitis.

RESEARCH: MICHAEL J. WELCH, MD

118. A placebo-controlled trial to evaluate once-daily versus twice-daily intranasal administration of aqueous fluticasone propionate versus beclomethasone dipropionate in patients with perennial allergic rhinitis.
119. A parallel group study of the safety, efficacy and duration-of-action of azelastine, albuterol sulfate repetabs and placebo tablets in subjects with chronic asthma.
120. The clinical evaluation of the safety and efficacy of astemizole suspension in the treatment of seasonal allergic rhinitis in children.
121. A placebo-controlled study to investigate RG-3988 aerosol in theophylline-dependent asthmatics.
122. A comparative study of the efficacy and safety of nedocromil sodium nebulizer solution vs. placebo in the management of patients with reversible airway obstruction.
123. A comparison of the effectiveness and safety of azelastine, chlorpheniramine maleate, and placebo tablets in the management of patients with seasonal allergic rhinitis.
124. A placebo-controlled study of aqueous fluticasone propionate given once-versus twice-daily versus aqueous beclomethasone dipropionate versus placebo in adult and adolescent patients with seasonal allergic rhinitis.
125. A comparison of inhaled ipratropium bromide placebo when each is added to inhaled albuterol for maintenance treatment of patients with asthma.
126. A study to evaluate the safety and efficacy of terfenadine suspension in the prophylactic treatment of children ages 6 through 12 with allergic asthma who experience seasonal exacerbations.
127. A stratified, group-sequential study to compare the efficacy of rising doses of MK-571 to placebo in patients with chronic stable asthma.
128. A study of cetirizine in the treatment of seasonal allergic rhinitis in children 6 to 11 years of age.
129. An evaluation of the therapeutic effect of oral ICI 204,219 on bronchial asthma.
130. Loratadine versus pseudoephedrine versus the combination versus placebo as treatment for seasonal allergic rhinitis.
131. A study of aqueous fluticasone propionate given once daily versus placebo in pediatric patients with seasonal allergic rhinitis.
132. A dose-ranging and duration-of-action trial of azelastine nasal spray (0.1%) in subjects with seasonal allergic rhinitis.
133. A comparative study of nedocromil sodium nebulizer solution versus placebo in children (6-12 years of age) with asthma induced by symptomatic respiratory infections.
134. A study of the comparative efficacy and safety of procaterol and albuterol aerosol in pediatric patients with reversible airway obstruction.
135. A clinical and electrocardiographic study of potential pharmacodynamic interactions of salmeterol hydroxynaphthoate and theophylline in patients with chronic reversible obstructive airways disease.
136. Open-label comparative safety and efficacy study of two theophylline formulations: TCR1 and Theo-Dur^R.
137. Auranifin versus placebo in the treatment of steroid-dependent asthma.
138. Crossover, dose-ranging study of inhaled ipratropium bromide and placebo in children with chronic asthma.
139. Evaluation of the applicability and sensitivity of the medical outcomes study short form 36 plus disease-specific questions to patients with asthma or allergic rhinitis.

RESEARCH: MICHAEL J. WELCH, MD

140. A double-blind, randomized, parallel study comparing the safety and efficacy of terfenadine 60 mg BID, astemizole 10 mg QD and placebo in the treatment of seasonal allergic rhinitis in an "in the park" setting.
141. Comparison of duration-of-action and side effects of metaproterenol sulfate liposome (metasome) and alupent in asthmatics.
142. Evaluation of flunisolide nasal spray as an adjunct in the treatment of sinusitis.
143. A clinical trial of twelve week courses of salmeterol hydroxynaphthoate versus albuterol versus placebo in patients with chronic reversible obstructive airways disease.
144. A pilot study of terfenadine 60 mg BID and placebo in the treatment of patients with mild to moderate atopic asthma who demonstrate a positive challenge to methacholine and exercise.
145. A trial to assess the safety and tolerability of azelastine nasal spray (0.1%) in subjects with perennial allergic rhinitis.
146. Histamine levels in nasal mucosa scraping of normal children and those with rhinitis and chronic otitis media.
147. A clinical study comparing the efficacy of intranasal triamcinolone acetonide spray and bioequivalent doses of intramuscular triamcinolone acetonide in patients with seasonal rhinitis.
148. A double-blind study to compare the efficacy of three doses of MK-0679 to placebo in patients with chronic stable asthma.
149. Auranifin vs. placebo in the treatment of steroid-dependent asthma.
150. An efficacy trial of comparable plasma concentrations of triamcinolone acetonide given by inhalation (Azmacort) and intramuscular injection (Kenalog-40) in the management of moderate asthmatics.
151. Beclomethasone dipropionate vs. cromolyn vs. placebo, effects in children with seasonal allergic rhinitis.
152. A parallel group comparison of the efficacy and safety of fluticasone propionate aqueous nasal spray 200 mcg QD versus terfenadine 60 mg BID versus placebo in patients with seasonal allergic rhinitis.
153. A double-blind, ascending, single-dose study of formoterol suspension aerosol vs. placebo in normal volunteers.
154. Pemirolast/placebo double-blind study of patients with a history of chronic, stable, reversible asthma requiring bronchodilator therapy.
155. Double-blind, crossover evaluation of repirinast (Bay u 2372) compared to placebo in attenuation of antigen-induced bronchospasm
156. Efficacy of SCH 37370 in the treatment of mild to moderate asthma.
157. A comparative study of the efficacy and safety of temafloxacin 600 mg BID and ceclor 500 mg Q8H in the treatment of patients with bacterial infection of the lower respiratory tract.
158. A placebo-controlled, double-blind, single-dose study of the effect of RG 12525 on pulmonary function in asthmatics.
159. Liposomal albuterol sulfate aerosol. Escalating dose tolerance safety and efficacy trial.
160. A placebo-controlled study of the efficacy and safety of aqueous fluticasone propionate given twice daily versus placebo for four weeks in patients with perennial non-allergic rhinitis.

RESEARCH: MICHAEL J. WELCH, MD

161. A cohort epidemiologic study to determine the effect of one year of triamcinolone acetonide on alternate day prednisone or alternate day prednisone plus inhalation or non-steroidal antiasthmatic therapy on growth patterns of asthmatic children.
162. Bioavailability and pharmacokinetic study of two formulations of flunisolide nasal spray in seasonal allergic rhinitis patients.
163. A comparative study of the safety and efficacy of cetirizine or placebo in patients with seasonal allergic rhinitis and asthma.
164. A study to determine the efficacy and safety of three different doses of budesonide delivered by the Turbuhaler to pediatric patients with glucocorticosteroid treated asthma.
165. A study of a single dose of 50 mcg salmeterol hydroxynaphthoate aerosol vs. 180 mcg albuterol aerosol vs. placebo in adolescents and adults with exercise induced bronchospasm.
166. Theophylline sprinkle extended release capsules, dose titration for 6-12 year olds.
167. A comparative trial of two doses of inhaled fluticasone propionate vs. placebo in patients aged 4 to 11 years with mild to moderate chronic asthma.
168. A tolerance study of aqueous film-coated 120 mg terfenadine tablets and placebo tablets administered QD in patients with seasonal or perennial allergic rhinitis.
169. A randomized placebo-controlled comparative study of the efficacy and safety of nedocromil sodium 0.5% nebulizer solution TID in the treatment of children 2-4 years of age with bronchial asthma.
170. A double-blind trial to examine the use of a rescue medication during 6 weeks of astemizole or terfenadine in patients with seasonal allergic rhinitis.
171. A placebo-controlled study of the efficacy and safety of two doses of budesonide delivered by the Turbuhaler to patients with chronic asthma not well controlled on non-steroid therapy.
172. Dose-ranging: six weeks' therapy with oral ICI 204,219 in bronchial asthma.
173. A comparison of long-term prophylaxis with cefuroxime axetil versus placebo in preventing an acute episode of sinusitis in patients with a history of recurrent sinusitis.
174. A comparison of long-term maintenance therapy with cefuroxime axetil versus placebo after treatment of an episode of sinusitis in patients with a history of recurrent sinusitis.
175. Clinical study to evaluate the Biotrack 516 system for therapeutic monitoring of theophylline.
176. Clinical acceptability evaluation of bitolterol inhalation solution 0.2%.
177. A comparison of the effects of astemizole/pseudoephedrine, terfenadine/pseudoephedrine and placebo on sleep and nasal congestion in subjects with seasonal allergic rhinitis.
178. A study to compare the effects of high and low oral doses of ICI 204,219 with placebo given over 6 weeks to patients with asthma.
179. A double-blind comparison of ebastine and placebo in adult patients with seasonal allergic rhinitis.
180. An open-label, long term safety study of ebastine in patients with seasonal allergic rhinitis.
181. MK-0591 Multicenter dose ranging study in patients with moderate asthma.
182. A comparison of budesonide dry powder and placebo in the treatment of children with perennial allergic rhinitis.
183. A placebo-controlled pilot study of the efficacy and safety of single intravenous doses of interleukin-1 receptor antagonist in patients with bronchial asthma.

RESEARCH: MICHAEL J. WELCH, MD

184. A double-blind comparison of ebastine and placebo in children with seasonal allergic rhinitis.
185. Placebo-controlled comparison of Flunisolide and Beclomethasone Dipropionate in allergic rhinitis.
186. Single intravenous dose efficacy study of MDL 26,024GO in skin reactivity to prick allergen challenge in atopic individuals.
187. A study of the effectiveness of pirbuterol acetate delivered by an Autohaler™ inhalation device vs. pirbuterol acetate delivered by a conventional "press and breathe" metered dose inhaler.
188. A safety/efficacy study of double-strength beclomethasone dipropionate, two inhalations per nostril once daily vs. beclomethasone dipropionate twice daily vs. high dose beclomethasone dipropionate once daily vs. placebo.
189. Multicenter, randomized, double-blind, placebo-controlled, parallel group study comparing the safety and efficacy of five doses of Ro 24-5913 in the treatment of mild to moderate asthma.
190. Double-blind, placebo-controlled, evaluation of azelastine nasal spray (0.1%) in the management of subjects with seasonal allergic rhinitis inadequately controlled by azelastine 0.5mg tablets.
191. A randomized, double-blind, comparative clinical trial of 12-week courses of salmeterol xinafoate rotadisk versus albuterol versus placebo in adolescent and adult patients with chronic reversible obstructive airways disease.
192. Acute pilot probe study of the flurbiprofen nasal spray to nasal allergen challenge in patients with allergic rhinitis.
193. Validation of quality of life questionnaire in patients with asthma using beclomethasone dipropionate.
194. A double-blind, placebo-controlled efficacy study of daily inhaled doses of 200, 400, 800 and 1600mcg triamcinolone acetonide (BID dosing) in moderate asthma.
195. A placebo-controlled trial of Accolate (ICI 204,219) in mild to moderate asthmatic patients needing chronic treatment: 13 weeks efficacy and up to a one year open label safety extension.
196. Phase II safety and efficacy study of Abbott - 73001 in patients with moderate asthma.
197. Placebo-controlled evaluation of the adjunctive therapy of azelastine nasal spray to terfenadine tablets in the management of seasonal allergic rhinitis.
198. A comparative trial assessing the long term safety of inhaled fluticasone propionate rotadisks via diskhaler 50mcg BID and 100mcg BID vs. placebo in patients aged 4 to 11 years with mild to moderate asthma.
199. A study comparing the efficacy and safety of Ro 24-5913 given twice daily with that of placebo for 4 weeks in the treatment of seasonal allergic rhinitis.
200. A double-blind, placebo-controlled study of the safety and efficacy of iodinated glycerol as adjunctive therapy in the treatment of subjects with chronic reversible obstructive airway disease.
201. A study of the safety and efficacy of levocabastine nasal spray twice a day or four times a day in the treatment of seasonal allergic rhinitis.
202. A parallel group study of the safety and inhaled corticosteroid-sparing effect of azelastine in inhaled corticosteroid-dependent asthmatics.

RESEARCH: MICHAEL J. WELCH, MD

203. A parallel group comparison of ebastine 10mg and 20mg versus placebo in patients with seasonal allergic rhinitis.
204. A 12-week study of HFA-134a salbutamol sulfate, HFA-134a salbutamol sulfate placebo formulation and the standard CFC 11/12 formulation of Ventolin in patients with reversible obstructive airways disease.
205. A double-blind, placebo-controlled, parallel group comparison of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate aqueous nasal spray in patients with seasonal allergic rhinitis.
206. A phase III study of the effects of Zileuton, 400 mg QID and 600 mg QID compared to beclomethasone in moderate asthma.
207. A safety and efficacy study of loratadine zydys versus loratadine tablet in the treatment of patients with seasonal allergic rhinitis.
208. A multicenter, double-blind comparison of Accolate™ (ICI 204,219) with cromolyn sodium (INTAL, Fisons) in mild to moderate asthmatic patients.
209. A 2-day, placebo- and beclomethasone aqueous nasal spray-controlled study of the safety and efficacy of Azelastine HC1 nasal solution) in the management of seasonal allergic rhinitis.
210. A single-blind, placebo-controlled, single-dose pilot study of the bronchodilator response to albuterol dry powder inhaler and metered dose inhaler in asthmatics.
211. An efficacy and safety study of mometasone furoate in perennial rhinitis.
212. A randomized trial to assess the topical versus systemic efficacy of fluticasone propionate rotadisks via diskhaler 500mcg BID, 100mcg BID, fluticasone propionate tablets 20mg QD, and placebo in adult patients with moderate asthma.
213. A comparison of ipratropium bromide nasal spray 0.03% (42 mcg/nostril) versus placebo administered twice a day in pediatric patients with allergic or nonallergic perennial rhinitis with an optional 6-month treatment comparison of ipratropium nasal spray 0.03% (42 mcg/nostril) versus beclomethasone dipropionate aqueous nasal spray (84 mcg/nostril).
214. A placebo-controlled study of the efficacy and safety of four weeks treatment with oral Pfizer CP-80,633 in adult patients with chronic, mild to moderate asthma.
215. A parallel-group park study to compare the onset of action of fluticasone propionate aqueous nasal spray QD versus beclomethasone dipropionate aqueous nasal spray BID for seasonal allergic rhinitis.
216. A study to compare the efficacy and safety of oral doses of Zeneca D2138 with placebo in subjects with bronchial asthma.
217. A long term study of the effects of intranasal beclomethasone dipropionate aqueous nasal spray on the growth and HPA axis function of children.
218. A study to determine the minimum effective dose of levocabastine nasal spray in the treatment of seasonal allergic rhinitis.
219. Nasal cytology - A multicenter study comparing the stained findings in smears of blown nasal secretions and epithelial scrapings.
220. A trial to assess the long term safety of fluticasone propionate Rotadisk^R via Diskhaler^R versus placebo in adult patients with moderate asthma.
221. A 12-month, open-label, follow-up of HFA-134a Salbutamol Sulfate.
222. A pilot study to evaluate the efficacy, tolerability and safety of two doses of HOE 140 (Icatabant) in comparison to placebo in the treatment of chronic bronchial asthma.

RESEARCH: MICHAEL J. WELCH, MD

223. Efficacy of Claritin^R versus Seldane^R versus placebo upon awakening in seasonal allergic rhinitis.
224. Comparative trial of salmeterol xinafoate rotadisk versus placebo in patients aged 4-11 years with reversible obstructive airways disease.
225. A study comparing duration of action and safety and efficacy of four dosage strengths of MDL 16,455A in the treatment of spring allergies.
226. An evaluation of quality of life and health economic measures in patients receiving MDL 16,455A in the treatment of spring allergies.
227. A crossover study comparing the effects of three oral doses of MK-0476 to placebo on exercise-induced bronchoconstriction 20 to 24 hours after dosing in asthmatics.
228. Attention and cognitive performance in children ages 6-10 years: a placebo-controlled pilot crossover study of the effects of first and second generation antihistamines in children with allergic rhinitis.
229. A placebo-controlled trial of the safety and efficacy of oral Bay x 1005 (100 mg BID vs. 250 mg BID vs. 500 mg BID vs. placebo for 6 weeks) in patients with asthma.
230. Long term safety of mometasone furoate in perennial rhinitis.
231. A trial of the effects of twelve-month courses of salmeterol xinafoate rotadisk versus placebo on methacholine-induced bronchial hyperresponsiveness in patients with chronic asthma.
232. Evaluation of undiluted albuterol inhalation solution in the treatment of acute asthma.
233. A trial of ATROVENT^R nasal spray 0.03% (42 mcg/nostil) alone, antihistamine alone, and the combination of ATROVENT^R nasal spray with an antihistamine in patients with seasonal allergic rhinitis.
234. A 12-month, open-label, safety and efficacy study of HFA-134a salbutamol sulfate and Ventolin in subjects with reversible obstructive airway disease.
235. A long term safety study of fluticasone propionate inhalation aerosol 100 mcg BID and 500 mcg BID versus placebo BID in adults with moderate asthma.
236. A 2-day, outdoor study of the safety and efficacy of cetirizine vs. loratadine and placebo in the treatment of seasonal allergic rhinitis.
237. Dose-ranging effect of Abbott-73001 on bronchial hyperresponsiveness to methacholine in patients with moderate asthma.
238. A placebo-controlled dose response study of Formoterol Turbuhaler 6, 12 and 24 ug administered twice daily in patients with asthma.
239. A long term safety study of mometasone furoate vs. triamcinolone acetonide in perennial rhinitis.
240. An evaluation of the safety, efficacy, and effect on asthma quality of life (AQL) of salmeterol in subjects receiving inhaled corticosteroids.
241. Comparison of 400 mcg HFA-134a beclomethasone dipropionate, 800 mcg CFC-11/12 beclomethasone dipropionate and placebo in subjects with asthma.
242. A dose ranging safety and toleration study of intranasal chlorpheniramine maleate solution in normal subjects.
243. Study of three dose levels of budesonide nebulizing suspension and placebo in asthmatic children aged eight years and younger.
244. A double-blind, crossover study in exercise-induced bronchospasm to compare the safety and efficacy of cromolyn sodium inhalation-isotonic to cromolyn sodium inhalation-hypotonic using placebo control.

RESEARCH: MICHAEL J. WELCH, MD

245. A study comparing the clinical effect of MK-0476 to placebo in patients with chronic asthma.
246. A comparison of four doses of Rhinocort^R aqua pump spray (Budesonide) and placebo in the treatment of adults and children with perennial allergic rhinitis.
247. A long-term surveillance study of Zileuton plus usual care versus usual care in patients with asthma.
248. A study of the prevalence of human rhinovirus in pediatric asthma patients with upper respiratory illness.
249. Safety and efficacy of mometasone furoate nasal spray vs. placebo in the treatment of elderly patients with perennial rhinitis.
250. Establishing the clinically important aeroallergens (pollens & mold spores) in California for skin testing the patient with respiratory allergy.
251. A placebo-controlled, parallel group comparison of the safety and efficacy of oral twice daily administration of SB 205312 with inhaled Vanceril in patients with mild to moderate asthma.
252. A randomized, double-blind, placebo-controlled, parallel-group evaluation of the safety and efficacy of cromolyn sodium inhalation solution in an isotonic formulation in pediatrics.
253. A multicenter placebo-controlled dose ranging study to assess and compare the activity of an oral administration of SR 27417A once a day during 12 weeks - in moderate asthmatic patients.
254. A placebo-controlled, parallel group, dose rising study to explore the safety, tolerability and preliminary pharmacokinetics of SB 205312 when given twice daily for a period of 7 days to pediatric patients (8-11 years) with mild to moderate asthma.
255. A six month safety/tolerance study of 120 mg MDL 16,455A BID and placebo BID in normal healthy subjects.
256. An efficacy study of RP 73401 DPI administered to moderate asthmatics.
257. A randomized open-label comparison of budesonide aqua pump spray, versus cromolyn sodium in the treatment of children with perennial allergic rhinitis.
258. A randomized open-label comparison of budesonide aqua pump spray, versus beclomethasone dipropionate in the treatment of adults with perennial allergic rhinitis.
259. Safety and efficacy of AA-2414 (ABT-001) in patients with moderate asthma.
260. A randomized, placebo-controlled study to determine the efficacy, maintenance effect, and safety of 200 ug and 400 ug Pulmicort^R Turbuhaler^R given once daily to adults with mild to moderate asthma.
261. A comparison of a daily dose of 100 mcg and 200 mcg of HFA-134a beclomethasone dipropionate with placebo in subjects with mild to moderate reversible obstructive airways disease.
262. An open, long-term study of the safety, tolerability, and efficacy of oral SB 205312 in patients with bronchial asthma.
263. Clinical use study comparing Nasalcrom^R Nasal Solution 4% to placebo nasal solution in the treatment of the symptoms associated with seasonal allergic rhinitis.
264. 4-week safety and efficacy study of HFA-134a salbutamol sulfate versus ventolin in children with reversible obstructive airway disease.
265. A 2-day, outdoor, double-blind, parallel multicenter study of the safety and efficacy of cetirizine vs. loratadine and placebo in the treatment of seasonal allergic rhinitis.

RESEARCH: MICHAEL J. WELCH, MD

266. A stratified trial assessing the efficacy and safety of fluticasone propionate via the multi-dose powder inhaler, 50mcg bid, 100mcg qd, and placebo in subjects aged 4 to 11 years with chronic asthma.
267. A stratified, comparative trial of inhaled fluticasone propionate via the multi-dose powder inhaler 100mcg QD, 200mcg QD, 500mcg QD, and placebo in adolescent and adult subjects with chronic asthma.
268. A 2-week, placebo-controlled study to assess the safety and efficacy of UK-112,214 (160 and 320 mg BID) in the treatment of adults with seasonal allergic rhinitis.
269. A single-dose, four-way crossover comparison of salmeterol 50mcg and 100mcg via the DiskusTM salmeterol 50mcg via the metered-dose inhaler and placebo for the prevention of exercise-induced bronchospasm in adolescent and adult subjects with asthma.
270. Safety and efficacy study of loratadine zydis vs. loratadine tablets vs. placebo in the treatment of patients with seasonal allergic rhinitis.
271. A placebo-controlled, dose ranging study of Azmacort^R HFA-134a oral inhaler compared to Azmacort^R oral inhaler in the treatment of asthma.
272. A safety study of levocabastine nasal spray used continuously for six months.
273. A placebo-controlled study to investigate the effects of twelve weeks of MK-0476 therapy on exercise and methacholine-induced bronchoconstriction in asthmatics.
274. A placebo-controlled, clinical study of the safety and efficacy of ALLERVAX^R CAT using a cat exposure room challenge model.
275. A placebo-controlled evaluation of the effect of salmeterol on methacholine-induced bronchial hyperresponsiveness over twenty-four weeks in adolescent and adult subjects with asthma.
276. Safety and efficacy of Claritin-D in lessening the exacerbation of asthma associated with seasonal allergic rhinitis.
Pr. No. P95-090
277. A trial of Zafirlukast (AccolateTM) in mild-to-moderate asthmatic subjects requiring first chronic therapy: 13 weeks efficacy and up to 52 weeks open-label safety extension.
Pr. No. 9188IL/0086:0040
278. A trial of Zafirlukast (AccolateTM) in mild-to-moderate asthmatic subjects requiring first 1.0 mg bid vs. placebo for allergy symptom relief.
Pr. No. HSC-305
279. A crossover study to evaluate the effects of chewable MK-0476 on exercise-induced bronchoconstriction in 6- to 14-year-old children (Tanner Stages I to V) with mild to moderate asthma.
Pr. No. 042-02
280. A study to investigate the efficacy and safety of GG167 administered twice or four times a day for the treatment of influenza A and B viral infections.
Pr. No. NAIA2008
281. A study to investigate the efficacy and safety of GG167 in the prevention and/or progression of influenza A and B viral infections.
Pr. No. NAIA2009
282. A dose ranging study of mometasone furoate pure dry powder in the treatment of asthma.
Pr. No. C94-127

RESEARCH: MICHAEL J. WELCH, MD

283. A comparison of the safety and efficacy of pranlukast (SB 205312), 150 and 300 mg BID, with Claritin^R 10 mg UID in patients with seasonal allergic rhinitis.
Pr. No. 205312/048
284. An open-label, four-week extension study to explore safety and efficacy of pranlukast (SB 205312), 300 mg BID, in patients with coexisting seasonal and perennial allergic rhinitis.
Pr. No. 205312/085
285. A single-dose, trial to assess the antagonism of oral Zafirlukast (AccolateTM) on exercise-induced bronchoconstriction in pediatric subjects with exercise-induced asthma.
Pr. No. 9188IL/0075
286. A study of the efficacy and safety of fluticasone propionate aqueous nasal spray versus placebo followed by a one year open-label safety extension in subjects with perennial nonallergic rhinitis.
Pr. No. FLTA3010
287. A six month clinical trial to examine the efficacy and safety of salmeterol xinafoate 42mcg bid, beclomethasone dipropionate 84mcg qid, and placebo in adolescent and adult subjects with mild to moderate asthma.
Pr. No. SLGA5015
288. A comparison of the safety and efficacy of 2 oral doses of PDA-641 (10mg and 30mg TID) and placebo in mild to moderate asthmatics.
Pr. No. 0805A-205-US
289. A five-way crossover clinical trial of single doses of salmeterol 25, 50, and 100mcg via the DiskusTM (multidose powder inhaler), albuterol Rotacaps 200mcg via Rotahaler, and placebo in pediatric subjects aged 4-11 years with asthma.
Pr. No. SLGA2016
290. Azelastine nasal spray market research study.
Pr. No. 362
291. Dose-ranging study of mometasone furoate nasal spray in the treatment of children (ages 6-11) with seasonal allergic rhinitis.
Pr. No. C95-161
292. A double-blind, placebo-controlled trial to determine the effects of zafirlukast on subjects with both asthma and seasonal allergic rhinitis.
Pr. No. 9188IL/0092
293. A double-blind comparison of the safety and efficacy of two doses of BAY x 7195 aerosol with placebo in patients with asthma.
Pr. No. D95-016-11
294. A validation study of the intraday and interday precision of methacholine challenge procedures.
Pr. No. 95/04
295. Objective and subjective measurements of the effectiveness of mometasone furoate nasal spray vs. placebo in patients with seasonal allergic rhinitis.
Pr. No. P95-219
296. A double-blind, placebo-controlled study to determine the efficacy and safety of 1, 10 and 100mg D7193 in adult asthma patients.
Pr. No. 120

RESEARCH: MICHAEL J. WELCH, MD

297. A double-blind, placebo controlled trial to assess the safety and efficacy of zafirlukast and loratadine in subjects with seasonal allergic rhinitis.
Pr. No. 9188IL/0126
298. A phase II, placebo-controlled study to evaluate the safety and efficacy of anti-IgE recombinant humanized monoclonal antibody (rhuMAb-E25) in subjects with moderate to severe allergic asthma.
Pr. No. Q0694g
299. A study of the safety and efficacy of ABT-761 150mg, 300mg QD versus placebo in moderate asthma.
Pr. No. M95-411
300. A placebo-controlled, 12-week safety and efficacy study of albuterol dry powder inhaler and albuterol metered-dose inhaler in asthmatics.
Pr. No. DDPIAS-III-01-0694
301. A randomized study evaluating the effect of montelukast sodium to salmeterol in the inhibition of exercise-induced bronchoconstriction in adult asthmatics.
Pr. No. 064
302. A 6 and 12 month, open label, safety and efficacy study of HFA-143a beclomethasone dipropionate (BDP) in pediatric patients with asthma.
Pr. No. 1196-BRON
303. Efficacy and safety of mometasone furoate nasal spray in the treatment of acute episodes and recurrences of sinusitis.
Pr. No. C96-195
304. A placebo-controlled, parallel-group study of [R]-albuterol in the reversal of bronchoconstriction and in the management of asthma.
Pr. No. 051-024
305. Exercise challenge dose response study of HFA-134a butixocort propionate, CFC-11/12 beclomethasone dipropionate and HFA-134a placebo in patients with reversible obstructive airway disease.
Pr. No. 1219-BUTI
306. An open-label, 12-month, safety study of Sprios™ dry powder inhaler (albuterol sulfate) in asthmatics.
Pr. No. DDPIAS-III-02-0995
307. A Long-term, Open-label, Safety study of Ebastine 20mg in Patients with Perennial Allergic Rhinitis
Pr. #RP 64305-141
308. One-year, evaluator-blind safety study of mometasone furoate nasal spray vs. beclomethasone dipropionate in children (ages 6-11) with perennial rhinitis.
Pr. No. C96-091
309. A six-week dose response study of RPR 106541T 10 mcg bid, 50 mcg bid and 400 mcg bid versus beclomethasone dipropionate 168 mcg bid versus placebo in chronic asthma.
Pr. No RPR 106541T-202
310. A placebo-controlled study examining the effect of fluticasone propionate aqueous nasal spray 200 mcg qd used in conjunction with an antibiotic in allergic subjects with recurrent sinusitis.
Pr. No. FLTA 4015

RESEARCH: MICHAEL J. WELCH, MD

311. Placebo-controlled, dose ranging study of mometasone furoate dry powder compared to beclomethasone dipropionate in the treatment of asthma in subjects previously maintained on inhaled corticosteroids.
Pr. No. C96-134
312. A Study of the Efficacy of Zileuton 1200mg BID, Controlled-Release (CR), and 600mg QID, Immediate Release (IR), and Placebo in Patients with Moderate Asthma.
Pr. #M95-337
313. A Single-Blind, Randomized, Parallel Group Comparison of the Efficacy and Safety of Beclomethasone Dipropionate Aqueous Nasal Spray Versus Cromolyn Sodium Nasal Solution Versus Placebo for Four Weeks in Subjects with Seasonal Allergic Rhinitis
Pr. #BDPA 4001
314. A Comparative Bronchoprovocation Challenge Study of Two Albuterol Metered-Dose Inhalers in Patients With Stable Mild Asthma
Pr. #94/11
315. Placebo-Controlled, Efficacy and Safety Study of Mometasone Furoate Dry Powder in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Beta-Agonists
Pr. #C96-186
316. START - Inhaled Steroid Treatment As Regular Therapy in Early Asthma, A Study of the Effect of Early Intervention With Long-Term Inhaled Budesonide (Pulmicort® Turbuhaler®) In Newly Diagnosed Asthma
Pr. #SD-004-0111
317. A Double-Blind Placebo Controlled Pilot Trial to Determine the Efficacy of Cisapride in Improving Respiratory Symptoms and Pulmonary Function in Asthmatics with Gastroesophageal Reflux (GER)
Pr. # CIS-USA-84
318. A Named-Patient Safety Study of Pulmicort [Budesonide] Nebulizing Suspension in Severe, Oral Steroid-Dependent Asthmatic Patients Aged Six Months to Eight Years
Pr. #04-3121
319. A Twelve-Month, Double-Blind, Between-Patient, Placebo-Controlled Trial Comparing the Safety, Tolerability and Efficacy of 12 mcg and 24 mcg Twice Daily Formoterol Dry Powder Capsules for Inhalation, Delivered by a Single-Dose Inhaler (Aeroliser™), in Children with Asthma in Need of Daily Treatment with Inhaled Bronchodilators and Anti-Inflammatory Treatment
Pr. #049
320. A Dose-ranging, Safety and Efficacy trial with Zafirlukast (ACCOLATE) in the Treatment of Pediatric Subjects with Mild-to-moderate Asthma; Up to a 52 Week Open Label Safety Extension
Pr. #9188IL-0139
321. A Double-Blind, Placebo-Controlled Study to Assess the Clinical Effect of Montelukast in Patients with Seasonal Allergic Rhinitis
Pr. #068
322. An Open Multicenter Study for the Validation of a Caregiver Asthma Diary (Pediatric)
Pr. # EPO7001.010
323. A Comparison of the Onset of Action of Claritin-D and Semprex-D in Patients with Moderate to Severe Seasonal Allergic Rhinitis
Pr. # SPX D-97-01

RESEARCH: MICHAEL J. WELCH, MD

324. A Clinical Study of the Effects of Three Types of Adhesive Nasal Strips on Nasal Airflow Resistance
Pr. #CL970003
325. The Cultural Adaptation into Hispanic of the Asthma Quality of Life Questionnaire (adult version)
Pr. #AQLQ
326. The Cultural Adaptation into Hispanic of the Rhinoconjunctivitis Quality of Life Questionnaire (adult version)
Pr. #95.3253
327. A Placebo-Controlled Parallel Study Comparing the Efficacy and Safety of Three Dosage Strengths of Fexofenadine HCl (15, 30 and 60 Mg BID) in Pediatric Patients (Ages 6 to 11 Years) in the Treatment of Seasonal Allergic Rhinitis
Pr. #PJPR0066
328. A Placebo-Controlled Parallel Study Comparing the Efficacy and Safety of Fexofenadine HCl 120 MG and 180 MG QD in the Treatment of Autumn Seasonal Allergic Rhinitis
Pr. #MO16455B/3081
329. An Evaluation of Quality of Life and Work, Study and Daily Activity Impairment Measures in Patients Receiving Fexofenadine HCl 120 MG and 180 MG in the Treatment of Autumn Seasonal Allergic Rhinitis
Pr. #MO16455B/3004
330. The Evaluation of Three Norastemizole Doses (15 mg, 30, 45 mg) and Loratadine When Administered to Subjects with Seasonal Allergic Rhinitis
Pr. #110-008
331. A Placebo-Controlled Evaluation of Histamine Skin Test Reactivity Following Single and Multiple Doses of Astelin® Nasal Spray
Pr. #364/C970003
332. A Placebo-Controlled, Multicenter Study Evaluating the Effect of Montelukast Sodium Compared to Inhaled Beclomethasone Dipropionate in Adult Asthmatics
Pr. #MK-070
333. A One-Day, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Clemastine Triple Combination (CTC), TheraFlu Sinus and Placebo in the Treatment of Seasonal Allergic Rhinitis
Pr. #HSC-306
334. A Placebo-Controlled Study to Investigate the Efficacy and Safety of Inhaled Zanamivir (GG167) 10mg Administered Twice a Day for Five Days In the Treatment of Symptomatic Influenza A and B Viral Infections in Adolescents and Adults.
Pr. #NAIA 3002
335. An Evaluation of Pulmicort Respules (Budesonide Nebulizing Suspension) Versus Intal (Cromolyn sodium) Nebulizer Solution on Asthma-Related Outcomes in Children Two to Six Years Old.
Pr. #DX-RES-2000
336. A Placebo-Controlled, Comparison of Inhaled Fluticasone Propionate (88mcg BID) with Oral Zafirlukast (20mg BID) in Subjects With Mild to Moderate Asthma.
Pr. #FLTA 5001

RESEARCH: MICHAEL J. WELCH, MD

337. A Comparative Study of Inhaled Fluticasone Propionate 88mcg BID Versus Zafirlukast 20mg BID in Asthmatic Subjects Who Are Currently Receiving Low Dose Inhaled Corticosteroids.
Pr. #FLTA 4035
338. A Comparative Study of the Efficacy and Safety of Zyrtec vs. Claritin and Placebo in the Treatment of Chronic Idiopathic Urticaria.
Pr. #L-0342
339. A Study of Albuterol Controlled Release Suspension in the Treatment of Children With Asthma.
Pr. #05
340. Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate HFA-227 Metered Dose Inhaler in the Treatment of Asthma in Subjects Previously Maintained on short-acting Inhaled Beta-Agonists.
Pr. #C97-226
341. Placebo-Controlled, Dose-Ranging Study of Mometasone Furoate HFA-227 Metered Dose Inhaler Compared to Beclomethasone Dipropionate (Vanceril 84 mcg Double Strength) in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids.
Pr. #C97-208-10
342. A Placebo-Controlled Study Examining the Effect of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD in Subjects with an Acute Episode of Recurrent Sinusitis.
Pr. #FLTA 4033
343. Placebo-controlled, dose ranging study of mometasone furoate dry powder compared to beclomethasone dipropionate in the treatment of asthma in subjects previously maintained on inhaled corticosteroids.
Pr. No. C96-134
344. A Study of the Efficacy of Zileuton 1200mg BID, Controlled-Release (CR), and 600mg QID, Immediate Release (IR), and Placebo in Patients with Moderate Asthma.
Pr. #M95-337
345. A Single-Blind, Randomized, Parallel Group Comparison of the Efficacy and Safety of Beclomethasone Dipropionate Aqueous Nasal Spray Versus Cromolyn Sodium Nasal Solution Versus Placebo for Four Weeks in Subjects with Seasonal Allergic Rhinitis.
Pr. #BDPA 4001
346. A Comparative Bronchoprovocation Challenge Study of Two Albuterol Metered-Dose Inhalers in Patients With Stable Mild Asthma.
Pr. #94/11
347. Placebo-Controlled, Efficacy and Safety Study of Mometasone Furoate Dry Powder in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Beta-Agonists.
Pr. #C96-186
348. START - Inhaled Steroid Treatment As Regular Therapy in Early Asthma, A Study of the Effect of Early Intervention With Long-Term Inhaled Budesonide (Pulmicort® Turbuhaler®) In Newly Diagnosed Asthma.
Pr. #SD-004-0111

RESEARCH: MICHAEL J. WELCH, MD

349. A Double-Blind Placebo Controlled Pilot Trial to Determine the Efficacy of Cisapride in Improving Respiratory Symptoms and Pulmonary Function in Asthmatics with Gastroesophageal Reflux (GER).
Pr. # CIS-USA-84
350. A Named-Patient Safety Study of Pulmicort [Budesonide] Nebulizing Suspension in Severe, Oral Steroid-Dependent Asthmatic Patients Aged Six Months to Eight Years.
Pr. #04-3121
351. A Twelve-Month, Double-Blind, Between-Patient, Placebo-Controlled Trial Comparing the Safety, Tolerability and Efficacy of 12 mcg and 24 mcg Twice Daily Formoterol Dry Powder Capsules for Inhalation, Delivered by a Single-Dose Inhaler (Aeroliser™), in Children with Asthma in Need of Daily Treatment with Inhaled Bronchodilators and Anti-Inflammatory Treatment.
Pr. #049
352. A Dose-ranging, Safety and Efficacy trial with Zafirlukast (ACCOLATE) in the Treatment of Pediatric Subjects with Mild-to-moderate Asthma; Up to a 52 Week Open Label Safety Extension.
Pr. #9188IL-0139
353. A Double-Blind, Placebo-Controlled Study to Assess the Clinical Effect of Montelukast in Patients with Seasonal Allergic Rhinitis.
Pr. #068
354. An Open Multicenter Study for the Validation of a Caregiver Asthma Diary (Pediatric).
Pr. # EPO7001.010
355. A Comparison of the Onset of Action of Claritin-D and Semprex-D in Patients with Moderate to Severe Seasonal Allergic Rhinitis.
Pr. # SPX D-97-01
356. A Clinical Study of the Effects of Three Types of Adhesive Nasal Strips on Nasal Airflow Resistance.
Pr. #CL970003
357. The Cultural Adaptation into Hispanic of the Asthma Quality of Life Questionnaire (adult version).
Pr. #AQLQ
358. The Cultural Adaptation into Hispanic of the Rhinoconjunctivitis Quality of Life Questionnaire (adult version).
Pr. #95.3253
359. A Placebo-Controlled Parallel Study Comparing the Efficacy and Safety of Three Dosage Strengths of Fexofenadine HCl (15, 30 and 60 Mg BID) in Pediatric Patients (Ages 6 to 11 Years) in the Treatment of Seasonal Allergic Rhinitis.
Pr. #PJPR0066
360. A Placebo-Controlled Parallel Study Comparing the Efficacy and Safety of Fexofenadine HCl 120 MG and 180 MG QD in the Treatment of Autumn Seasonal Allergic Rhinitis.
Pr. #MO16455B/3081
361. An Evaluation of Quality of Life and Work, Study and Daily Activity Impairment Measures in Patients Receiving Fexofenadine HCl 120 MG and 180 MG in the Treatment of Autumn Seasonal Allergic Rhinitis.
Pr. #MO16455B/3004

RESEARCH: MICHAEL J. WELCH, MD

362. The Evaluation of Three Norastemizole Doses (15 mg, 30, 45 mg) and Loratadine When Administered to Subjects with Seasonal Allergic Rhinitis.
Pr. #110-008
363. A Placebo-Controlled Evaluation of Histamine Skin Test Reactivity Following Single and Multiple Doses of Astelin® Nasal Spray.
Pr. #364/C970003
364. A Placebo-Controlled, Multicenter Study Evaluating the Effect of Montelukast Sodium Compared to Inhaled Beclomethasone Dipropionate in Adult Asthmatics.
Pr. #MK-070
365. A One-Day, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Clemastine Triple Combination (CTC), TheraFlu Sinus and Placebo in the Treatment of Seasonal Allergic Rhinitis.
Pr. #HSC-306
366. A Placebo-Controlled Study to Investigate the Efficacy and Safety of Inhaled Zanamivir (GG167) 10mg Administered Twice a Day for Five Days In the Treatment of Symptomatic Influenza A and B Viral Infections in Adolescents and Adults.
Pr. #NAIA 3002
367. An Evaluation of Pulmicort Respules (Budesonide Nebulizing Suspension) Versus Intal (Cromolyn sodium) Nebulizer Solution on Asthma-Related Outcomes in Children Two to Six Years Old.
Pr. #DX-RES-2000
368. A Placebo-Controlled, Comparison of Inhaled Fluticasone Propionate (88mcg BID) with Oral Zafirlukast (20mg BID) in Subjects With Mild to Moderate Asthma.
Pr. #FLTA 5001
369. A Comparative Study of Inhaled Fluticasone Propionate 88mcg BID Versus Zafirlukast 20mg BID in Asthmatic Subjects Who Are Currently Receiving Low Dose Inhaled Corticosteroids.
Pr. #FLTA 4035
370. A Comparative Study of the Efficacy and Safety of Zyrtec vs. Claritin and Placebo in the Treatment of Chronic Idiopathic Urticaria.
Pr. #L-0342
371. A Study of Albuterol Controlled Release Suspension in the Treatment of Children With Asthma.
Pr. #05
372. Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate HFA-227 Metered Dose Inhaler in the Treatment of Asthma in Subjects Previously Maintained on short-acting Inhaled Beta-Agonists.
Pr. #C97-226
373. Placebo-Controlled, Dose-Ranging Study of Mometasone Furoate HFA-227 Metered Dose Inhaler Compared to Beclomethasone Dipropionate (Vanceril 84 mcg Double Strength) in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids.
Pr. #C97-208-10
374. A Placebo-Controlled Study Examining the Effect of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD in Subjects with an Acute Episode of Recurrent Sinusitis.
Pr. #FLTA 4033

RESEARCH: MICHAEL J. WELCH, MD

375. A Placebo-controlled, 12-week Safety and Efficacy Study of Beclomethasone Dipropionate Dry Powder Inhaler and Beclomethasone Dipropionate Metered-dose Inhaler in Asthmatics.
Pr. #DPIBDP-03
376. Dose Ranging Study of SCH 34117 in the Treatment of Patients with Seasonal Allergic Rhinitis.
Pr. #C98-001
377. A Comparison of Zafirlukast (ACCOLATE) with Placebo in Pediatric Subjects with Mild-to-Moderate Asthma.
Pr. #9188IL/0150
378. A Phase II/III Placebo-Controlled, Efficacy, Safety and Dose Response Study of Azmacort® (triamcinolone acetonide) HFA-134a Inhalation Aerosol 225 mcg, 450 mcg and 900 mcg Administered Once Daily for 12 Weeks in the Treatment of Mild Persistent and Moderate Persistent Asthma in 800 Adolescents and Adults.
Pr. #RG5016Y-204
379. A Study of the Efficacy and Safety of Tylenol® Allergy Sinus (AS) Compared with Claritin® in the Treatment of Seasonal Allergic Rhinitis
Pr. #97-034
380. A Placebo-Controlled Study to Investigate the Safety and Efficacy of Omeprazole, 10 mg qd and 20 mg qd in Preventing Heartburn.
Pr. #171
381. A Placebo-Controlled Study to Compare Concomitant Montelukast and Loratadine With Intranasal Beclomethasone in Patients With Seasonal Allergic Rhinitis.
Pr. #077
382. A Comparison of the Effect of Two Doses of Levalbuterol with Ventolin® on Pulmonary Function in Subjects with Mild-To-Moderate Asthma.
Pr. #051-027
383. Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate Dry Powder Inhaler in the Treatment of Asthma in Children Previously Maintained on Inhaled Corticosteroids.
Pr. #C97-300
384. Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate Dry Powder Inhaler in the Treatment of Asthma in Children Previously Maintained on Beclomethasone Dipropionate (Vanceril® 84 mcg Double Strength).
Pr. #C97-380
385. A Placebo-Controlled Comparison of the Safety and Efficacy of Claritin vs. Fexofenadine vs. Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis.
Pr. #P97-344
386. A Parallel-Group Chronic Asthma Study Comparing Montelukast With Placebo in 2- to 5-Year-Old Patients.
Pr. #072
387. A Long-Term Open-Label Study to Evaluate the Safety of HFA Flunisolide in Adult and Adolescent Patients with Mild to Moderate Asthma.
Pr. #ANC-MD-02-000

RESEARCH: MICHAEL J. WELCH, MD

388. Efficacy and Safety of SCH 34117 in the Treatment of Patients With Seasonal Allergic Rhinitis.
Pr. #C98-223
389. Efficacy and Safety of SCH 34117 in the Patients With Seasonal Allergic Rhinitis.
Pr. #C98-224
390. Efficacy and Safety of 800 mcg or 400 mcg of Mometasone Furoate Nasal Spray or Placebo in the Treatment of Acute Episodes of Sinusitis.
PR # C97-251
391. A Study Comparing the Clinical Effect of Concomitant Montelukast + Loratadine with Montelukast, Loratadine, and Inhaled Beclomethasone in Patients With Chronic Asthma.
Pr. #074
392. A Phase III 7-month placebo-controlled trial with a 5-month open label extension period to assess safety and tolerability, steroid reduction, pharmacokinetics, and pharmacodynamics of subcutaneous rhuMAb-E25 in children (6-12 years) with allergic asthma requiring daily treatment with inhaled corticosteroids.
Pr. #rhuMAb-E25 01 010
393. The Evaluation of Three Norastemizole Doses (30mg, 60mg 90mg) and Loratadine When Administered to Subjects with Seasonal Allergic Rhinitis.
Pr. #110-024
394. One-Year Study of the Effects of Mometasone Furoate Dry Powder Inhaler versus Placebo on Growth of Children with Asthma.
Pr. #C97-384
395. Efficacy and Safety of SCH 34117 in the Treatment of Patients With Seasonal Allergic Rhinitis (Four Weeks Treatment).
Pr. #C98-225
396. A Double-Dummy, Comparison of Inhaled Fluticasone Propionate (88 mcg BID) versus Zafirlukast (20mg BID) over 12 Weeks in Subjects with Persistent Asthma.
Pr. # FAS40023
397. The Pharmacodynamics and Safety of Levalbuterol Syrup in Pediatric Subjects with Mild-to-Moderate Asthma.
Pr. #051-202
398. Long Term Safety of Mometasone Furoate HFA 227 Nasal Aerosol in Perennial Allergic Rhinitis.
Pr. #C97-302
399. A Comparison of the Ease of Teaching Correct Inhaler Technique and Patient Device Preference Between Pulmicort Turbuhaler® (budesonide inhalation powder) and Several Pressurized Metered Dose Inhalers in Patients with Asthma.
Pr. #DX-PUL-1002
400. A Double-Blind Study of Inhaled Fluticasone Propionate (88mcg BID) Versus Montelukast Sodium (10mg QD) in Subjects Currently Receiving Beta Agonists Alone.
Pr. #FLTA4039
401. A study comparing the Efficacy and safety of Fexofenadine HCl 120 mg q.d. Cetirizine HCl 10 mg q.d. and Placebo q.d. in the Treatment of Perennial Allergic Rhinitis.
PR. #M016455M/309.

RESEARCH: MICHAEL J. WELCH, MD

402. Phase II Placebo-Controlled Eight Week Study of Efficacy and Safety of Inhaled CP-325, 366 in Adults with Persistent Asthma.
Pr. #264-101-5012
403. 401.A Phase I Safety and Pharmacokinetic Study of IL-4R Comparing Two Aerosol Delivery Devices.
Pr. #013.0009
404. An Open-Label Placebo-Controlled Study to Compare the Endocrine Effects of Aerobid Inhaler System (flunisolide), Flovent Inhalation Aerosol (fluticasone propionate), and Oral Prednisone in patients with Mild to Moderate Asthma.
Pr. #AER-MD-08-000
405. A Placebo-Controlled Study of Ro 64-0796 (also known as GS 4104) in Children with Influenza.
Pr. #WV15758
406. Placebo-Controlled Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol 50 mcg BID and Fluticasone Propionata 250 mcg BID Individually and in Combination as Compared to Placebo in COPD Subjects
PR.#SFCA3007
407. A Placebo Controlled Study of the Clinical Effect of Nebulized L-808,065 in Patients with Chronic Asthma.
Pr. #004-00
408. A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial to Assess the Effect of Zafirlukast (Accolate) 20mg Twice Daily when Administered with Food on Exercise-Induced Bronchoconstriction in Subjects with Asthma
Pr. #9188US/0025
409. An Evaluation of Safety and Tolerance of Cromolyn Sodium Following the Administration of a Nasal Solution to Pediatric Subjects
Pr. #M\3235\0002
410. A Parallel Study Comparing the Efficacy and Safety of Fexofenadine HCl 120 mg qd., 180 mg qd., Cetirizine 10 mg qd., and Placebo qd. In the Treatment of Perennial Allergic Rhinitis
Pr. #M016455M/3097
411. A Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous SB 240563 (250mg and 750mg) in Patients with Asthma
Pr. # SB 240563-006
412. Four-Week, Double-Blind, Safety and Efficacy Study of Beclomethasone Dipropionate Nasal Aerosol vs. Placebo in Children (Age 3-5) with Perennial and/or Seasonal Allergic Rhinitis
Pr. # C98-641-07
413. Dose Ranging Study of Mometasone Furoate HFA-227 nasal Aerosol in the Treatment of Patients with Seasonal Allergic Rhinitis
Pr. #C97-297
414. Safety and Efficacy Study of HFA-134a Albuterol Sulfate Delivered from a Press-and-Breathe MDI, HFA-134a Albuterol Sulfate Delivered from the Autohaler™ Inhalation Device, and HFA-Placebo in Patients with Asthma
Pr. #1332-SILV

RESEARCH: MICHAEL J. WELCH, MD

415. Multi-Center, Randomized Comparison of the Efficacy, Onset of Action and Safety of a Single Dose of Fexofenadine 180 mg vs. Loratadine 10 mg vs. Placebo in Treating Seasonal Allergic Rhinitis in an Outdoor Environment
Pr. #M016455/4104
416. A 12-Week Comparison of Daily Doses of 100 mcg and 200 mcg of HFA-134a Beclomethasone Dipropionate in the Autohaler™ Device Versus Placebo in Pediatric Patients with Symptomatic Asthma
Pr. #1343-BRON
417. Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Adults
Pr. #013.0014
418. Development and Validation of a Questionnaire to Measure Health-Related Quality of Life in Adults with Allergic Rhinitis: The Relationship of Allergic Rhinitis, Sleep Quality and Daytime Fatigue
Pr. #MCS99001
419. A Twelve-Month Safety Study of 90mg Norastemizole in Subjects with Seasonal Allergic Rhinitis/Perennial Allergic Rhinitis
Pr. #110-029
420. Phase IIA Multicenter, Randomized, Double-Blind, Double-Dummy, Active and Placebo-Controlled, Parallel Group, Dose-Response Study of the Efficacy, Safety, and Tolerability of Six Weeks Oral Dosing with CJ-13,610 Compared to Montelukast and Placebo in Adults with Persistent Asthma
Pr. #253-102
421. Efficacy and Safety of SCH 34117 and Cetirizine in the Treatment of Subjects with Seasonal Allergic Rhinitis
Pr. #P00384
422. A Placebo-Controlled Pilot Study Evaluating the Effects of Montelukast Sodium versus Salmeterol Xinafoate on Beta-agonist Induced Bronchodilation following Challenge – (Exercise) Induced Bronchoconstriction
Pr. #113-00
423. The Evaluation of Norastemizole (30 mg) and Loratadine When Administered to Subjects with Seasonal Allergic Rhinitis
Pr. #110-032
424. A Study to Assess the Growth Effects of a One-Year Course of Fluticasone propionate Aqueous Nasal Spray (200mcg QD) Versus Placebo in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis
Pr. #FNM40017
425. Efficacy and Safety of SCH 29851 8 mg QD in Subjects with Seasonal Allergic Rhinitis
Pr. #P00677
426. An open-label extension of rhuMAb-E25 treatment to children with allergic asthma who participated in the one-year study (rhuMAb-E25 Protocol No. 01 010)
Pr. #rhuMAb-E25 01 010 Extension 1
427. Efficacy and Safety of SCH 34117 + Pseudoephedrine, BID, vs its Components in the Treatment of Subjects with Seasonal Allergic Rhinitis
Pr. #P0035

RESEARCH: MICHAEL J. WELCH, MD

428. A Placebo-Controlled Comparative Trial of Albuterol Delivery by a New, Hand-Held, Ultrasonic Metered Dose Solution Inhaler (MSI) Compared to a Standard Metered Dose Inhaler (MDI) in Moderate Persistent Asthmatic Children (≥ 4 Years of Age and ≤ 12 Years of Age)
Pr. #7102-JAUS-02
429. Efficacy and Safety of SCH 34117 in Subjects with Seasonal Allergic Rhinitis and Concurrent Asthma
Pr. #P00214
430. A Phase II, Placebo-controlled, Study of AG7088 Nasal Spray, 2% Suspension for the Treatment of Natural Rhinovirus Infection in the General Population Including Patients with a History of Chronic Respiratory Disease
Pr. #AG7088-304
431. A Placebo-Controlled Study with SCH 34117 in the Treatment of Subjects > 12 Years of Age with Perennial Allergic Rhinitis
Pr. #P00217
432. A Placebo Controlled Comparative Trial of Albuterol Delivery by a New, Hand-Held, Ultrasonic Metered Dose Solution Inhaler (MSI) Versus a Standard Metered Dose Inhaler (MDI) in Patients with Bronchial Asthma
Pr. #7102-JAUS-04
433. A Placebo-Controlled, Cross-Over Study Evaluating the effect of a Single Dose of LDP-977 on the Acute Bronchodilator Response in Asthmatics
Pr. #L97799-018
434. An Open-Label, Multiple-Dose, Study to Evaluate the Safety of Beclomethasone Dipropionate and Reliability of the To-Be-Marketed Spiros Dry Powder Inhaler in patients with Asthma
Pr. #DPIBDP-07
435. A Parallel-Group, Placebo-Controlled, 12-Week Study of Fluticasone Propionate 44mcg BID and 88mcg BID delivered via CFC MDI and a Valved Holding Chamber with Facemask in Subjects with Asthma Age 24 months to 47 months
Pr. #FMS30058
436. Salmeterol vs. Montelukast for Asthmatics who Require more Therapy (SMART Study) A Randomized, Double-Blind Multicenter Study to Evaluate the Effect of Adding Either Montelukast Sodium or Salmeterol Xinafoate to Inhaled Fluticasone in Adult Asthmatics
Pr. #120
437. A Pilot Study to Evaluate Objective Measurements in Normal and Allergic Rhinitis Subjects
Pr. #X99-047
438. A Placebo-Controlled, Therapeutic Confirmatory Study Evaluating the Safety and Efficacy of 0.31 mg and 0.63 mg Levalbuterol and 1.25 mg and 2.5 mg Racemic Albuterol and Placebo
Pr. #051-031
439. A Placebo-Controlled, 12-Week Study of Fluticasone Propionate 44mcg BID and 88mcg BID delivered via CFC MDI and a Valved Holding Chamber with Facemask in Subjects with Asthma Age 6 months to 23 months
Pr. #FMS30059

RESEARCH: MICHAEL J. WELCH, MD

440. Parallel-Group Study Comparing the Effect on Linear Growth of Montelukast With Placebo and Inhaled Beclomethasone in Pediatric Patients (Prepubertal, Tanner Stage I) With Mild Asthma
Pr. #097
441. Validation of a Nocturnal Rhinitis Quality of Life Questionnaire: Pre-Test Phase
Pr. #RG5029Y.US1.900
442. A Comparison of the Safety and Efficacy of Three Once Daily Doses of BAY 19-8004 with Placebo and Montelukast 10 mg Daily in Patients with Symptomatic Asthma
Pr. #100245
443. A Multicenter, Randomized, Double-Blind, Placebo-controlled Study of the Effect of Long-Term Treatment with Rhinocort® Aqua (Budesonide) Nasal Spray in Children with Perennial Allergic Rhinitis
Pr. #SD-005-0414
444. A Parallel-Group Study Evaluating the Protective Effects of the Salmeterol Xinafoate/Fluticasone Propionate Combination Product (50/100mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma
Pr. #SAS40024
445. A Parallel-Group Study Evaluating the Protective Effects of the Salmeterol Xinafoate/Fluticasone Propionate Combination Product (50/250mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma
Pr. #SAS40025
446. A Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients With Seasonal Allergic Rhinitis-Spring Study
Pr. #162-00
447. A Placebo-Controlled, Parallel-Group, Multiple-Dose, Multicenter, 12-Week Study to Compare the Safety and Efficacy of Beclomethasone Dipropionate via the To-Be-Marketed Spiros Dry Powder Inhaler to Vancertil Metered-Dose Inhaler in Patients with Asthma
Pr. #DPIBDP-06
448. A Placebo-Controlled Study to Assess the Safety and Tolerability of Fexofenadine HCL 30 mg Twice a Day During Treatment of Children 2 through 5 Years of Age with Allergic Rhinitis
Pr. #M016455I/3112
449. A Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100 mcg DISKUS Inhaler BID versus Fluticasone Propionate 250 mcg DISKUS Inhaler BID in Adolescents and Adults with Moderate Persistent Asthma
Pr. #SAS40027
450. Clinical and Objective measurements of the Effectiveness of Desloratadine 5 mg vs. Placebo in Subjects with Symptomatic Seasonal Allergic Rhinitis (SAR)
Pr. #P00765

RESEARCH: MICHAEL J. WELCH, MD

451. A Single Dose Study to Examine Anti-histamine and Sedation Potential of Concentrated Oral Liquid Formulations of Chlorpheniramine Maleate in Healthy Volunteers
Pr. #2000047
452. A Parallel Group Comparison of 200mcg Fluticasone Propionate Aqueous nasal Spray, Placebo and 10 mg Encapsulated Loratadine Administered (No more than Once Daily) As-Needed in Subjects with Seasonal Allergic Rhinitis
#FNM30030
453. A Multicenter, Placebo-Controlled, Open-Label Study to Evaluate the Safety of Omalizumab in Moderate to Severe Persistent Asthma Subjects Already Treated With Other Therapies (ALTO).
#Q2143g
454. An open-label extension study of Xolair™ (omalizumab) in moderate to severe, persistent asthma subjects who completed study Q2143g (ALTO)
#2195g
455. A Placebo-controlled, Parallel Group Study Assessing the Efficacy and Safety of Oral Fexofenadine HCl Tablets 30 mg Twice A Day in Pediatric Subjects (6 to 11 Years) in the Treatment of Seasonal Allergic Rhinitis
#M016455C/3212
456. Phase II Safety and Efficacy Study of Nebulized Recombinant Human IL-4 Receptor in Asthma
#013.0017
457. A Randomized, Double-Blind, Double Dummy, Parallel Group Comparison of Fluticasone Propionate Inhalation Powder (50mcg BID) via DISKUS® with Oral Montelukast (5mg QD) Chewable Tablets in Children 6-12 Years of Age with Persistent Asthma
#FPD40012
458. A Placebo-Controlled, Environmental Study of PATANOL® Nasal Spray versus ASTELIN® in the Treatment of Seasonal Allergic Rhinitis
#C-00-33
459. A Phase IIa Cross-Over Study of Once Daily Inhalations of Three Doses of AlbuLast™ in Adults with Mild to Moderate Asthma
#AIR01-004
460. A Multicenter, Parallel-Group Study Investigating the Clinical Effect of L-858674 in Patients With Seasonal Allergic Rhinitis – A Pilot Study During the Fall Season
#003
461. Phase II Safety and Efficacy Study of Nebulized Recombinant Human IL-4 Receptor in Asthma Patients Using Inhaled Corticosteroids
#013.0019
462. A 2-Period Study in Subjects with Allergic Rhinitis to Assess the Response and Variability of Nasal Airway Resistance to Allergen Provocation
#002
463. Multi-Symptom Allergy Sinus Efficacy and Safety Study
#AD-99-02
464. Efficacy, Safety and Tolerability Study of Daily Dosing with Levalbuterol, Racemic Albuterol and Placebo in Pediatric Subjects 2-5 Years Old with Asthma.
#051-032

RESEARCH: MICHAEL J. WELCH, MD

465. A Multicenter, Parallel-Group Study Comparing Montelukast With Placebo in Pediatric Patients Aged 2 Through 14 Years With Seasonal Allergic Rhinitis
#219-00
466. A Placebo and Loratadine Controlled Parallel-Group Study of Montelukast in Patients With Seasonal Allergic Rhinitis – Spring 2001 Study
#235-00
467. A Placebo-Controlled, Multi-Dose Study of the Potential Effects of Ciclesonide and Fluticasone Propionate on HPA-Axis in Adult Asthma Patients
#XRP1526B-102
468. A Double-Blind, Placebo-Controlled, Parallel Group Study of Four Doses of Loteprednol Etabonate Nasal Spray (100µg, 200µg, 400µg and 800µg) with Flonase® (200µg) as an Open Active-Control in the Treatment of Adults and Adolescents with Allergic Rhinitis Induced by Grass Pollen
#H-01075-3212
469. A Placebo-Controlled Efficacy and Safety Study of a Once-Daily PM and Twice Daily Regimens of Mometasone Furoate Administered Via Dry Powder Inhaler in Subjects With Asthma Who Were Previously Maintained On Inhaled Corticosteroids
#P01545
470. A Multicenter, Randomized, Parallel Group Study Of The Efficacy, Safety, Health Care Utilization and Health Related Quality Of Life With Nasacort® AQ (triamcinolone acetonide aqueous) Nasal Spray and Flonase® (fluticasone propionate) Nasal Spray In The Treatment Of Patients with Seasonal Allergic Rhinitis
#NAS.US1.435
471. A Study of the Efficacy and Safety of Zyrtec® (Cetirizine HCl) Syrup vs. Claritin® (Loratadine) Syrup vs. Placebo in the Treatment of Children with Seasonal Allergic Rhinitis
#A1431009
472. A Randomized, Open Label, Cross Over Trial, Assessing Correct Use And Patient Preference of Fluticasone Propionate Inhalation Powder (100 mcg bid) via the Diskus Versus Fluticasone Propionate Aerosol via The Metered Dose Inhaler (88 mcg bid) in Subjects At Least 12 Years of Age with Persistent Asthma Currently Receiving Short Acting Beta Agonists Alone
#FPD40016
473. A Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Seasonal Allergic Rhinitis Over a 4-Week Treatment Period – Fall 2001
#240-00
474. Chronic-Dose Comparison of the Efficacy and Safety of Albuterol-HFA-MDI (*SALAMOL*™), Albuterol-HFA-BOI (*SALAMOL EASI-BREATHE*™) and *PROVENTIL*® HFA in Mild-to-Moderate Asthmatics
#BNP-301-4-167
475. A Phase III Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety and Dose Response Study of Ciclesonide Metered Dose Inhaler 100mcg/day, 200 mcg/day, and 400mcg/day (ex-valve) Administered Once Daily and 400mcg/day (ex-valve) Administered Twice Daily for 12-weeks in the Treatment of Mild to Moderate Persistent Asthma in Adolescents and Adults
#XRP1526B-322

RESEARCH: MICHAEL J. WELCH, MD

476. A Placebo-Controlled Study to Assess the Safety and Efficacy of Dey Beclomethasone Dipropionate Monohydrate Nasal Spray 0.042% in Adolescent and Adult Patients with Seasonal Allergic Rhinitis
#DL-047
477. A placebo-controlled, 12-week trial evaluating the efficacy and safety of the fluticasone propionate/salmeterol DISKUS combination product 250/50mcg once daily fluticasone propionate/salmeterol DISKUS combination product 100/50mcg twice daily versus fluticasone propionate DISKUS 250mcg once daily versus placebo in symptomatic adolescent and adult subjects with asthma that are not controlled on short acting beta ₂-agonists alone
#SAS30022
478. A Phase II, Placebo-Controlled, Double-Blind, Parallel Group, Dose-Finding Study to Evaluate the Effectiveness of 28 days of Treatment with LDP-977 in Adult Asthmatics
#M97700-023
479. A Single Center, Placebo-Controlled, Ascending-Dose Safety and Tolerability Study of INS37217 Aqueous Nasal Spray in Healthy Non-Rhinitic Volunteers and Healthy Volunteers with Perennial Allergic Rhinitis
#07-101
480. A Dose Response Comparison of the Topical Efficacy of HFA-134a Beclomethasone Dipropionate versus Fluticasone Propionate in Subjects with Persistent Asthma
#1434-BRON
481. A 12-week, placebo and active controlled, parallel group study evaluating the safety and efficacy of Formoterol fumarate (10 µg bid) delivered by the multi-dose dry powder inhaler (MDDPI) versus placebo versus albuterol pMDI qid in patients with persistent asthma
#CFOR258 F2302
482. A Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis
#246-00
483. 16-Week Comparison of Asthma Control in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50 mcg BID, Fluticasone Propionate DISKUS 100 mcg BID, Salmeterol Xinafoate DISKUS 50 mcg BID, or Oral Montelukast 10 mcg QD
#SAS40036
484. An efficacy and safety study of fluticasone propionate aqueous nasal spray (FP) in subjects with seasonal allergic rhinitis (SAR)
#R1810221
485. Study of the efficacy and patient preference of albuterol delivered via the Pocketchamber™ (PC) versus the Aerochamber Plus™ (AC) in patients with asthma.
001
486. A double-blind, placebo-controlled, safety and efficacy study of three doses of INS37217 nasal spray in subjects with symptomatic perennial allergic rhinitis
#07-102

RESEARCH: MICHAEL J. WELCH, MD

487. A multicenter, double-blind, randomized, parallel groups placebo-controlled study to assess the efficacy and safety of fexofenadine 120 mg bid in patients with mild to moderate persistent asthma
M016455P/3001
488. A multicenter, double-blind, randomized, placebo-controlled, parallel study to assess the safety and tolerability of fexofenadine HCL 30 mg in children with allergic rhinitis
#M016455T/3002
489. Phase II, randomized, three-arm, double-blind, placebo controlled, evaluation of the safety and efficacy of doxepin hydrochloride 0.04%, Civamide (zucapsaicin) 0.01%, and placebo nasal solution in the treatment of subjects with vasomotor rhinitis.
#WL-1002-03-01
490. An open-label, one year long-term safety study of ciclesonide metered dose inhaler 50 µg/Day to 200 µg/Day (Ex Valve) administered once daily or fluticasone dry powder inhaler (Flovent®Rotadisk®) 50 µg or 100 µg administered twice daily for the treatment of children with persistent asthma
#XRP1526B-344/68
491. A phase II study comparing the efficacy and safety of oral efletirizine immediate release (IR) 7 mg, 10 mg, and 15 mg tablets administered twice a day and oral efletirizine extended release (ER) 35 mg tablets administered once a day in the morning for two weeks versus placebo in subjects suffering from seasonal allergic rhinitis
#A00321
492. The evaluation of tecastemizole administered to subjects with seasonal allergic rhinitis
#110-073
493. Evaluation of a newly developed preference questionnaire for intranasal corticosteroids in patients with allergic rhinitis treated with Nasacort® AQ (triamcinolone acetonide) nasal spray 220 mcg and Nasonex® (mometasone furoate) nasal spray 200 mcg – a pilot study
#4006
494. A twelve-week, randomized, double-blind, double-dummy, placebo-controlled trial of Symbicort™ (80/4.5 mcg) versus its mono products (budesonide and formoterol) in children (>12 years of age) and adults with asthma
#SD-039-0716
495. A phase IIIa, multi-center, randomized, double-blind, parallel-group, placebo-controlled study on the efficacy and safety of fexofenadine HCL 180 mg once daily in chronic idiopathic urticaria
#M016455A/4121
496. An efficacy and safety study of levalbuterol, racemic albuterol and placebo in subjects twelve years of age and older with asthma
#051-353
497. A randomized, placebo-controlled, crossover study to assess the antihistamine activity and sedation potential of a new loratadine lingual spray formulation versus Claritin® tablets in healthy volunteers
#001

RESEARCH: MICHAEL J. WELCH, MD

498. A multicenter, randomized, double-blind, double-dummy, placebo controlled, parallel group, four-week study assessing the efficacy of fluticasone propionate aqueous nasal spray 200 mcg QD versus montelukast 10mg QD in adolescent and adult subjects with asthma and seasonal allergic rhinitis who are receiving concurrent open-label Advair Diskus[†] 100/50 mcg BID
#SAM40066
499. A placebo- and active-controlled efficacy and safety study of a once-daily fixed combination tablet of desloratadine 5 mg/pseudoephedrine 120 mg (SCH483 [5/120]) in subjects with seasonal allergic rhinitis
#P01861
500. A randomized, multicenter, placebo-controlled parallel group study of four months duration per patient treatment to evaluate the safety and efficacy of treatment with 24 µg b.i.d. and 12 µg b.i.d. formoterol, double-blind, and 12 µg b.i.d. formoterol with additional on-demand formoterol doses, open-label, in adolescent and adult patients with persistent stable asthma
#CFOR258D2307
501. A randomized, double-blind, placebo-controlled trial of Astelin® (azelastine hydrochloride) nasal spray, Clarinex® (desloratadine) and Astelin® nasal spray plus Claritin® (loratadine) in patients with seasonal allergic rhinitis
#414
502. A placebo-controlled, efficacy and safety study of olopatadine nasal spray for the treatment of seasonal allergic rhinitis
#C-02-37
503. A multicenter, double-blind, randomized, parallel study comparing the efficacy and safety of fexofenadine 120 mg BID, fexofenadine 240 mg QD, and placebo in subjects with perennial allergic rhinitis
#M016455TM/3001
504. A multicenter, randomized, parallel-group, double-blind efficacy and safety study of INS37217 nasal spray versus placebo in subjects with perennial allergic rhinitis
#07-105
505. A randomized, double-blind, placebo-controlled trial of Astelin® (azelastine hydrochloride) nasal spray 137 mcg plus Allegra (fexofenadine hydrochloride 60 mg) in patients with seasonal allergic rhinitis
#415
506. A randomized, double-blind, placebo-controlled trial of Astelin® (azelastine hydrochloride) nasal spray 137 mcg at a dosage of one spray per nostril twice daily in patients with seasonal allergic rhinitis
#420
507. An open label pilot study of Astelin® (azelastine hydrochloride) nasal spray 137 mcg in the treatment of nasal congestion in patients with seasonal allergic rhinitis
#421
508. Distribution of the clearance and terminal-phase half-life of tecastemizole 30 mg (population pharmacokinetic screen)
#110-083

RESEARCH: MICHAEL J. WELCH, MD

509. A multicenter, double-blind, randomized study investigating the clinical effect of montelukast on allergic rhinitis in patients with seasonal allergic rhinitis and chronic asthma – Spring 2003 study
#269-00
510. An efficacy and safety study of levalbuterol 90 mcg, racemic albuterol 180 mcg and placebo in subjects twelve years or older with asthma
#051-355
511. Efficacy and safety of 200 mcg QD or 200 mcg BID mometasone furoate nasal spray (MFNS) vs. amoxicillin vs. placebo as primary treatment of subjects with acute rhinosinusitis
#P02683
512. A randomized, double-blind, parallel-group multicenter efficacy and safety phase IIB pilot study of esomeprazole 40mg twice daily versus placebo twice daily in adult asthmatics treated for 4 months
#SD-NEE-0003
513. A comparison of fexofenadine HCL 180 mg, desloratadine 5 mg and placebo in suppression of wheal and flare induced by histamine
#M016455A/4145
514. An open-label, multi-center study to evaluate the performance and patient satisfaction of fluticasone propionate/salmeterol HFA with counter in asthma or COPD subjects at least 12 years of age
#SAS30033
515. An open-label, multi-center study to evaluate the performance and patient satisfaction of albuterol HFA with counter in asthma or COPD subjects at least 4 years of age
#SB030003
516. Term safety study of olopatadine nasal spray
#C-01-92
517. A twelve week, randomized, double-blind, parallel group trial comparing the efficacy, safety and tolerability of a 20mg daily dose of IPL512, 602 oral tablets to placebo in patients with mild to moderate persistent asthma
#AVE0547A/2001
518. A randomized, double-blind, placebo-controlled multicenter, parallel-group dose-response study evaluating the safety and efficacy of oral NGD 2000-1 dibesylate tablets in patients with mild to moderate asthma
#NC-00-004
519. Dose ranging study of Ro 27-2441 in patients with persistent asthma not treated with inhaled corticosteroids.
#BA16631-A
520. A multicenter, parallel study comparing the efficacy and safety of PULMOCORT RESPULES® (budesonide inhalation suspension) at 0.5 mg, QD, 1.0 mg QD, 1.0 BID, 2.0 BID and PULMICORT TURBUHALER ® (budesonide) at 400 mcg BID in adolescents (12 Years of Age and Older) and adults with moderate to severe asthma
#SD-004- 0764
521. A parallel-group study investigating the clinical effect of L-000888839 in patients with seasonal allergic rhinitis – a pilot study during the fall season
#005

RESEARCH: MICHAEL J. WELCH, MD

522. A 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long term treatment in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS BID or fluticasone propionate DISKUS BID (or placebo BID if asymptomatic)
#SAM40086
523. A placebo-controlled, parallel-group study investigating the clinical effects of montelukast in patients with perennial allergic rhinitis
#265
524. A twelve-week, active-controlled study of SYMBICORT® pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma – SPROUT
#SD-039-0725
525. A twelve-week, placebo- and active-controlled study of SYMBICORT® pMDI administered once daily in adults and adolescents with asthma – STEM
#SD-039-0726
526. Qualitative assessment of patient diary questions to assess patient perception of the onset of effect if asthma medication using cognitive debriefing methodology.
#A2-3269
527. 3-week, open-label, uncontrolled, multicenter study evaluating the functionality of the Foradil® Certihaler® device in patients with asthma
#CFOR258F2304A
528. Efficacy and Safety of 200mcg QD or 200mcg BID Mometasone Furoate Nasal Spray (MFNS) vs. Amoxicillin vs. Placebo as Primary Treatment of Subjects with Acute Rhinosinusitis
#P02692
529. A 1 year, randomized, double-blind, parallel-group, placebo-controlled, multicenter evaluation of efficacy, safety, pharmacokinetics and pharmacodynamics of omalizumab in children (6 - <12 years) with moderate-severe, persistent, inadequately controlled allergic asthma.”
#CIGE025AIA05
530. Psychometric Evaluation of Patient Satisfaction with Asthma Treatment
#HRA 23-371B
531. A Multicenter, double-blind, placebo-controlled, randomized, parallel-group study to evaluate the clinical effect of oral Montelukast versus placebo during the allergy season in patients with seasonal aeroallergen sensitivity and chronic asthma which is also active during allergy season
#289
532. A Multicenter, Randomized, Double-Blind Parallel Group Study of the Effects of Ciclesonide HFA-MDI 640 µg/day & beclomethasone HFA-MDI 640 µg/day on lens opacification in adult subjects w/ moderate to severe persistent asthma
#XRP1526B – 3027
533. A Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Mast Cell Inhibitor, R-926112, in Patients with Symptomatic Seasonal Allergic Rhinitis in a Park Setting
#R-926112-004

RESEARCH: MICHAEL J. WELCH, MD

534. A randomized, controlled study of roflumilast (250 mcg and 500 mcg) versus placebo in patients with asthma. A 24-week, multicenter, multinational, double-blind, parallel group clinical study
#BY217/M2-023
535. Ability to swallow with and without the aid of a pill cup in pediatrics subjects ages >6 to <12 years of age
#M016455C/6001
536. A 3-week, open-label, uncontrolled, multicenter study evaluating the functionality of the Foradil[®] Certihaler[®] device in patients with asthma
#CFOR258 F2306
537. 12 week study to assess the efficacy and safety of Symbicort[®] pMDI 160/4.5 µg x 2 actuations once-daily (QD) compared to Symbicort pMDI 80/4.5 µg x 2 actuations QD, Symbicort pMDI 80/4.5 µg x 2 actuations twice-daily (BID) and to budesonide pMDI 160 µg x 2 actuations QD in asthmatic subjects 12 years of age and older
D5896C0001
538. A placebo controlled study of the efficacy and safety of desloratadine vs. fexofenadine 180 mg. in the treatment of subjects with symptomatic seasonal allergic rhinitis (SAR)
P04053-11
539. Pediatric Questionnaire on Asthma Control: Initial Validation Study
GHO102199
540. Crossover study comparing the effect of L-000888839 with placebo & concomitant administration of L-000888839 plus montelukast in adults with chronic asthma
#008
541. A placebo-controlled, dose ranging study, to assess the efficacy and safety of 4 doses of QAB149 (50, 100, 200 & 400 ug) delivered via a multiple dose inhaler, and 1 dose of QAB149 (400 µg) delivered via a single dose inhaler, in adult and adolescent patients (12 – 75 years old inclusive) with stable, persistent asthma
CQAB149A2216
542. A four-week, placebo-controlled, study of ventolin HFA MDI delivered TID with facemask and valved holding chamber (Aerochamber Plus;) in subjects birth to <24 months in age with symptoms of bronchospasm (i.e. wheeze, cough, dyspnea or chest tightness) consistent with obstructive airways disease.
SB030001
543. A Phase 3 clinical trial designed to assess the efficacy and safety of ciclesonide applied as a nasal spray at three dose levels (100 mg, 200mg, or 25mg, once daily) in the treatment of perennial allergic rhinitis (PAR) in patients 6–11 years of age
BY9010/M1-403
544. Pharmacodynamics of the 88 mcg BID dose of the hydrofluoroalkane propellant formulation of inhaled fluticasone propionate following administration via the metered-dose inhaler in pediatric subjects 4 to 11 years of age with asthma
FAP 19052
545. A preference evaluation of Nasonex nasal spray (unscented vs. Flonase nasal spray (scented) in subjects with symptomatic allergic rhinitis (AR) single-dose cross-over
P04207

RESEARCH: MICHAEL J. WELCH, MD

546. A placebo-and active-controlled (ciclesonide metered dose inhaler), dose range finding study of ciclesonide administered by dry powder inhaler (Ultrahaler[®]) in adult and adolescent patients with persistent asthma.
AVE2635A/2001
547. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 100 mcg for 4 weeks in adult and adolescent subjects (12 years of age) with perennial allergic rhinitis (PAR)
#FFR30002
548. Randomized double-blind trial of Astelin[®] (azelastine hydrochloride) nasal spray compared to Zyrtec[®] (cetirizine) in patients with seasonal allergic rhinitis
MP 426
549. A randomized, double-blind, placebo-controlled study evaluating the effects of MN-001 in subjects with mild to moderate asthma
#MN-001-CL-001
550. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of once-daily, intranasal administration of GW685698X aqueous nasal spray 50mcg and 100mcg for 12 weeks in pediatric subjects ages 2 to <12 years with perennial allergic rhinitis (PAR)
#FFR30008
551. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 50mcg and 100mcg for 2 weeks in pediatric subjects Ages 2 to <12 years with seasonal allergic rhinitis (SAR)
#FFR100010
552. randomized, double-blind, placebo-controlled, single-dose, 3-period crossover study to determine the effect of PLA-902 on exercise-induced bronchoconstriction
#PLA-902
553. Pilot efficacy and safety field trial of Desloratadine administered concomitantly with Oxybutynin, in subjects with seasonal allergic rhinitis and post-nasal drip
#SP4258
554. safety and efficacy of olopatadine hydrochloride nasal spray in pediatric patients
#C-04-20
555. Safety and bioequivalence of Triamcinolone Acetonide Nasal Spray compared w/ Nasacort AQ[®] nasal spray 55 mcg in the relief of signs & symptoms of SAR
#CPL-404
556. A randomized, double-blind, placebo-controlled, parallel-group study of ciclesonide metered-dose inhaler administered at a daily dose of 160 ug either in a once-daily (160 ug qd) or a twice-daily (80 ug bid) regimen for 12 weeks in adults and adolescents with mild to moderate persistent asthma treated previously with inhaled corticosteroids
#XRP1526B/3030
557. A 3-week multicenter study investigating patient use and functionality of the Foradil[®] Certihaler[®] device in patients with asthma
#CFOR258F2309
558. A multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 µg

RESEARCH: MICHAEL J. WELCH, MD

administered either in a once-daily in the morning regimen (160 µg qd AM) for 16 weeks or in a 160 µg AM regimen for 12 weeks preceded by a twice-daily regimen (80 µg bid) for 4 weeks, or in an 80 µg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids

#XRP1526B/3031

559. A phase II multi-center, randomized, double-blind, active and placebo--controlled 7 day study of mast cell inhibitor, R926112, in patients with symptomatic seasonal allergic rhinitis
#C-926112-005
560. Qualitative Research Into Asthma Control
#25-586A
561. A placebo- and active-controlled, parallel-group, dose-finding study of formoterol fumarate given by dry powder inhalation using the Ultrahaler® in adult and adolescent patients with persistent asthma
#AVE2635A-2003
562. Randomized, multicenter, crossover study to evaluate sensory attributes of olopatadine 0.6% nasal spray and Astelin® in patients with allergic rhinitis#C-03-49
563. A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair® DISKUS 250/50 mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults with Mild Persistent Asthma
#NONE0-1-00081
564. A Phase III Multicenter Study to Demonstrate the Sensitivity and Specificity of Aridol (Mannitol) Challenge to Predict Bronchial Hyperresponsiveness as Manifested by a Positive Exercise Challenge in Subjects Presenting with Signs and Symptoms Suggestive of Asthma but Without a Definitive Diagnosis
#DPM-A-305
565. Childhood asthma control test: Longitudinal validation study.
8ADA106614
566. Efficacy and safety of combination Loratadine/Montelukast QD vs Pseudoephedrine and placebo in the treatment of subjects with seasonal allergic rhinitis.
#P04095
567. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily intranasal administration of GW685698X aqueous nasal spray 100mcg for 6 weeks in adult and adolescent subjects 12 years of age and older with perennial allergic rhinitis (PAR).
FFR106080
568. Assessment of safety, tolerability, and pharmacokinetics of Zileuton Injection in patients with asthma.
CTI-04-C05-201
569. A multicenter, randomized, double-blind, triple dummy, placebo-controlled, parallel group, four-week study assessing the efficacy of fluticasone propionate aqueous nasal spray 200 mcg QD versus Montelukast 10 mg QD in adolescent and adult subjects with asthma and seasonal allergic rhinitis who are receiving Advair DISKUS® 100/50mcg BID or placebo BID.
ADA103578

RESEARCH: MICHAEL J. WELCH, MD

570. Randomized, double-blind, placebo-controlled trial of the safety and efficacy of MP03-33 in patients with seasonal allergic rhinitis.
430
571. Psychometric evaluation of the asthma control outcome and risk assessment measures.
A2-3721
572. A placebo-controlled, parallel-group, clinical trial designed to assess the safety and efficacy of Ciclesonide (200 mcg and 100 mcg, once daily) applied as a nasal spray for two weeks in the treatment of seasonal allergic rhinitis (SAR) in patients 6 to 11 years of age.
BY9010/M1-417
573. A Multi-Center, No Drug Treatment, Cross-Sectional Survey Study to Develop and Validate the Rhinitis Control Assessment Questionnaire (RCAQ) in Adult and Adolescent Subjects 12 Years of Age and Older with Non-Infectious Allergic Rhinitis
FFU 108675
574. Pilot polysomnography study in subjects with seasonal allergic rhinitis who report sleep disturbances and daytime somnolence
P04827
575. A Randomized, Cross-Over Design Study Evaluating a Traditional Paper Symptom Diary vs. the VOCEL® Mobile Diary in Subjects 12 years and Older with Mild to Moderate Persistent Asthma Receiving Alvesco® 80 µg BID
CICLE-L-01335
576. Double-Blind Multi-Centre, Placebo-Controlled, Clinical Study to Evaluate the Clinical Equivalence of 128 mcg of Budesonide Nasal Spray (Apotex Inc., Canada) vs. 128 mcg of Rhinocort Aqua® Nasal Spray (AstraZeneca, USA) for the Indication of Seasonal Allergic Rhinitis
BUDE-NASO-01NB01-CE
577. Psychometric Evaluation of the Asthma Control Outcome and Risk Assessment Measures
UBC A2-3721C
578. A multicenter, randomized, double-blind, placebo-controlled parallel group 8-week study to evaluate the efficacy and safety of chewable Montelukast when initiated at the start of the school year in pediatric patients with chronic asthma
340-00
579. A Clinical Study to Evaluate the Safety and Efficacy of Claritin 12-Hour 5 mg Loratadine Tablet BID vs. Placebo Tablet in the Treatment of Allergic Rhinitis
CL2006-03
580. An eight week, randomized, double-blind, parallel group, multicenter trial comparing the efficacy and safety of Oral IPL512,602 to placebo in subjects with moderate to severe persistent asthma inadequately controlled on inhaled corticosteroids
2002
581. A Patient Preference Evaluation Study of Fluticasone Nasal Spray and Fluticasone Propionate Aqueous Nasal Spray in Subjects with Allergic Rhinitis
FFU108556
582. A phase3, double-blind, placebo-controlled, multi-center, randomized study evaluating the safety and efficacy of SPRC-AB01, Tobramycin Solution for nasal inhalation, in post-surgical subjects with chronic rhinosinusitis
SPRC-AB01-003
583. Safety Study of Olopatadine Nasal Spray

RESEARCH: MICHAEL J. WELCH, MD

- # C-05-69
584. A placebo-controlled, stratified, multicenter, 12-week study comparing the safety and efficacy of fluticasone and formoterol combination (FlutiForm™ 100/10µg or 250/10µg twice daily) in a single inhaler (SkyePharma HFA pMDI) with the administration of placebo of fluticasone (100/10µg or 250/10µg twice daily) and formoterol (10µg twice daily) alone in adult patients with asthma
2028-3-004
585. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Multiple Dosing Regimens of Nasal CO2 in the Treatment of Allergic Rhinitis
C211
586. A randomized, double-blind, placebo controlled, 3 arm, parallel group, phase 2 study investigating the efficacy, tolerability and pharmacokinetics of MAP0010 in asthmatic children and adolescents
0010-CL-P201
587. A double-blind placebo-controlled, randomized, parallel-group, single-site study of Nasonex Nasal Spray in subjects with mild-moderate obstructive sleep apnea-hypopnea (OSAHS) associated with perennial allergic rhinitis (PAR) using home-monitored cardio-respiratory methodology
P04726
588. Assessment of the content validity of the asthma Quality of Life Questionnaire (AQLQ) in patients with moderate to severe asthma
A2-4158 000
589. A Placebo-Controlled Study of the Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure # P04295
590. Inhaler Technique Evaluation for Pediatric Asthma
HRA 25-587A
591. A comparative study of the efficacy and tolerability of maintenance treatment of patients with mild/moderate persistent asthma with Asmanex Twisthaler 220 mcg QD PM versus “Asmanex” Placebo QD PM
P04654
592. Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 years or older) with Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy
#BY9010/M1-490
593. Study to Evaluate Efficacy & Safety of GW685698X 200mcg BID GW685698X 200mcg & 400mcg QD in AM, & GW685698X 200mcg & 400mcg QD in the Evening Compared w/ Pbo for 8 Wks in Subjects 12+ w/persistent asthma
#FFA106783
594. Placebo Controlled Study of Nasonex in the Treatment of Seasonal Allergic Rhinitis
#P05067A
595. Randomized, Double-blind, Placebo-controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 317 in Subjects With Moderate to Severe Asthma
#20060161

RESEARCH: MICHAEL J. WELCH, MD

596. Randomized, double-blind, placebo controlled trial of the safety and efficacy of MP03-36 and MP03-33 in patients with perennial allergic rhinitis
#MP434
597. Active-Controlled Trial of the Safety and Tolerability of MP03-36 in Patients with Perennial Allergic Rhinitis
#MP436
598. A Double-Blind, Placebo Controlled, Randomized Study to Evaluate the Clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma Which is Also Active During Allergy Seasons in Pediatric Patients with Seasonal Aeroallergen Sensitivity
#336
599. A two-week, randomised, double-blind study assessing the Onset of Effect Questionnaire (OEQ) administered daily versus weekly in adult subjects (≥ 18 years of age) with mild to moderate asthma, receiving SYMBICORT® pMDI 80/4.5 μg x 2 actuations twice daily or budesonide HFA pMDI 80 μg x 2 actuations twice daily
#D5896C00023
600. A double-blind, randomized, placebo-controlled, dose-ranging study to assess the efficacy and safety of ciclesonide HFA nasal aerosol in adult and adolescent patients 12 years and older with seasonal allergic rhinitis (SAR)
#BY9010/M1-602
601. A 26-week placebo-controlled efficacy and safety study of mometasone furoate/formoterol fumarate combination formulation compared with mometasone furoate and formoterol monotherapy in subjects with persistent asthma previously treated with low-dose inhaled glucocorticosteroids
#P04073
602. A 26-week placebo-controlled efficacy and safety study of mometasone furoate/formoterol fumarate combination formulation compared with mometasone furoate and formoterol monotherapy in subjects with persistent asthma previously treated with medium-dose inhaled glucocorticosteroids
#P04334
603. A 26 week treatment, randomized, multi center, double blind, double dummy, parallel-group study to assess the safety of indacaterol (300 and 600 μg o.d.) in patients with moderate to severe persistent asthma using salmeterol (50 μg b.i.d.) as an active control
#CQAB149B2338
604. Randomized, double-blind, placebo-controlled trial of the safety and efficacy of MP03-36 in patients with seasonal allergic rhinitis
#439
605. A phase II, double-blind, placebo-controlled, multi-center, randomized study evaluating the safety and efficacy of SPRC-AB01, tobramycin solution for nasal inhalation, in post-surgical subjects with chronic sinusitis
SPRC-AB01
606. A randomized, double-blind, placebo-controlled study to evaluate the efficacy of Ziluten controlled-release (CR) tablets versus placebo in adult patients with asthma poorly controlled on moderate dose inhaled corticosteroids (ICS)
CTI-03-C07-401
607. Efficacy and safety of concurrent administration of mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray administered once daily (QD) vs. oxymetazoline

RESEARCH: MICHAEL J. WELCH, MD

- twice daily (BID), mometasone furoate QD, and placebo in the treatment of subjects with seasonal allergic rhinitis
P04500
608. A randomized, double-blind, placebo-controlled, active comparator, one-week, cross-over, multicenter study to evaluate the efficacy and patient preference of nasal spray characteristics of once-daily, intranasal administration of 110mcg fluticasone furoate nasal spray and 200mcg fluticasone propionate nasal spray in adult subjects with seasonal allergic rhinitis
FFU105927
609. Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy (Bronchodilation) and Safety of 4 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (2 µg, 5 µg, 10 µg, 20 µg) Delivered by the Respimat® Inhaler in Patients with Asthma
#1222.6
610. Efficacy and safety of 200 mcg BID mometasone furoate nasal spray (MFNS) vs placebo as adjunctive treatment to antibiotics in relief of symptoms of acute bacterial sinusitis
P04824
611. A randomized, double blind, placebo controlled, parallel group, study investigating the safety and efficacy over 12 weeks treatment period of MAP0010 in asthmatic infants and children 12 months to 8 years of age
#0010-CL-P301
612. Validation of patient-reported outcomes in patients with moderate to severe asthma
#20070787
613. A randomized, double-blind, placebo-controlled, parallel-group study comparing the bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (APOTEX, INC.) to that of Nasacort® AQ Nasal Spray (Aventis Pharmaceutical Products, Inc.) in the treatment of seasonal allergic rhinitis
TRIA-NASO-05RB02-CE
614. Test for respiratory and asthma control in kids (TRACK)
CTI-07-503
615. Safety and efficacy of olopatadine HCl nasal spray in 6-11 year old patients
C-07-01
616. Evaluation of successful use of a breath-actuated inhaler: a prospective, randomized, open-label, 2 arm parallel study
IXR-304-04-167
617. Exploratory study to measure the effect of Breathe Right Strips on nasal patency in healthy children
B3340547
618. Randomized, double-blind trial of MP29-02 nasal spray compared to placebo, azelastine hydrochloride nasal spray, and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis
#4002
619. A randomized, double blind, active controlled, phase 3 extension study investigating the safety and efficacy over 40 weeks of 2 doses of MAP0010 in asthmatic infants and children (aged 12 months to 8 years at enrollment into the MAP0010-CL-P301 study)
#0010-CL-P301X

RESEARCH: MICHAEL J. WELCH, MD

620. A multi-center, randomized, double blind, placebo controlled parallel group study of the safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d. dosing in children aged 2 to 6 years suffering from allergic rhinitis or chronic urticaria of unknown origin
A00426
621. A randomized, double-blind, double-dummy, placebo-controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily and salmeterol 50mcg administered twice daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma.
B2C109575A
622. Placebo-controlled study of mometasone furoate nasal spray (MFNS) 200 mcg QD in the relief of nasal congestion associated with seasonal allergic rhinitis (SAR)
P05529
623. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study Comparing the Safety and Efficacy of MAP0010 (0.135 mg And 0.25 mg) with Placebo in 12-Month-Old to 8-Year-Old Children with Asthma
#0010-CL-P302
624. Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults & Adolescents 12 and Older w/ PAR
#FFR110537
625. A double-blind, randomized, multicenter, cross-over evaluation of the sensory attributes of Olopatadine 0.6% and Azelastine 137 mcg nasal sprays in patients with allergic rhinitis (Sensory II)
SMA-08-21
626. Double-blind, randomized, placebo-controlled, multi-center, parallel group, dose-ranging study of MK0633 in adult patients with chronic asthma
007
627. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide in the Treatment of Seasonal Allergic Rhinitis
C215
628. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Sublingual Immunotherapy (SLIT) in Adults Sensitized to the Standardized Allergenic Extract, Cat Hair (*Felis domesticus*)
ALI002-08
629. A double-masked, randomized, parallel group comparison of seasonal allergic rhinitis treatment with olopatadine 0.6% and azelastine 0.1% when treatments are used in combination with fluticasone propionate 50 mcg nasal spray
#SMA-08-23
630. A multicenter, randomized study starting with a 4-week, 2-way crossover double-blind treatment phase comparing the efficacy and safety of Combivent® CFC MDI to albuterol HFA MDI followed by a 4-week open-label Combivent Respimat® treatment phase when all study drugs are used for symptom relief “as needed” in patients with moderate-to-severe asthma (GINA 2007 Treatment Steps 3 to 5)
#1012.57

RESEARCH: MICHAEL J. WELCH, MD

631. A double-blind, randomized, placebo-controlled, parallel-group, multi-center, dose-range-finding study to assess the efficacy and safety of BDP HFA nasal aerosol in adult and adolescent patients (12 years and older) with seasonal allergic rhinitis (SAR)
BDP-AR-201
632. Safety of PATANASE® Nasal Spray in Patients with Perennial Allergic Rhinitis
C-08-32
633. Pulmonary safety of Staccato® Loxapine for inhalation in patients with asthma
AMDC-004-105
634. Randomized, double-blind trial of MP29-02 nasal spray compared to placebo, azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis
MP4006
635. A phase 4, multicenter, double-blind, randomized, placebo-controlled study of the safety and tolerance of Regadenoson in subjects with asthma or chronic obstructive pulmonary disease (COPD)
#3606-CL-3001
636. A double-blind, randomized, placebo-controlled, parallel group exploratory study of the safety and efficacy of JNJ-39758979 in the treatment of adults with persistent asthma
39758979ASH2001
637. A double-masked, randomized, multi-center study examining the safety and efficacy of olopatadine 0.6% and azelastine 137 mcg nasal sprays in a two-week vasomotor rhinitis trial
SMA-09-03
638. Phase 2b, randomized study to evaluate the efficacy and safety of subcutaneous MEDI-258 in adults with uncontrolled asthma
CP198
639. Randomized, double-blind, placebo-controlled trial of the safety and efficacy of mp03-36 (0.15% solution) and mp03-33 (0.10% solution) in children ages >6 to <12 with perennial allergic rhinitis
MP441
640. A randomized, double-blind, placebo controlled, multiple dose phase 2 study to determine the safety and efficacy of amg 853 in subjects with inadequately controlled asthma
#20080615
641. A 6- month randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of once daily ciclesonide HFA nasal aerosol (80 and 160 µg) in the treatment of perennial allergic rhinitis (PAR) in subjects 12 years and older
#060-633
642. A randomized, multi-center, parallel group, double blind, study to assess the safety of QMF Twisthaler® (500/400 µg)and mometasone furoate Twisthaler® (400 µg) in adolescent and adult patients with persistent asthma.
CQMF149A2210

RESEARCH: MICHAEL J. WELCH, MD

643. A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control.
#CQAB149B2357
644. A long-term, randomized, double-blind study of the safety, tolerability and efficacy of acclidinium bromide at two dosage levels when administered to patients with moderate to severe, stable chronic obstructive pulmonary disease.
#LAS-MD-35
645. A Randomized, Double-blind, Single-dose Efficacy Study of 0.05% Oxymetazoline Fine Mist Spray in Adult Subjects Suffering from Nasal Congestion.
#2010042
646. Qualitative Interviews with Patients who have Asthma.
#10-1378A
647. A 6-Month Open-Label, Long-Term Safety Extension Study of Once Daily Ciclesonide HFA Nasal Aerosol (160 µg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older.
#060-635
648. A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax versus Placebo in Subjects 12 years and older with Persistent Asthma.
ABS-AS-301
649. A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma while Treated with Short Acting Beta₂-agonist.
LPA112186
650. A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 µg bid with placebo: a 6-week efficacy and safety study in children aged 6 to <12 years with asthma.
D589GC00001
651. A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 weeks in patients with moderate persistent asthma.
#204.418
652. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol (320 mcg, once daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Adult and Adolescent Subjects (12 Years of Age and Older).
BDP-AR-302
653. A randomized, dose-ranging, placebo-controlled trial to evaluate the effects of phenylephrine HCl immediate release tables on nasal congestion in subjects with seasonal allergic rhinitis
CL2010-06

RESEARCH: MICHAEL J. WELCH, MD

654. Psychometric evaluation of a novel questionnaire designed to assess patient satisfaction with and preference of intranasal corticosteroids administered via HFA aerosol or aqueous suspension used for the treatment of allergic rhinitis
#060-301
655. A prospective, open label, Assessment of the Albuterol ProAir HFA MDI integrated dose counter
ABM-AS-307
656. A randomized, double-blind, placebo-controlled, parallel-group study comparing the bioequivalence of ciclesonide nasal spray (APOTEX, Inc.) to that of Omnaris nasal spray (Sepracor, Inc.) in the treatment of seasonal allergic rhinitis
CICE-NASU-05SB03-CE
657. A randomized, placebo- controlled, parallel group study to assess the efficacy, safety, and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma
CQAW039A2201
658. A randomized, placebo-controlled trial to evaluate the effects of Phenylephrine HCl 30 mg Extended Release Tablets on nasal congestion in subjects with allergic rhinitis
CL2011-06
659. A randomized, double-blind, placebo-controlled, parallel-group, multi-center study to assess the efficacy and safety of BDP HFA Nasal Aerosol in pediatric subjects (6 to 11 years of age) with seasonal allergic rhinitis (SAR)
BDP-AR-305
660. A 12-week, double-blind, randomized, multi-centre, parallel-group study evaluating the efficacy, safety, and patient use (User Study) of Symbicort ® (budesonide/formoterol) Breath Actuated Metered Dose Inhaler (BA MDI) 2x160/4.5 µg twice daily compared with Symbicort (budesonide/formoterol) AC (actuation counter) pMDI ® 2x160/4.5 µg twice daily and budesonide AC pMDI 2 x 160 µg twice daily in adult and adolescent asthmatics
D5890C00003
661. An open label randomized two period two-way crossover study to evaluate efficacy, patient preference and satisfaction with Ciclesonide Nasal aerosol versus Mometasone Furoate Aqueous Suspension used for the treatment of allergic rhinitis
#060-302
662. Double-blind, double-masked, randomized, placebo-controlled, cross-over study of the bronchoprotective effect of generic levalbuterol tartrate HFA and Xopenex HFA® (levalbuterol tartrate) metered-dose inhaler (MDI) formulations against methacholine-induced bronchoconstriction in asthmatic subjects
C-2010-05
663. A 12-month, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations and change in lung function in patients (12-75 years of age) with eosinophilic asthma
C3072/3082
664. A 12-Week randomized, double-blind, placebo-controlled, parallel group, safety and efficacy study of ciclesonide nasal aerosol in subjects 6-11 years with perennial allergic rhinitis
SEP 060-306

RESEARCH: MICHAEL J. WELCH, MD

665. A 12-week dose-ranging study to evaluate the efficacy and safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) administered twice daily compared with placebo in adolescent and adult subjects with persistent asthma uncontrolled on non-steroidal therapy
#FpS-AS-201
666. A multicenter, consumer product evaluation of a single dose of Phenylephrine HCl 30mg Extended Release Tablets (Sinus Comfort)
#CL2012-03
667. A randomized, placebo-controlled, dose-ranging, multi-centre trial of QAW039 (1- 450 mg p.o.) to investigate the effect on FEV₁ and ACQ in patients with moderate-to-severe, persistent, allergic asthma, inadequately controlled with ICS therapy
#CQAW039A2206
668. A 2-week randomized, double blind, placebo controlled, parallel group, safety and efficacy study of Ciclesonide Nasal Aerosol in subjects 6 to 11 years with seasonal allergic rhinitis
#060-305
669. Non-invasive neurostimulation of the Vagus Nerve for the relief of acute bronchoconstriction due to asthma
#BC-US-06
670. Evaluation of hypoallergenicity of an amino acid-based infant formula
#09.55 PED
671. A phase 2, multicenter, parallel-group, randomized, double-blind, placebo- and active comparator-controlled, combination study of S 555739 and Cetirizine HCl in adult patients with seasonal allergic rhinitis
#1210D1526
672. A double-blind, placebo-controlled, four-way crossover study to compare the safety and efficacy of ONO-6950 20 mg and 200 mg QD versus placebo and Montelukast (Singulair) in asthmatic patients who exercise-induced bronchoconstriction
#ONO6959POU004
673. ACQ, AQLQ, RQLQ Equivalence Study
#1788A
674. Asthma Control Diary (ACD) Equivalence Study
#1643A
675. A phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of inhaled R940343 in patients with mild to moderate allergic asthma
#C-940343099
676. A multi-center, randomized, double-blind, vehicle-controlled, cross-over evaluation of the effects of KD1157 nasal spray on nasal challenge with allergen
#KD1157-AR02
677. A multi-center 52-week study to assess the safety of Albuterol *Spiromax*® in subjects with asthma
#ABS-AS-307
678. A randomized, placebo-controlled, Phase IIb dose-finding study of CYT003-QbG10, a TLR9-agonist, in patients with moderate to severe allergic asthma not sufficiently controlled on current standard therapy (GINA steps 3+4)
#CYT003-QbG10 12

RESEARCH: MICHAEL J. WELCH, MD

679. A Prospective, Open label, Assessment of the Albuterol ProAir HFA MDI integrated dose counter
#ABM-AS-307 Sub-Investigator
680. A 12-week Comparison of Efficacy and Safety of Albuterol Spiromax® Versus Placebo in Subjects 12 years and older with Persistent Asthma
#ABS-AS-301 Principal-Investigator
681. A Single-Dose Study to Assess the Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients with Exercise-Induced Bronchoconstriction (EIB)
#ABS-AS-302 Sub-Investigator
682. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week, Clinical Study Designed to Assess the Efficacy and Safety of BDP Nasal Aerosol (80 mcg, once daily) in Pediatric Subjects (4 to 11 Years of Age) With Perennial Allergic Rhinitis (PAR)
#BDP-AR-306 Principal-Investigator
683. A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Subjects with Severe Persistent Asthma Uncontrolled on Highdose Inhaled Corticosteroid Therapy
#FpS-AS-202 Sub-Investigator
684. Validation of the Morning Symptom Diary in Patients with COPD: Assessing Content Validity through Concept Elicitation and Cognitive Interviewing
#M-12674 Sub-Investigator
685. A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Cross-Over Evaluation of the Effects of KD1157 Nasal Spray on Nasal Challenge with Allergen
KD1157-AR02 Sub-Investigator
686. A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-38518168 in Symptomatic Adult Subjects with Uncontrolled, Persistent Asthma
#38518168ASH2001 Sub-Investigator
687. A Prospective, Open Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
#ABS-AS-308 Principal-Investigator
688. Double-blind, Placebo-Controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-Atopic, Asthmatic Patients with a Baseline, Pre-Bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled with Low Dose ICS Therapy
#CQAW039A2214A Sub-Investigator
689. A One-Year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects with House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma
#P05607 Principal-Investigator
690. A Randomized, Double-Blind, Multiple-Dose Trial of Mometasone Nasal Spray, 50 µg (Mylan), Nasonex® Nasal Spray, 50 µg (MSD-US), Nasonex® Nasal Spray Suspension, 50 µg (MSD-EU) and Placebo for the Treatment of the Signs and Symptoms of Seasonal Allergic Rhinitis in 1,520 Male and Female Volunteers
#MOMT-12084.

RESEARCH: MICHAEL J. WELCH, MD

691. A Randomized, Double-Blind, Double Dummy, Placebo Controlled, Parallel Group, 12 week Clinical Study to Assess the Efficacy and Safety of 80mcg or 160mcg/Day of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) in Adolescent and adult patients 12 years of age and older with Persistent Asthma.
#BDB-AS-302
692. A Randomized, Double Blind, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate (80 and 160 mcg/day) Delivered via Breath Actuated Inhaler (BAI) in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma
#BDB-AS-302
693. Double-Blind, Randomized, Crossover Allergy Study of an Extensively Hydrolyzed Casein Formula (NPS-G19A) Followed by a 16 Week Double Blind Feeding Period to Assess Growth, Safety and the Development of Tolerance to Cow's Milk Protein
#PRG-VA-14-001
694. A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older with Persistent Asthma.
#FSS-AS-305
695. Oral Desensitization to Peanut in Peanut-Allergic Children and Adults using Characterized Peanut Allergen (CPNA) Oral Immunotherapy (OIT) Safety Follow-On Study
#ARC002

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

1. The Nasal Acilia Syndrome. The American Academy of Pediatrics, Detroit, Michigan, October, 1980.
2. Autostimulatory Activity of Antigen Activated Human Mononuclear Cells. The Society for Pediatric Research, Poster session, San Francisco California, April, 1981.
3. Food Allergies. University of California, Los Angeles, Extension Program, "Asthma and Allergies", May, 1981.
4. A Minisymposium on Mucocutaneous Lymph Node Syndrome (MCLS): Possible etiologies for MCLS. The American Heart Association Pediatric Symposium: "Advances in the Management of Cardiopulmonary Distress and Emergencies in Children", Los Angeles, California, May, 1981.
5. Kawasaki's Disease. Pediatric Grand Rounds, Children's Hospital and Health Center, San Diego, California, March, 1982.
6. Steroids in Asthma. Pediatric Grand Rounds, Mercy Hospital, San Diego, California, September, 1982.
7. Coping with Allergies and Asthma. University of California, San Diego, Extension Course, October, 1982.
8. Immunology of Juvenile Rheumatoid Arthritis. University of California, San Diego, Pediatric Immunology/Allergy Division Seminar, December, 1982.
9. Juvenile Rheumatoid Arthritis. Pediatric Grand Rounds, Children's Hospital and Health Center, San Diego, California, January, 1983.
10. Immunodeficiencies. San Diego State University Nursing School, San Diego, California, November, 1983.
11. Evaluation of Twice-A-Day Dosing Theo-Dur Sprinkle in Young Children with Asthma. The American Association for Clinical Immunology and Allergy, Orlando, Florida, October, 1983.
12. Team Approach to the Child with Painful, Stiff Joints. Pediatric Grand Rounds, Children's Hospital and Health Center, San Diego, California, February, 1984.
13. Assessment of the Correlation of Rhinometry with the Symptoms and Signs of Allergic Rhinitis in Children. The American Academy of Allergy and Immunology, Chicago, Illinois, March, 1984.
14. Correlation of a MAST Profile with RAST. The American College of Allergists, San Francisco, California, April, 1984.
15. Lupus in Children and Adolescents. Community Conference on Lupus Erythematosus, Scripps Clinic and Research Foundation, San Diego, California, October, 1984.
16. Update on Management of Upper Respiratory Tract Allergies in Children. Symposium for Physicians - Moderator, San Diego, California, October, 1984.
17. Touching Tenderly: An OT Approach to Juvenile Arthritis and a Comparison to Rheumatoid Arthritis. OTAC 1984: Touch to Technology, Eighth Annual Conference of the Occupational Therapy Association of California, San Diego, California, October, 1984.
18. Evaluation of a Bead-Filled Capsule Product in Young Children with Asthma. Symposium on Childhood Asthma and Sustained-Release Theophylline, Whistler, Canada, September, 1985.
19. Evaluation of Ketotifen in Children with Chronic Moderately-Severe Extrinsic Asthma. Scientific Sessions of the Section on Allergy and Immunology at the 54th Annual Meeting of the American Academy of Pediatrics, San Antonio, Texas, October, 1985.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

20. Sorting Out Allergies versus Colds in the Childcare Setting. San Diego County Childcare Coordinating Council and the American Academy of Pediatrics Seminar "Health Needs in Child Care", San Diego, California, January, 1986.
21. Comparison of Bitolterol Mesylate and Isoproterenol by Metered-Dose Inhaler for Regular, Long-Term Treatment in Asthmatic Children. Scientific Sessions of the Section on Allergy and Immunology at the 55th Annual Meeting of the American Academy of Pediatrics, Washington, D.C., November, 1986.
22. Comparison of Bitolterol Mesylate and Isoproterenol by Metered-Dose Inhaler for Regular, Long-Term Treatment in Asthmatic Children. Poster Session of the American Academy of Allergy and Immunology, Washington, D.C., February, 1987.
23. Experience with Seldane-D. Merrell Dow Pharmaceuticals Conference, Lexington, Kentucky, September, 1987.
24. Diurnal Variation of Serum Theophylline Levels in Children on BID Theo-Dur. American Academy of Pediatrics, Section on Allergy & Immunology, New Orleans, Louisiana, October, 1987.
25. Evaluation of the Child with Recurrent Infection. American Academy of Pediatrics, San Diego, California, February, 1988.
26. Office Evaluation of the Child with Arthritis. American Academy of Pediatrics, San Diego, California, February, 1988.
27. Diurnal Variation of Serum Theophylline Levels in Children on BID Theo-Dur. The American Academy of Allergy and Immunology, Anaheim, California, March, 1988.
28. Bronchodilators in the Management of Asthma. The American Academy of Allergy and Immunology, Anaheim, California, March, 1988.
29. Evaluation of the Child with Joint Complaints. Children's Hospital, San Diego, March, 1988.
30. Common Problems in Pediatric Allergy and Asthma. Pediatric Grand Rounds, Children's Hospital, San Diego, California, August, 1988.
31. Pharmacokinetic Evaluation of Theo-Dur 450 mg (Theo 450) Tablets Given BID vs. Theo-Dur 300 mg (Theo 300) TID. American College of Allergy and Immunology, Los Angeles, November, 1988.
32. "Sorting Out Allergies from Infection." San Diego Home Day Care Provide Association Symposium, San Diego County Department of Education, February 11, 1989.
33. Juvenile Rheumatoid Arthritis. The Pediatric Upper Extremity, Department of Occupational Therapy, Children's Hospital and Health Center, San Diego, March, 1989.
34. Cromolyn use in asthma. Panamerican Pediatric Pulmonology Symposium, Latin American Cystic Fibrosis Congress, Mexico City, Mexico, July 17-21, 1989.
35. Rhinitis: Differentiation and Management for the Family Physician. American Academy of Family Physicians' Scientific Assembly. Los Angeles, California. September 21, 1989.
36. Clinical and Rhinomanometric Evaluation of Triamcinolone Acetonide Nasal Aerosol (TANA) in Children with Perennial Allergic Rhinitis (AR). American Academy of Pediatrics, Section on Allergy & Immunology Program for Scientific Sessions, Chicago, Illinois, October 21, 1989.
37. Hot Topics in Treatment of Allergic Disease. California Medical Assistants Association, Inc., San Diego Chapter, San Diego, California, December 13, 1989.
38. Advances in Treatment of Asthma. March Air Force Base, Riverside, California, January 10, 1990.
39. A Pediatric Respiratory Update. San Diego County Office of Education, School Nurses, San Diego, California, January 29, 1990.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

40. Children's Health Issues in Day Care. San Diego Family Day Care Association, San Diego, California, February 3, 1990.
41. Intranasal Fluocortin Butyl in Patients with Perennial Rhinitis: A 12-Month Study Including Nasal Biopsy. American Academy of Allergy and Immunology, Baltimore, Maryland, March 24, 1990.
42. When to Worry About the Child with Frequent Respiratory Infections and What to Do. Current Concepts in Pediatric Allergy and Otolaryngology. Children's Hospital and Health Center, San Diego, California, June 29, 1990.
43. Diagnosing Allergy: RAST versus Skin Test; When and Who to Refer. Current Concepts in Pediatric Allergy and Otolaryngology. Children's Hospital and Health Center, San Diego, California, June 29, 1990.
44. New Concepts in the Management of Asthma and Allergic Disease. Grand Rounds. Palomar Hospital, Escondido, California, November 15, 1990.
45. Office Practice of Allergy (Course Leader). American Academy of Pediatrics, San Diego, March 16, 1991.
46. The Role of Inflammation in Asthma. XLVI Congreso Nacional de la Sociedad Mexicana de Alergia e Inmunologia, A.C., Oaxaca, Mexico, August 22, 1991.
47. Drugs That Modify the Course of Asthma. XLVI Congreso Nacional de la Sociedad Mexicana de Alergia e Inmunologia, A.C., Oaxaca, Mexico, August 22, 1991.
48. Comparison of Intranasal Therapy With Beclomethasone Dipropionate vs. Cromolyn Sodium vs. Placebo in Children With Seasonal Allergic Rhinitis. American Academy of Pediatrics, New Orleans, Louisiana, October 26, 1991.
49. The Killer Bee Story: To "Bee" or Not "Bee" Concerned?. Grand Rounds, Children's Hospital and Health Center, San Diego, California, November 1, 1991.
50. New Concepts in Beta-agonist Therapy. San Diego Pharmacy Association, San Diego, California, November, 1991.
51. Anaphylaxis and Other Reactions to Foods, Drugs, Venoms, and Exercise-Induced Asthma. Current Concepts in Pediatric Medicine, Children's Hospital and Health Center, San Diego, California, February 7, 1992.
52. Drug Allergy. Current Concepts in Pediatric Medicine, Anaheim, California, March 7, 1992.
53. Update on Juvenile Rheumatoid Arthritis. Pediatric Grand Rounds, Mercy Hospital, San Diego, California, February 13, 1992.
54. Controversies in Pharmacotherapy of Asthma. (Program Planner and Moderator) Annual Session and Western Scientific Assembly, California Medical Association, Anaheim, California, March 16, 1992.
55. New Aspects of Bronchodilator Therapy for Asthma. San Diego Pharmacist Association, San Diego, California, May 15, 1992.
56. New Concepts in Bronchial Asthma. Current Concepts in Pediatric Respiratory Diseases 1992, San Diego, California, June 27, 1992.
57. Outpatient Management of Asthma in the 90's. San Ysidro Health Clinic, San Ysidro, California, April 16, 1993.
58. Update on Asthma Management in Children. TriCity Hospital Pediatrics Department, Oceanside, California, April 20, 1993.
59. When to Refer to an Allergist. Palomar Hospital, San Diego, California, September 9, 1993.
60. Inhaled Corticosteroids and Viral Infections. American Academy of Pediatrics, Section on Allergy and Immunology, Washington, D.C., October 30, 1993.
61. Insect Allergy. National Medical Equestrian Society, San Diego, California, November 6, 1993.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

62. New Approaches to Asthma. College of Osteopathic Medicine of the Pacific, Continuing Professional Education, San Diego, California, December 3, 1993.
63. Stretch Your Minds: Come Learn About Latex Allergy. Grand Rounds, Children's Hospital and Health Center, San Diego, California, December 17, 1993.
64. Being in Control of Asthma Instead of Vice Versa. Mary Birch Hospital for Women, San Diego, California, January 18, 1994.
65. Latex Allergy and Anaphylaxis. Children's Hospital of Orange County, Grand Rounds, March 9, 1994.
66. Immunology of Atopic Dermatitis. Children's Hospital and Health Center, San Diego Case Conference, San Diego, California, April 19, 1994.
67. Approaching Asthma in the Adolescent. Mercy Hospital, San Diego, California, April 22, 1994.
68. Summer Allergy - Sneeze, Wheeze and Killer Bees. Pediatric Grand Rounds, Children's Hospital and Health Center, July 8, 1994.
69. Bukstein D, Adinoff A, Bell T, Bronsky E, Ellis M, Geller D, Klimas J, Kraemer M, Lemen R, Mellon M, Pearlman D, Smith T, Szeffler S, Thomas M, Welch M, Wood R: 0.5% Nebulized nedocromil sodium reduces asthma symptoms in very young children. (abstr) Presented to the International Congress of Allergology and Clinical Immunology in Stockholm, Sweden, July, 1994.
70. Anaphylaxis Update. San Diego State University Continuing Medical Education Conference, San Diego, California, August 22, 1994.
71. Asthma Therapy 1994. Glaxo-sponsored educational meeting for primary care physicians, El Centro, California, September 21, 1994.
72. Asthma Pathway. Going Down the Clinical Pathway Together - Introducing New Guidelines for Optimal and Cost Effective Care for Bronchiolitis and Asthma. Children's Hospital and Health Center, San Diego, California, October 8, 1994.
73. Update on Beta-Agonists. San Diego Physician Assistant Association, San Diego, California, October 23, 1994.
74. Pharmacologic Management of the Child with a Rheumatologic Condition. Children's Hospital and Health Center, San Diego, California, November 11, 1994.
75. 3 Pediatricians Answer Your Most Commonly Asked Questions. Parent & Child Expo, San Diego Convention Center, San Diego, California, November 12, 1994.
76. Approach to the Child with Difficult Chronic Asthma. Pediatric Department, San Marcos Community Clinic, San Marcos, California, December 12, 1994.
77. Being in Control of Asthma. Mary Birch Hospital for Women, San Diego, California, January 19, 1995.
78. Use of Pulmonary Function Testing in the Office. One Hour Seminar for Annual Meeting of the American Academy of Allergy, Asthma and Immunology, New York, New York, February 27, 1995.
79. Current Trends in the Management and Treatment of Rhino-Sinusitis. American Academy of Allergy & Immunology, Modesto, California, March 25, 1995.
80. Update on Allergic Rhinitis Management. Sharp Memorial Hospital Department of Family Practice, Chula Vista, California, September 12, 1995.
81. Are the Schools Failing Our Children with Asthma or are the Doctors? Grand Rounds, Children's Hospital and Health Center, San Diego, California, September 15, 1995.
82. Pediatric Rheumatology. Children's Hospital and Health Center, San Diego, California, September 16, 1995.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

83. Pediatric Allergy. Scripps Clinic Noon Allergy Conference, La Jolla, California, September 19, 1995.
84. The Killer Bee Story: To "Bee" or Not "Bee" Concerned? Family Practice Division Meeting, Sharp Memorial Hospital, San Diego, California, October 9, 1995.
85. School and the Child with Asthma: The Role of the Pediatrician. American Academy of Pediatrics Annual Meeting, San Francisco, California, October 17, 1995.
86. How to Recognize and Treat Asthma and Allergies in Children. Palomar Medical Center, Escondido, California, October 14, 1995.
87. How to Recognize and Treat Asthma and Allergies in Children. Palomar Medical Center, Escondido, California, October 21, 1995.
88. Basic Approach to Control of Allergic Rhinitis, or, Sneezes and Sniffles and Snorts, Oh My! Words of Wisdom from the Wizard of Schnoz. Schering-Plough, San Diego, California, November 15, 1995.
89. Overview of Asthma/Asthma Therapy, Brief Review of Pathophysiology. American Lung Association, San Diego, California, November 18, 1995.
90. Humor and Magic: Approaches in Relaxing the Pediatric Patients. Grand Rounds, Children's Hospital and Health Center, San Diego, California, December 15, 1995.
91. Asthma. Sharp Grossmont Family Practice Residency Conference. San Diego, California, February 14, 1996.
92. Managing Allergies and Anaphylaxis at Camp. Association of Camp Nurses, 1996 National Education Conference, San Diego, California, March 2, 1996.
93. Practical Approach to Control of Allergic Rhinitis, or, Sniffles, and Snorts and Sneezes, Oh My! Practical Words of Wisdom from the "Wizard of Schnoz." Pomona Valley Hospital Medical Center, Pomona, California, March 5, 1996.
94. Pulmonary Function Testing in an Office Practice. American Academy of Allergy, Asthma and Immunology, New Orleans, Louisiana, March 19, 1996.
95. Pharmacologic Therapy: Options, Efficacy and Outcomes. American College of Occupational and Environmental Medicine (ACOEM). April 29, 1996.
96. Inhalers, Spacers, Powders, Meters, Nebulizers - Getting IT Right. Current Concepts in Pediatric Allergy and Otolaryngology 1996, Coronado, California, July 5, 1996.
97. Asthma 1996 - Breathing Made Easy. Current Concepts in Pediatric Allergy and Otolaryngology 1996, Coronado, California, July 6, 1996.
98. Our Love Affair with Corticosteroids. Current Concepts in Pediatric Allergy and Otolaryngology 1996, Coronado, California, July 6, 1996.
99. Primary Approach to Control of Allergic Rhinitis or Sniffles, Snorts and Sneezes, Oh My! Practical Words of Wisdom from the "Wizard of Schnoz." Grand Rounds, Children's Hospital and Health Center, San Diego, California, Friday, August 16, 1996.
100. Allergic Diseases of Childhood: The History, Physical Exam, Diagnosis and Treatment Options. Scripps Clinic Lecture Series, San Diego, California, August 20, 1996.
101. Exercise-Induced Asthma. Fitness Expo, Cigna Health Care, San Diego, California, August 24, 1996.
102. New Inhaled Steroid Therapy for Asthma, or How to Reach 1st Base and Beyond with Your Patients with Asthma. Glaxo Wellcome Research, San Diego, California, September 10, 1996.
103. New Inhaled Steroid Therapy for Asthma, or, How to Reach 1st Base and Beyond With Your Patients With Asthma. Allen and Hanbury, San Diego, California, September 10, 1996.
104. Rational Use of Antihistamines in Allergic Disease. Pfizer Pharmaceuticals, San Diego, California, September 18, 1996.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

105. All About Kids. Children's Hospital Foundation, San Diego, California, September 18, 1996.
106. Asthma and the School Child. National Association of Pediatric Nurse Associates and Practitioners, San Diego, California, September 21, 1996.
107. Practical Medical Approach to Chronic or Recurrent Sinusitis. Rancho Bernardo Inn, San Diego, California, November 21, 1996.
108. Appointment with the allergist. Current Concepts in Pediatric Medicine, Children's Hospital and Health Center, San Diego, California, March 1, 1997.
109. Using all the gadgets for asthma: getting it right. Current Concepts in Pediatric Medicine, Children's Hospital and Health Center, San Diego, California, March 1, 1997.
110. Inhaled Asthma Therapy: Getting the Technique Right. Children's Hospital San Diego, San Diego, California, May 10, 1997.
111. Asthma in the school-age child. San Diego Unified School Nurses CME Course, Double Tree Hotel, San Diego, California, March 14, 1997.
112. Our Love Affair with Corticosteroids - potential impact on children with asthma. Scripps Clinic and Research Foundation, Noon Conference, La Jolla, California, July 23, 1997.
113. Taking control of your asthma. Longs Drugs, San Diego, California, August 12, 1997.
114. Asthma Therapy: Inhalers, Spacers, Meters, and Nebulizers. Mercy Hospital Grand Rounds, San Diego, California, September 16, 1997
115. Asthma: Inhalers, Spacers, Meters, Nebulizers. Internal Medicine 1997 CMEA Fall Program, Coronado, California, September 28, 1997.
116. The New Revolution in Asthma Care. Internal Medicine 1997 CMEA Fall Program, Coronado, California, September 29, 1997.
117. Prevention and Treatment of Anaphylaxis. Internal Medicine 1997 CMEA Fall Program, Coronado, California, September 29, 1997.
118. Tricks to Stamping out Sneezes, Snuffles and Salutes. Pediatric Respiratory Conference, Mercy Hospital, San Diego, California, October 24, 1997.
119. Asthma: What the Pediatrician Needs to Know in 1997. American Academy of Pediatrics, 1997 Annual Meeting, New Orleans, Louisiana, November 1, 1997.
120. Debate: The Role of Nebulizer Use for Asthma in Children Less Than 3 Years Old - Why Not MDI by Aerochamber? American Academy of Pediatrics, 1997 Annual Meeting, New Orleans, Louisiana, November 2, 1997.
121. "Workshop: Outpatient Asthma Management: Understanding PFTs and ALL the available Gadgets for Treatment" - National Primary Care Conference, San Diego, CA, February 11, 1998.
122. "Workshop: Optimizing Care for the Asthmatic Child" - 1998 CMEA Winter Program, Hyatt Islandia, San Diego, CA February 15-18, 1998.
123. "Who Should Take Care of the Asthma Patient - the Primary Care Physician or the Specialist?" - 1998 AAAAI National Meeting, Washington, DC, March 14, 1998.
124. "New Corticosteroids for Asthma: Moving into the 21st Century." Allergy for Health Care Professional General Session, 1998 AAAAI National Meeting, Washington, DC, March 16, 1998.
125. "All The Gadgets Used for Asthma: Getting It Right" - Children's Hospital San Diego annual CME meeting, Hilton Hotel, San Diego, CA, June 19, 1998.
126. "Our love affair with inhaled corticosteroids" - Grand Rounds, Scripps - Encinitas Hospital, San Diego, CA, June 29, 1998.
127. "Achoo!" - Noses, Sneezes and Wheezes - Children's Hospital San Diego, CA, September 17, 1998.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

128. Debate: Is Skin Testing Valid Under Age Two? American Academy of Pediatrics 1998 Annual Meeting, October 18, Moscone Convention Center, San Francisco Marriott.
129. Puffers, Powders, Spacer, Meters, and Nebulizers: Using Gadgets for Asthma and Getting It Right. American Academy of Pediatrics 1998 Annual Meeting, October 18, 1998, Moscone Convention Center, San Francisco Marriott.
130. "New Treatment Therapy for Asthma." Singulair Symposia/Museum of Man, October 8, 1998, El Prado, Balboa Park, San Diego, CA.
131. The New Revolution In Asthma Care. Internal Medicine CME Fall Program 1998. October 9-13, 1998, Loews Coronado Bay Resort, San Diego, CA.
132. Current Techniques in Managing Allergic Rhinitis. October 25, 1998, Marriott Desert Springs Resort, Palm Springs, CA.
133. "Asthma Devices, Making Sense of it All." November 15, 1998, Kalima Point, San Diego Wild Animal Park, San Diego, CA.
134. New medications and delivery devices for asthma. February 9, 1999, El Cajon Medical Group, El Cajon, CA.
135. "WORKSHOP - Office Allergy Evaluation." February 15, 1999, Hyatt Islandia, San Diego, CA.
136. "WORKSHOP - Our Love Affair with Inhaled Corticosteroids." 55th AAAAI Annual Meeting, February 27, 1999, Orlando, FL.
137. "The Ultimate Asthma Gadget Workshop." Workshop/55th AAAAI Annual Meeting, Orlando, FL, February 28, 1999.
138. "Therapy of Rhinosinusitis." 55th AAAAI Annual Meeting, Orlando, FL, February 28, 1999.
139. "Pleasing the Wheezing Patient! How to Cool the Inflammation." Long Beach Convention Center, Long Beach, CA, April 10, 1999.
140. "The Latest in Asthma Management." Symposium/Pri-Med West 99, Long Beach Convention Center, Long Beach, CA, April 11, 1999.
141. Pediatric Asthma. Medical reporter for Medscape ATS meeting, San Diego, California, April 25, 1999.
142. "Theory to Treatment", abstract presented, Asthma'99 Conference, April 30 – May 3, 1999, Honolulu, Hawaii.
143. Current Concepts in Pediatric Allergy and Otolaryngology. Welcome and Introduction of Session 1, Friday, July 16, 1999, San Diego Hilton Beach and Tennis Resort, San Diego, CA.
144. "Inhalers, Spacers, Meters and Nebulizers: Using All Those Gadgets Right!" Friday, July 16, 1999, San Diego Hilton Beach and Tennis Resort, San Diego, CA.
145. "Inhalers, Spacers, Meters and Nebulizers: Using All Those Gadgets Right!" Saturday, July 17, 1999, San Diego Hilton Beach and Tennis Resort, San Diego, CA.
146. "Our Love-Hate Relationship with Corticosteroids" Sunday, July 18, 1999, San Diego Hilton Beach and Tennis Resort, San Diego, CA.
147. "Asthma Drug Delivery Systems: A hands-on update of the newest delivery devices, from nebulizers to dry-powder inhalers and more!!" Glaxo Wellcome, Thursday, July 29, 1999, Santa Rosa, California.
148. "Our Love/Hate Relationship with Corticosteroids" Tuesday, September 7, 1999, Grand Rounds, UCSD Medical Center, Dept of Pediatrics, San Diego, CA.
149. "Noses, Sneezes and Wheezes" Pediatrics 101, Wednesday, September 8, 1999, Children's Hospital and Health Center, San Diego, CA
150. T.A.R.G.E.T. Investigators Follow-up Meeting, Welcoming Moderator, Recap and Close General Session, September 11, 1999, Phoenix, Arizona.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

151. The US Experience in Inhaled Steroid Therapy, Satellite Symposium to the European Respiratory Society, Annual Congress, October 12, 1999, Madrid, Spain, Europe.
152. “Wheezes and Sneezes, Breakthroughs in New Therapy” Thursday, February 10, 2000, Allied Gardens Optimist Club, San Diego, California.
153. “Inhaled corticosteroids versus leukotriene antagonists: one man’s confused opinion”. American Academy of Allergy, Asthma & Immunology 56th Annual Meeting, March 3, 2000, San Diego, California.
154. Conquering Barriers to Patient Adherence with Asthma Therapy. American Academy of Allergy, Asthma & Immunology 56th Annual Meeting, March 4, 2000, San Diego, California.
155. Inhaled Corticosteroids and Growth. American Academy of Allergy, Asthma & Immunology 56th Annual Meeting, March 5, 2000, San Diego, California.
156. “Practical Tricks to Stamping Out the Sneezes, Sniffles, & Salutes of Allergic Rhinitis” Sharp Community Medical Group Primary Care Physician Forum, Sharp HealthCare Office of CME, Tuesday, March 7, 2000, San Diego, California.
157. “A Breath of Fresh Air: Where Does It End Up? Gadgets, Toys, Devices and Aerosol Deposition”. Celebration of Pediatric Pulmonology 2000, March 31, 2000, Coronado Island Marriott Resort, Coronado, California.
158. “A Breath of Fresh Air: Where Does It End Up? Gadgets, Toys, Devices and Aerosol Deposition”. Celebration of Pediatric Pulmonology 2000, April 1, 2000, Coronado Island Marriott Resort, Coronado, California.
159. “A Breath of Fresh Air: Where Does It End Up? Gadgets, Toys, Devices and Aerosol Deposition”. Celebration of Pediatric Pulmonology 2000, April 2, 2000, Coronado Island Marriott Resort, Coronado, California.
160. Pleasing the Wheezing Patient! How to Cool the Inflammation. Medical World Conferences and PriMed, April 6, 2000, Long Beach, California.
161. “Summer Allergies: A Potpourri.” Children’s Hospital and Health Center Grand Rounds. San Diego, California, July 7, 2000.
162. “New Medicines and Devices.” Association of Asthma Educators Conference 2000. Chicago, Illinois, July 29, 2000.
163. “Meeting an Unmet Medical Need: Development of Budesonide Inhalation Suspension.” The Asthma Educators Workshop. Coronado, California, August 19, 2000.
164. “Asthma: Practical Take-Home Lessons from the NHLBI Treatment Guidelines.” Mercy Medical Grand Rounds. San Diego, California, August 22, 2000.
165. “Factors in Choosing an Inhaled Corticosteroid: Safety.” AstraZeneca National Advisory Boards. San Francisco, California, August 26, 2000.
166. “The Ultimate Asthma Gadget Session.” Practical Pediatrics CME Course. Seattle, Washington, August 31, 2000.
167. “Update on Delivery Systems for Asthma Medications.” Kaiser Permanente Medical Center. San Diego, California, October 4, 2000.
168. “Use of Nebulized Steroids in Infant Asthma.” AAP Chapter 3 CME Program. San Diego, California, October 26, 2000.
169. “Tricks (and Treats) in Gaining Control of Childhood Asthma: A Halloween Update on Anti-Inflammatory Therapy.” CME Symposium. Chicago, Illinois, October 27, 2000.
170. “Ultimate Asthma Gadgets.” American Academy of Pediatrics 2000 Annual Meeting. Chicago, Illinois, October 29, 2000.
171. “Improved Asthma-Related Outcomes and Health Resource Utilization with Budesonide Inhalation Suspension (Pulmicort RespulesTM) Compared to Nebulized Cromolyn Sodium in

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

- Young Asthmatic Patients.” ACAAI Annual Meeting. Seattle, Washington, November 6, 2000.
172. “Nebulized Budesonide: A New Choice for Asthma Therapy.” Asthma Educators Summit. Las Vegas, Nevada, November 17, 2000.
173. “Office Management of Urticaria, Angioedema & Anaphylaxis.” Pediatric Update 2001: New Office Treatment. Coronado, California, February 13, 2001.
174. “Advances in Atopy.” Pediatric Update 2001: New Office Treatment. Coronado, California, February 13, 2001.
175. “Asthma-Controller Medications/Nonsteroids”; moderator. Pediatric Allergy: and Asthma The Complete Course for Primary Care Providers. Orlando, Florida, March 2, 2001.
176. “Asthma Gadget Workshop – Getting the Technique Right!” Pediatric Allergy: and Asthma The Complete Course for Primary Care Providers. Orlando, Florida, March 2, 2001.
177. “Who Wants to Be A Millionaire?” Moderator. Pediatric Allergy: and Asthma The Complete Course for Primary Care Providers. Orlando, Florida, March 2, 2001.
178. “The Ultimate Asthma Gadget Workshop.” AAAAI 57th Annual Meeting. New Orleans, Louisiana, March 18, 2001.
179. “So Now What Do We Tell Our Patients About This Growth Issue With ICSs.” AAAAI 57th Annual Meeting. New Orleans, Louisiana, March 18, 2001.
180. “Pharmacotherapy and Asthma”; moderator. AAAAI 57th Annual Meeting. New Orleans, Louisiana, March 19, 2001.
181. “Hot Topics in ARRD”; moderator. AAAAI 57th Annual Meeting. New Orleans, Louisiana, March 20, 2001.
182. “Tratamiento Óptima en Asma.” Sociedad Mexicana de Neumología y Cirugía de Tórax, A.C., Tijuana 2001. Tijuana, B.C., April 19, 2001.
183. “Want to Breathe Like a Millionaire?” Update on Nasal Corticosteroid Therapy. Dinner lecture; San Diego, California, April 26, 2001.
184. “Pediatric Asthma Management.” San Diego County Office of Education: Leadership Tools for the 21st Century. San Diego, California, May 1, 2001.
185. “Patients Preference For Pulmicort Turbuhaler® vs. Pressurized Metered-Dose Inhalers.” Poster, ATS 2001 97th International Conference, San Francisco, California, May 18, 2001.
186. “Allergic Rhinitis for the Primary Care Physician: Do it Yourself.” UCSD sponsored symposium: Challenges Facing the Primary Care Physician: Time to Treat or Refer. San Diego, California, May 19, 2001.
187. “Asthma Gadgets Workshop.” Super CME 2001: Medicine, Leadership, and Practice Medicine. New York, New York, June 15-16, 2001.
188. “New Asthma Medications: Do They Make a Difference?” Children’s Hospital San Diego sponsored course: Current Concepts in Pediatric Respiratory Diseases: San Diego 2001. San Diego, California, June 29, 2001.
189. “Workshop A: Inhaler Devices.” Children’s Hospital San Diego sponsored course: Current Concepts in Pediatric Respiratory Diseases: San Diego 2001. San Diego, California, June 29, 2001.
190. “Innovations in Allergic Rhinitis Therapy: Who Wants to Be a Millionaire?” Aventis Pharmaceuticals, Carlsbad, California, August 11, 2001.
191. “Leukotriene Modifiers Versus Inhaled Corticosteroids for Asthma – One Man’s Confused Opinion.” Practical Pediatrics, American Academy of Pediatrics, Providence, Rhode Island, August 31, 2001.
192. “The Ultimate Gadget Workshop.” Practical Pediatrics, American Academy of Pediatrics, Providence, Rhode Island, August 31, September 1, and September 2, 2001.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

193. "A Pediatricians Approach to the Child with Chronic Rhinitis." Practical Pediatrics, American Academy of Pediatrics, Providence, Rhode Island, September 1, 2001.
194. "Treatment of Allergic Rhinitis – What's New on the Block?" Practical Pediatrics, American Academy of Pediatrics, Providence, Rhode Island, September 2, 2001.
195. "Anaphylaxis: Screen, Educate, and Protect to Improve Patient Outcomes." Talk for general pediatricians, Dey Pharmaceuticals. La Jolla, California, September 26, 2001.
196. "Patient and Caregiver Perspectives on the Pharmacologic Treatment of Asthma and Its Impact on Asthma Management." Living with Asthma: Current Perspectives in the Management of Pediatric Asthma, American Academy of Pediatrics 2001 National Conference and Exhibition Session, San Francisco, California, October 21, 2001.
197. "The Ultimate Asthma Gadget Workshop." American Academy of Pediatrics 2001 National Conference and Exhibition Session, San Francisco, California, October 22, 2001.
198. "Total Asthma Management: Guidelines, Spirometry, Action Plans, Pt. Education, and Outcomes." American Academy of Pediatrics 2001 National Conference and Exhibition Session, San Francisco, California, October 23, 2001.
199. "New Advances in Nebulized Therapy for Children with Asthma." Sepracor, Inc and Ross Pediatrics. San Diego, California, November 23, 2001.
200. "Practical Update on the Approach to Asthma Therapy." Beaver Clinic Physicians. Temecula, California, January 10, 2002.
201. "Pediatric Asthma at the Front Lines." American Academy of Pediatric in collaboration with American Lung Association. Terra Restaurant, San Diego, California, January 31, 2002.
202. "Millionaire Management of Allergies in the Younger Population." Pfizer, Inc. Ruth's Chris-Del Mar, Del Mar, California, February 19, 2002.
203. "The World of Private Practice." American Academy of Allergy, Asthma and Immunology Chrysalis Program, New York, New York, March 1, 2002.
204. "Co-Morbid Conditions in Asthma in Pediatric and Adult Patients." AAAAI 58th Annual Meeting, New York, New York, March 3, 2002.
205. "Inhaled Steroids and Growth in children: What Do We Tell Our Patients?" AAAAI 58th Annual Meeting, New York, New York, March 4, 2002.
206. "Systemic Effects of Inhaled Corticosteroids." AAAAI 58th Annual Meeting, New York, New York, March 5, 2002.
207. "Ultimate Gadget Workshop." AAAAI 58th Annual Meeting, New York, New York, March 3, 2002.
208. "Nasal Corticosteroids – Who Wants to Breathe Like a Millionaire." Aventis Pharmaceuticals Nasacort AQ Respiratory National Visiting Professors (NVP) Program, San Diego, California, April 28, 2002.
209. "What Is the Treatment of Mild Persistent Asthma? Debate Between Dr. Florence Vent and Dr. Singh U. Lair." Family Practice Dept., Merck Pharmaceuticals, Sharp Rees-Steeley, Chula Vista, California, April 30, 2002.
210. "New Approaches to Asthma Therapy." Mini Seminar "Rheum to Grow: New Treatments and Trends to Pediatric Inflammatory Conditions," Children's Hospital and Health Center, San Diego, California, May 4, 2002
211. "Advances in Pediatrics." Thirteenth Annual Las Vegas Postgraduate Pediatric Meeting, The Flamingo Hotel, Las Vegas, Nevada, May 9-12, 2002.
212. "The Role of Xopenex in Reversible Airway Disease." Grand Rounds, Scripps Mercy Hospital, San Diego, California, May 14, 2002.
213. "How to Make Your Patients Breathe Like a Millionaire: Use of Antihistamines in Allergic Rhinitis." Rancho Mirage, California, June 8, 2002.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

214. "Update: Seasonal Rhinitis." Educational Golf Tournament, Maderas Golf Club, Poway, California, June 15, 2002.
215. "How to Make Your Patients Breathe Like a Millionaire: Use of Nasal Corticosteroids in Allergic Rhinitis." Aventis Pharmaceuticals Nasacort AQ Respiratory National Visiting Professors (NVP) Program, Saratoga, California, June 23, 2002.
216. Hands on Issues of Rhinitis Workshop. Pediatric Allergy and Otolaryngology Conference, Children's Hospital, San Diego, California, June 29, 2002.
217. "Pediatric Asthma at the Front Lines." 94th Aero Squadron Restaurant, San Diego, California, July 10, 2002.
218. "Update on Inhaled Therapy for Pediatric Asthma – Delivering it Right." Paradise Valley Hospital, San Diego, California, July 24, 2002.
219. "Multiple Controller Therapy for Additional Asthma Control." Sante's, San Diego, California, July 25, 2002
220. "Safety of Inhaled Corticosteroids." AstraZeneca's 2002 Visiting Asthma Consultants Program, Mandarin Oriental, San Francisco, California, September 14-15, 2002.
221. "Practical approach to asthma with overview of recent 2002 Update of NHLBI Asthma Guidelines." Empire Physician Medical Group, Palm Desert, California, October 8, 2002.
222. "Management of Acute Asthma: Newer Strategies." 44th Annual Southern California Permanente Pediatric Symposium, Hyatt Regency, La Jolla, California, November 1, 2002.
223. "Management of Chronic Asthma: Newer Strategies." 44th Annual Southern California Permanente Pediatric Symposium, Hyatt Regency, La Jolla, California, November 1, 2002.
224. "Asthma Gadgets." 44th Annual Southern California Permanente Pediatric Symposium, Hyatt Regency, La Jolla, California, November 2, 2002.
225. "Treatment Options for Persistent Asthma." Thorton Winery, Temecula, California, November 19, 2002.
226. "Treatment Options for Persistent Asthma." Thorton Winery, Temecula, California, November 20, 2002.
227. "Asthma Update." PMA CME/Dinner Meeting, Bob's on the Bay, San Diego, California, November 21, 2002.
228. "Asthma and Allergies." School Health 2003, Program for nurses, Northside Medical Center, Youngstown, Ohio, January 21, 2003.
229. "Food Allergy in the Schools." Temecula Valley School District, January 23, 2003.
230. "Management of Asthma in the Schools." California School Nurses Organization (CSNO) 53rd Annual Conference, "Reaching New Heights," San Diego, California, January 29 – February 2, 2003.
231. "Use of antihistamines in allergic diseases." Mercy Hospital, San Diego, California, February 7, 2003.
232. "Multiple Controller Therapy for Additional Asthma Control." Merck, Solana Beach, California, February 27, 2003.
233. "Private Practice Career Paths." 60th Anniversary AAAAI Annual Meeting, Denver, Colorado, March 6, 2003.
234. "The Ultimate Asthma Gadgets Workshop." 60th Anniversary AAAAI Annual Meeting, Denver, Colorado, March 6, 2003.
235. "Asthma Update: Steroid Phobia." Le Papillion, AstraZeneca, San Jose, California, March 27, 2003.
236. "Update on Inhaled Delivery Systems and the New NHLBI Guidelines, 2003." Gordon Biersch Restaurant, San Diego Society of Health-System Pharmacists and San Diego County Pharmacist Association, San Diego, California, April 22, 2003.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

237. “New Battle Plans for the War on Asthma in Children.” Pediatric Grand Rounds, Continuing Medical Education, Children’s Hospital and Health Center, San Diego, California, May 2, 2003.
238. “Debating the Role of Leukotriene Antagonists vs. Inhaled Corticosteroids in Asthma: One Man’s Confused Opinion.” American Lung Association of Minnesota, The Sixteenth Annual Richard T. Cushing, MD Memorial Lecture Program, Golden Valley, Minnesota, June 12, 2003.
239. “New Battle Plans for Our War on Asthma in Children.” CME Dinner Program, American Academy of Pediatrics, San Diego, California, July 16, 2003.
240. Office Spirometry and Pulmonary Function Testing, When to Order and How to Interpret, Sharp Mission Park Medical Center, Vista, CA, September 2003.
241. “Xolair®: A Novel Treatment for Asthma.” Genentech, Inc. and Novartis Pharmaceuticals, Betrand’s Restaurant, San Diego, CA, October 14, 2003.
242. “Update on the Diagnosis and Management of Asthma: Find Out What’s New in the Latest National Expert Panel Report and How to Put Principles in to Practice.” 2003 American Academy of Pediatrics NCE Meeting, New Orleans, LA, November 3, 2003.
243. “Office Spirometers-Hands On.” American Academy of Pediatrics NCE Meeting, New Orleans, LA, November 2, 2003.
244. “The Asthma Gadget Workshop.” American Academy of Pediatrics NCE Meeting, New Orleans, LA, November 4, 2003.
245. “Inhalers & Spacers & Powders & Meters-oh my! Tips on proper inhaler technique from the Wizard of Asthma Gadgets!” American Academy of Pediatrics CME Dinner Program, Encinitas, CA, November 19, 2003.
246. “Demonstration of Asthma Devices.” The Asthma Educator Course, American Lung Association, San Diego, CA, January 23, 2004.
247. “Our War on Asthma and the Latest Battle Plans At the Front Lines.” Blue Cross of California, San Diego, CA, February 11, 2004.
248. Pediatric Potpourri, American Academy of Pediatrics, Maui, Hawaii, February 21-27, 2004. “Leukotriene Modifiers vs. Inhaled Corticosteroids for Asthma: One Man’s Confused Opinion.” “Asthma Gadgets & Delivery Systems: Getting the Technique Right.” “Our War on Asthma in Children: New Battle Plans Recently Issued by the NHLBI.” “Take-home Lessons for Pediatricians About Venom, Drug and Food Allergy.”
249. “The Primary Care Physician Challenge: Decision 2004. Making a Difference in Allergic Rhinitis.” Aventis, Phoenix, AZ, April 3, 2004.
250. American Academy of Pediatrics “PREP® The Course 2004.” Costa Mesa, CA, September 13, 2004.
251. American Academy of Pediatrics National Conference & Exhibition, Section on Allergy & Immunology. “Minimizing the Impact of Asthma on School Performance.” San Francisco, CA, October 11, 2004.
252. American Academy of Pediatrics National Conference & Exhibition, Section on Allergy & Immunology. “The Ultimate Asthma Gadget Workshop.” San Francisco, CA, October 12, 2004.
253. “Mild Persistent Asthma: When Is It Time to Start Maintenance Therapy.” Merck, La Jolla, CA, November 14, 2004.
254. “Achieving Goals in Asthma Therapy.” AstraZeneca, El Centro, California, February 9, 2005.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

255. "Achieving Goals in Asthma Therapy." AstraZeneca, Roy's, San Diego, California, February 15, 2005.
256. "Pharmacotherapeutic Approach to Asthma Management." American Academy of Pediatrics PPC Allergy and Asthma Course, San Diego, California, April 1, 2005.
257. "Immunotherapy." American Academy of Pediatrics PPC Allergy and Asthma Course, San Diego, California, April 2, 2005.
258. "Hot Topics in Allergy." American Academy of Pediatrics PPC Allergy and Asthma Course, San Diego, California, April 3, 2005.
259. "Pediatric Asthma." Diagnosis and Treatment of Asthma in Children, DoubleTree Hotel, San Diego, California, April 6, 2005.
260. "Updates in the trends and treatment of allergic rhinitis." Sanofi-Aventis, Tutto Mare, San Diego, California, June 9, 2005.
261. "Jeopardy Game – Approach to learning about management of allergic rhinitis." UCB Pharma, Ruth Chris Steakhouse, San Diego, California, June 14, 2005.
262. "Helping Patients Breathe Like a Millionaire: Management of Allergic Rhinoconjunctivitis." American Academy of Pediatrics, Pediatrics in the Islands-Clinical Pearls 2005, Maui, Hawaii, July 3, 2005.
263. "Care of the Acutely Ill Asthma Patient." American Academy of Pediatrics, Pediatrics in the Islands-Clinical Pearls 2005, Maui, Hawaii, July 5, 2005.
264. "Controversies in Diagnosis and Treatment of Asthma." American Academy of Pediatrics, Pediatrics in the Islands-Clinical Pearls 2005, Maui, Hawaii, July 5, 2005.
265. "Toxic Mold, The Indoor Environment and Health Effects." American Academy of Pediatrics, Pediatrics in the Islands-Clinical Pearls 2005, Maui, Hawaii, July 6, 2005.
266. "Allergy Potpourri for \$100." American Academy of Pediatrics, Pediatrics in the Islands-Clinical Pearls 2005, Maui, Hawaii, July 7, 2005.
267. "Toxic Mold, The Indoor Environment and Health Effects." Course for San Diego Lawyers, San Diego, California, September 2005.
268. "At What Age Can a Child Swallow a Pill? A Practical Guide for School Nurses." Abstract Poster Session, American Academy of Pediatrics, National Conference and Exhibition, Washington, DC, October 8, 2005.
269. "Treatment of Pediatric Asthma: Managing Inflammation First." Symposium: *Understanding the Allergic Inflammatory Continuum: From the Nose to the Lung*, American Academy of Pediatrics, National Conference and Exhibition, Washington, DC, October 8, 2005.
270. "The Runny, Stuffy Nose: Allergies, Adenoids, or Anatomy?" American Academy of Pediatrics, National Conference and Exhibition, Washington, DC, October 10, 2005.
271. "Asthma Gadgets for the Primary Care Office." Workshop, American Academy of Pediatrics, National Conference and Exhibition, Washington, DC, October 11, 2005.
272. "Controlling Asthma and an Updated on the Delivery Devices." Sharp Community Medical Group, 6th Annual CME Conference, Indian Wells, CA October 22, 2005.
273. "2005 Update on Asthma Therapy." Sharp Mission Park Medical Group, Oceanside, CA, November 22, 2005.
274. "Controversies in the Diagnosis and Treatment of Asthma (Part II)." Kaiser Permanente, Los Angeles, November 29, 2005.
275. "Diagnosis and Management of Pediatric Asthma – Update 2005." AstraZeneca, El Paso, Texas, December 5, 2005.
276. "Allergy Potpourri for \$100" Pediatric Grand Rounds, San Diego, CA, December 22, 2005.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

277. "Disease States of Asthma & Rhinitis, Associated Co-Morbidities." Brigantine, San Diego, CA, January 26, 2006.
278. "Clinical Trial Jeopardy Game." American Academy of Allergy, Asthma & Immunology Annual Meeting, Miami Beach, Florida, March 3, 2006.
279. "Asthma Gadgets." Interactive Small Group. American Academy of Pediatrics – SuperCME 2006 Course, Washington DC, April 27, 2006.
280. "Rhinitis, sinusitis in children." Interactive Small Group. American Academy of Pediatrics – SuperCME 2006 Course, Washington DC, April 28, 2006.
281. "Allergy. Cutting Edge Topics", American Academy of Pediatrics – SuperCME 2006 Course, Washington DC, April 29, 2006.
282. "Current Concepts in Pediatric Allergy and Otolaryngology." Moderator. San Diego, CA, May 28, 2006.
283. "Asthma and Inhaled Corticosteroids." Center for Healthcare, San Diego, August 8, 2006.
284. "An Overview of the S.M.A.R.T. Study and the Use of L.A.B.A.'s in Asthma." GlaxoSmithKline, Escondido, CA, August 17, 2006.
285. "Asthma Guidelines and Effective Utilization of Long-Acting Beta Agonists." CME Conference, Palomar Medical Center, Escondido, September 21, 2006.
286. "Nuts & Bolts of Food Allergy." The Food Allergy & Anaphylaxis Network. Food Allergy Conference, Food Allergy: A Brighter Future. Orange, Ca, October 28, 2006.
287. "Anaphylaxis Case Studies." The Food Allergy & Anaphylaxis Network. Food Allergy Conference, Food Allergy: A Brighter Future. Orange, Ca, October 28, 2006.
288. "Enhancing Asthma Management: A Practical Approach." Allied Health Asthma CE Series, San Diego, California, January 25, 2007.
289. "Inhaled Steroids in Children With Asthma." 25th Binational Pediatric Conference & 3rd Congress for Contemporary Pediatric Concepts. Tijuana, Mexico, February 9, 2007.
290. "Clinical Trial Jeopardy Game." Clinical Research Symposium, American Academy of Allergy, Asthma & Immunology Annual Meeting, San Diego, California, February 23, 2007.
291. "Asthma Delivery Devices." Asthma Educator Course, American Lung Association, San Diego, California, March 2, 2007.
292. "Barriers to Asthma Control." Setting a New Course: Cost & Quality in Asthma Management, AdvanceMed, San Diego, California, April 12, 2007.
293. "Inhaled Corticosteroid (ICS) Delivery in Young Children." Astra Zeneca, La Jolla, California, May 9, 2007.
294. "Nuts & Bolts of Food Allergy." San Diego Food Allergy, San Diego, California, May 23, 2007.
295. "Update on Asthma Management with Focus on the New 2007 NHLBI Guidelines." Inland Empire Health Plan, San Bernardino, California, June 5, 2007.
296. "The Toxic Mold and Mildew Scare." Pediatrics for the Practitioner: 44th Annual Teaching Conference, San Antonio, California, June 8, 2007.
297. "Allergy Potpourri for \$100." Pediatrics for the Practitioner: 44th Annual Teaching Conference, San Antonio, California, June 8, 2007.
298. "Management of Asthma in Children." Medical staff meeting for Scamp Camp. Julian, California, June 25, 2007.
299. "Diagnosis and Treatment of Asthma." Abbott Laboratories, La Jolla, California, July 19, 2007.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

300. "Just What You Needed (You're Still Trying to Remember the Last Set): The New 2007 NHLBI Asthma Management Guidelines." Sharp Community Medical Group 8th Annual CME Conference, Palm Desert, California, September 29, 2007.
301. "Improving Pediatric Asthma Patient Outcomes: The Impact of Novel Therapies and New NAEPP Treatment Guidelines." Practitioner's Edge – Nycomed, San Francisco, California, October 28, 2007.
302. "Cultivating Patient Care Strategies That Improve Asthma Management." AdvancMed, San Diego, California, November 3, 2007.
303. "Asthma Gadgets: Getting the Technique Right!" California School Nurses Organization, San Diego, California, January 26, 2008.
304. "Pharmacotherapy II: Corticosteroids (Rx=0.25)." American Academy of Pediatrics, Practical Pediatrics Asthma and Allergy Course, Orlando, Florida, March 6, 2008.
305. "Asthma Gadgetry (Rx=0.5)." Workshop - American Academy of Pediatrics, Practical Pediatrics Asthma and Allergy Course, Orlando, Florida, March 7, 2008.
306. "Immunotherapy and Allergic Rhinitis (Rx=0.15)." American Academy of Pediatrics, Practical Pediatrics Asthma and Allergy Course, Orlando, Florida, March 7, 2008.
307. "Anaphylaxis (Rx=0.15)." American Academy of Pediatrics, Practical Pediatrics Asthma and Allergy Course, Orlando, Florida, March 8, 2008.
308. "Comparison of Mastery of Use of Nebulization Therapy versus MDI with Spacer With/Without Mask in Caregivers of Young Children with Asthma." American Academy of Allergy, Asthma & Immunology Annual Meeting, Philadelphia, Pennsylvania, March 16, 2008.
309. "Update on treatment of the child with allergic rhinitis." Larman Lectureship, Riley Children's Foundation, Indianapolis, Indiana, May 7, 2008.
310. "Practical Management of Pediatric Asthma." Essential Topics in Pediatrics 2008: Exploring the Developmental Spectrum. San Diego, California, May 17, 2008.
311. "A New Treatment Option for the Management of Chronic Idiopathic Urticaria." Sanofi Aventis, San Diego, California, June 16, 2008.
312. "Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional." The Network for Continuing Medical Education, Anaheim, California, June 14, 2008.
313. "ICS Rx in Young Children: MDI with Spacer/Mask vs. Nebulizer." American Lung Association Asthma Camp Committee, San Diego, California, August 28, 2008.
314. "Recognizing Allergic Reactions & Knowing How To Use Epinephrine Auto-Injectors (EpiPen and TwinJect)." San Diego Food Allergy Support Group, San Diego, California, October 16, 2008.
315. "Asthma: Updates and Advances." Sharp Community Medical Group 9th Annual CME Conference, Palm Desert, California, September 27, 2008.
316. "The Ultimate Asthma Gadget Workshop." American Academy of Pediatrics National Conference and Exhibition, Boston, Massachusetts, October 11, 2008.
317. "Asthma and Allergy Potpourri for \$200." American Academy of Pediatrics National Conference and Exhibition, Boston, Massachusetts, October 12, 2008.
318. "Recognizing Allergic Reactions and Knowing How to Use Epinephrine Auto-Injectors (EpiPen and Twinject)." San Diego Food Allergy Support Group, San Diego, California, October 16, 2008.
319. "Respiratory Pharmacology." Nurse Practitioner Class, San Diego State University, San Diego, California, October 21, 2008.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

320. “Hot Topics in Pediatric Allergy, Asthma and Immunology.” American College of Allergy, Asthma and Immunology Annual Meeting, Seattle, Washington, November 9, 2008.
321. “Gadgets and Gizmos for Meds.” Rally Together for Respiratory Health, American Lung Association, November 11, 2008.
322. “Asthma Updates – How school nurses can collaborate with physicians to improve asthma outcomes in the school age child.” California School Nurses Organization & Rady Children’s Hospital San Diego, December 11, 2008.
323. “New NHLBI Guidelines for Asthma – Is There Really Anything New?” American Academy of Pediatrics, Advances in Pediatrics Conference, Las Vegas, NV, April 17, 2009.
324. “Office Gadgets and Devices for Treating Allergic Diseases.” American Academy of Pediatrics, Advances in Pediatrics Conference, Las Vegas, NV, April 17, 2009.
325. “Allergy Potpourri for \$\$ - The Jeopardy Game.” American Academy of Pediatrics, Advances in Pediatrics Conference, Las Vegas, NV, April 18, 2009.
326. “Office Gadgets and Devices for Treating Allergic Diseases.” American Academy of Pediatrics, Advances in Pediatrics Conference, Las Vegas, NV, April 18, 2009.
327. “Practical Management of Food Allergies.” American Academy of Pediatrics, Advances in Pediatrics Conference, Las Vegas, NV, April 19, 2009.
328. “Rational Use of ICS’s in Young Children.” Teva Pharmaceuticals, Omaha, NE, September 10, 2009.
329. “Role of Allergy in ENT Diseases.” Teva Pharmaceuticals, Omaha, NE, September 11, 2009.
330. “Burning Questions in Treatment of Pediatric Asthma.” Teva Pharmaceuticals, Lincoln, NE, September 12, 2009.
331. “Recognizing Allergic Reactions and Knowing How to Use Epinephrine Auto-Injectors (EpiPen and Twinject).” San Diego Food Allergy Support Group, Educational CD, October 2009.
332. “Allergy and Asthma Gadgets.” American Academy of Pediatrics National Conference & Exhibition. Washington DC, October 19, 2009.
333. “NHBLI New Asthma Guidelines: So What’s So New?” The 12th Annual School Health Leadership Conference “Back To School”. Naval Medical Center, San Diego, California, October 24, 2009.
334. “Keeping You and Your Patient’s Adrenaline From Running: Managing Acute Allergic Reactions.” American Academy of Pediatrics. Pediatrics in the Islands-Clinical Pearls 2010, Maui, Hawaii, February 14, 2010.
335. “Latest Approach of Acute Asthma Management at Home and in the Office: Nuts and Bolts Behind an Asthma Action Plan.” American Academy of Pediatrics. Pediatrics in the Islands-Clinical Pearls 2010, Maui, Hawaii, February 16, 2010.
336. “The Best Offense is a Good Defense: Use of Asthma Controller Therapy and Prevention of Acute Flare-Ups.” American Academy of Pediatrics. Pediatrics in the Islands-Clinical Pearls 2010, Maui, Hawaii, February 16, 2010.
337. “Down and Dirty Approach to the Child With Allergic Rhinoconjunctivitis.” American Academy of Pediatrics. Pediatrics in the Islands-Clinical Pearls 2010, Maui, Hawaii, February 17, 2010.
338. “New Pharmacologic Treatments for Allergic Disease: Improved Medication or Industry Hype?” American Academy of Pediatrics. Pediatrics in the Islands-Clinical Pearls 2010, Maui, Hawaii, February 18, 2010.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

339. “The Ultimate Asthma Gadget Workshop.” American Academy of Pediatrics. Pediatrics in the Islands-Clinical Pearls 2010, Maui, Hawaii, February 18, 2010.
340. “Food Allergies and the School Nurse.” California School Nurses Organization – San Diego/Imperial Section, San Diego, California, September 18, 2010.
341. “Allergy and Asthma Gadget Workshop.” American Academy of Pediatrics National Conference & Exhibition. San Francisco, California, October 4 & 5, 2010.
342. “Asthma in Children: News Stories That Need to be Told.” Merck program. 8th Latin American Seminar on Science and Health Journalism. San Diego, California, November 2, 2010.
343. “NHLBI Asthma Guidelines: How to Integrate the Guidelines into Your Daily Practice.” Kaiser 52nd Annual Pediatric Symposium. Long Beach, California, November 12, 2010.
344. “Update on Food Allergy.” Kaiser 52nd Annual Pediatric Symposium. Long Beach, California, November 12, 2010.
345. “Allergy Update Pearls.” Sharp Community Medical Group 2011 Conference. Huntington Beach, California, September 24, 2011.
346. Leading the Way to Education as We Fight For Air. Speaker at a benefit concert – An Evening of Champions. LEAD Foundation & American Lung Association, San Diego, California, November 12, 2011.
347. The Asthma Gadget Workshop MDI, DPI, spacer, peak flow meter, nebulizer. University of California, San Diego & Skaggs School of Pharmacy and Pharmaceutical Sciences, 1st year pharmacy students. San Diego, California, February 15, 2012.
348. The Asthma Gadget Workshop MDI, DPI, spacer, peak flow meter, nebulizer. University of California, San Diego & Skaggs School of Pharmacy and Pharmaceutical Sciences, 3rd year pharmacy students. San Diego, California, March 5, 2012.
349. Asthma Medicine Devices & Demonstration. Asthma Educator Institute, American Lung Association. San Diego, California, May 15, 2012.
350. Benefits, Challenges and Controversies of Inhaled Asthma Therapy in Children. 2012 American College of Clinical Pharmacology Annual Meeting. San Diego, CA, September 22, 2012.
351. Complications Related to Allergic Rhinitis. 29th Binational Day. Rady Childrens Hospital San Diego. Tijuana, Mexico, May 25, 2013.
352. Treatment of Asthma with Corticosteroids in Children. Importance of Small Airways Asthma. Lincoln Pediatric Group. Lincoln, Nebraska, September 12, 2013.
353. Review of Emerging Pharmacotherapy for Asthma. Importance of Small Airways Asthma. Lincoln Pediatric Group. Omaha, Nebraska, September 16, 2013.
354. Complications Related to Allergic Rhinitis. 29th Binational Day. Rady Childrens Hospital San Diego. Tijuana, Mexico, May 25, 2013.
355. Properly Preparing the Patient and Family for That Possible Accidental Exposure. “Practical Update for Pediatricians on Food Allergy” CME Webinar Series for Pediatricians, August 2013.
356. Treatment of Asthma with Corticosteroids in Children. Importance of Small Airways Asthma. Lincoln Pediatric Group. Lincoln, Nebraska, September 12, 2013.
357. Review of Emerging Pharmacotherapy for Asthma. Importance of Small Airways Asthma. Lincoln Pediatric Group. Omaha, Nebraska, September 16, 2013.
358. The Non-Medical But Important Aspects Of Food Allergy: Minimizing Its Impact On Quality Of Life. “Practical Update for Pediatricians on Food Allergy” CME Webinar Series for Pediatricians, November 2013.

SELECTED PRESENTATIONS: MICHAEL J. WELCH, MD

359. Prognosis Of Patients With Food Allergy: Who Outgrows Which Food Allergy? “Practical Update for Pediatricians on Food Allergy” CME Webinar Series for Pediatricians, January 2014.
360. Pulmonary Devices Used in Asthma. UCSD Skaggs School of Pharmacy. San Diego, California. February 12, 2014.
361. Food Allergy Prevention: What Can The Pediatrician Do? “Practical Update for Pediatricians on Food Allergy” CME Webinar Series for Pediatricians, March 2014.
362. “Pediatrics in the Islands - Clinical Pearls 2014” (Food allergy, asthma gadgets, asthma update, managing allergic rhinitis). Childrens Hospital of Los Angeles CME. Lahiana, HI. June 28 – July 4, 2014
363. “Asthma and Anaphylaxis – 2 A’s that can ruin your day.” 17th Annual School Health Leadership Conference. American Academy of Pediatrics. San Diego, CA – November 8th, 2014.
364. Chronic Bronchitis / Rhinorrhea: “Rhinorrhea: Is it allergy, preschool, or sinusitis?” Audio-Digest CME / CE program. Volume 60, Issue 44. Published on November 17th, 2014.